inline xbrl viewer application relies heavily javascript need allow javascript to use this application inline viewer menu menu information save xbrl instance save xbrl zip file open html setting help section section additional search option include fact name include fact content include label include definition include dimension reference option include topic include sub topic include paragraph include publisher include section match case clear search submit search data data amount text only calculation only negative only additional item only tag tag all standard only custom only filter more filter selecting will take moment period measure axis explicit typed member explicit typed scale balance debit credit reset all filter link fact loading inline form tagged section search all search in internal section only search in external section only clear section search submit section search help getting started the inline xbrl viewer allows user to quickly easily review detail of the tagged information in inline document automatically placing top and bottom highlight border around tagged numeric fact and left and right border each block tagged fact hovering tagged fact will highlight shade all content related to the tagged fact and clicking on tagged fact will reveal tagging detail in the fact review window navigation search and filter option also provided to easily refine and identify specific type of tagged information fact review window the fact review window show the tagging detail for the currently selected fact highlighted solid blue border are four category of fact detail which viewed an value indicates there is available information for the item within the given category attribute all primary information applicable describing the tagged fact including period sign decimal dimensional detail ax and member scale measure and data type label detailed documentation definition for the tag used and label reference authoritative reference information applicable for the selected tag calculation balance and calculation hierarchy detail numeric non dimensioned item only searching there are two way to search the document fact and section to search information enter keyword in search box and select the magnifying glass icon to return matching result search operator and via and and or via or or are available to refine search fact the search fact box can be used to find tagged fact matching entered keywords by default tag name tag label and tagged content are included in search tagged fact matching the search criterion are shown with yellow colored default shading on the page and appear in the fact list select the button to the left of the magnifying glass icon to clear the search the content included in search can be increased to included tag definition dimension and authoritative reference by selecting the cog wheel icon to the left of the search box see setting for more information section the search section box can be used to filter the tagged section of the financial statement filter filter change the number of highlighted fact and item in the fact list by providing several way to review and pinpoint certain tagged information multiple filter can be used data filter filter option allow the user to refine the highlighted tagged fact by data type all display all tagged data default amount only numeric fact only text only textual fact only calculation only numeric fact participating in calculation only negative only negative numeric amount only additional item only tagged fact without corresponding html presentation hidden fact only tag filter these filter allow the user to refine the highlighted fact by tag type all display all tagged data default standard only fact with standard tag common taxonomy us_gaap ifrs dei custom only fact with extension custom tag unique to the entity document more filter additional filter allow user to further refine the highlighted fact period list of all used context year and reporting period measure list of all used unit of measure dollar applicable axis list of all used axis dimension applicable dimension applicable scale list of all used scaled option thousand million applicable balance debit credit applicable multiple filter work in conjunction with each other for example selecting the amount only data filter and custom only tag filter will highlight only numeric tagged fact using custom tag and list in the fact list active filter are displayed in the filter toolbar are selected active filter can be removed individually by unchecking or selecting all option for each filter or all at once via the reset all filter option fact list result on the toolbar select the count to the right of the word fact fact to reveal the fact list result navigable listing of all currently highlighted tagged fact the count represents the current number of fact by default all tagged fact are displayed in the fact list result the list content and count reflects the currently highlighted fact filter and search criterion refine the list to match the highlighted tagged fact navigation control are available to move the list well move the current view to the corresponding highlighted fact location automatically fact in the fact result list is selected will reveal the fact review window certain letter may appear to the right of an item in the fact result list to indicate certain property the letter appears for fact it indicates the fact is additional data hidden with potentially no corresponding html presentation if the letter appears the fact is tagged with custom tag if the letter appears the fact is tagged with dimensional information section the section toolbar item provides listing of the tagged section of the inline document section are divided three group document entity information financial statement note to the financial statement by expanding group and selecting section item in the listing inline xbrl viewer will navigate to that section when the tagged section feature is open the search section box will additionally filter the list of section to only section that match the entered criterion menu information the information menu item provides additional detail the current inline document and customizable viewer setting company and document basic company and document information tag fact and tag standard and custom information file file used additional item additional hidden data that tagged potentially corresponding location in the html save xbrl instance the save xbrl instance menu item allows an xbrl instance document xml that is extracted from the inline document to be saved locally for use by software supporting the xbrl format save xbrl zip the save xbrl zip menu item allows zip file zip that contains the provided xbrl instance document and related custom taxonomy file to be saved locally setting the setting menu item provides the ability to customize viewer feature tagged fact hover on display the hover fact review window for any tagged fact hide the hover fact review window for any tagged fact default may impact performance with certain web browser auto scrolling position this setting will have no effect on ie or safari top selecting fact from the section menu or the fact menu will automatically scroll that element to the top of the inline xbrl viewer window default center selecting fact from the section menu or the fact menu will automatically scroll that element to the middle of the inline xbrl viewer window highlight color use the save and reset button to save the selected setting or reset to default tagged data change the highlight color of the tagged fact border search result change the background color of tagged item matching the search result selected fact change the color of highlight border used to identify the currently selected fact tag shading hover change the color of the shading applied to tagged data on hover search option match case match the specific case of the entered search keyword include label extends search to include tag label include definition extends search to include tag definition include dimension extends search to include dimensional detail include reference extends search to include authoritative reference information optionally specify the reference part to include in the search topic subtopic section help this content version indicates the current build of the inline xbrl viewer application fact select page loading mrk fasb org gaap deferredincometaxesandotherassetsnoncurrenthttp fasb org gaap deferredincometaxesandotherassetsnoncurrenthttp fasb org gaap otherliabilitiescurrenthttp fasb org gaap otherliabilitiescurrenthttp fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap usdxbrli gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap minimummembermrk pharmaceuticalsegmentmembercountry animalhealthsegmentmembersrt minimummembercountry maximummembercountry minimummemberus gaap maximummemberus gaap minimummemberus gaap maximummemberus gaap minimummemberus gaap maximummemberus gaap minimummemberus gaap gaap softwareandsoftwaredevelopmentcostsmembersrt maximummembermrk minimummembermrk maximummembermrk gaap gaap gaap gaap gaap licensingagreementsmembermrk minimummemberus gaap licensingagreementsmembermrk maximummemberus gaap licensingagreementsmembermrk regulatorymilestonesmemberus gaap licensingagreementsmembermrk salesbasedmilestonesmemberus gaap licensingagreementsmembermrk acceleronpharmaincmemberus gaap gaap collaborativearrangementtransactionwithpartytocollaborativearrangementmembermrk gileadsciencesmembermrk oralformulationmemberus gaap collaborativearrangementtransactionwithpartytocollaborativearrangementmembermrk gaap collaborativearrangementtransactionwithpartytocollaborativearrangementmembermrk gileadsciencesmembermrk artivabiotherapeuticsincmemberus gaap artivabiotherapeuticsincmemberus gaap licensingagreementsmembermrk artivabiotherapeuticsincmembermrk regulatorymilestonesmemberus gaap artivabiotherapeuticsincmembermrk salesbasedmilestonesmemberus gaap artivabiotherapeuticsincmembersrt minimummemberus gaap artivabiotherapeuticsincmembersrt maximummemberus gaap gaap seagenmembermrk salesbasedmilestonesmembermrk tukysamembermrk tukysamembermrk regulatorymilestonesmembermrk minimummembermrk tukysamembermrk tukysamembersrt maximummembermrk sentinelmemberus gaap sentinelmemberus gaap themismembermrk regulatorymilestonesmembermrk salesbasedmilestonesmembermrk arqulememberus gaap pelotonmembermrk pelotonmembermrk pelotonmembermrk minimummembermrk maximummembermrk gaap measurementinputdiscountratemembermrk lynparzamembermrk astrazenecamembermrk lynparzamembermrk astrazenecamembermrk lynparzamemberus gaap collaborativearrangementtransactionwithpartytocollaborativearrangementmembermrk lynparzamembermrk astrazenecamembermrk lynparzamembermrk astrazenecamembermrk lynparzamemberus gaap gaap salesmembermrk astrazenecamembermrk alliancerevenuelynparzamemberus gaap gaap salesmembermrk astrazenecamembermrk alliancerevenuelynparzamemberus gaap gaap salesmembermrk astrazenecamembermrk alliancerevenuelynparzamemberus gaap alliancerevenuekoselugomemberus gaap salesmembermrk astrazenecamemberus gaap alliancerevenuekoselugomemberus gaap salesmembermrk astrazenecamemberus gaap alliancerevenuekoselugomemberus gaap salesmembermrk astrazenecamemberus gaap gaap salesmembermrk astrazenecamemberus gaap gaap salesmembermrk astrazenecamemberus gaap gaap salesmembermrk astrazenecamemberus gaap astrazenecamemberus gaap costofsalesmemberus gaap astrazenecamemberus gaap costofsalesmemberus gaap astrazenecamemberus gaap costofsalesmemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk astrazenecamemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk astrazenecamemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk astrazenecamemberus gaap astrazenecamemberus gaap researchanddevelopmentexpensememberus gaap astrazenecamemberus gaap researchanddevelopmentexpensememberus gaap astrazenecamemberus gaap researchanddevelopmentexpensememberus gaap astrazenecamemberus gaap othercurrentassetsmemberus gaap astrazenecamemberus gaap othercurrentassetsmemberus gaap gaap accountspayableandaccruedliabilitiesmembermrk astrazenecamemberus gaap gaap accountspayableandaccruedliabilitiesmembermrk astrazenecamemberus gaap salesbasedmilestonesmembermrk lenvimamembermrk salesbasedmilestonesmembermrk lenvimamembermrk salesbasedmilestonesmembermrk lenvimamembermrk gaap collaborativearrangementtransactionwithpartytocollaborativearrangementmembermrk lenvimamembermrk lenvimamembermrk regulatorymilestonesmembermrk lenvimamembermrk regulatorymilestonesmembermrk gaap licensemembermrk gaap salesmemberus gaap collaborativearrangementmembermrk gaap salesmemberus gaap collaborativearrangementmembermrk gaap salesmemberus gaap collaborativearrangementmembermrk gaap costofsalesmemberus gaap collaborativearrangementmembermrk gaap costofsalesmemberus gaap collaborativearrangementmembermrk gaap costofsalesmemberus gaap collaborativearrangementmembermrk gaap sellinggeneralandadministrativeexpensesmemberus gaap collaborativearrangementmembermrk gaap sellinggeneralandadministrativeexpensesmemberus gaap collaborativearrangementmembermrk gaap sellinggeneralandadministrativeexpensesmemberus gaap collaborativearrangementmembermrk gaap researchanddevelopmentexpensememberus gaap collaborativearrangementmembermrk gaap researchanddevelopmentexpensememberus gaap collaborativearrangementmembermrk gaap researchanddevelopmentexpensememberus gaap collaborativearrangementmembermrk gaap othercurrentassetsmemberus gaap collaborativearrangementmembermrk gaap othercurrentassetsmemberus gaap collaborativearrangementmembermrk gaap accountspayableandaccruedliabilitiesmemberus gaap collaborativearrangementmembermrk gaap accountspayableandaccruedliabilitiesmemberus gaap collaborativearrangementmembermrk gaap othernoncurrentliabilitiesmemberus gaap collaborativearrangementmembermrk gaap othernoncurrentliabilitiesmemberus gaap collaborativearrangementmembermrk adempasmembermrk salesbasedmilestonesmembermrk gaap collaborativearrangementtransactionwithpartytocollaborativearrangementmembermrk adempasmemberus gaap verquvomemberus gaap gaap salesmembermrk bayeragmemberus gaap gaap salesmembermrk bayeragmemberus gaap gaap salesmembermrk bayeragmemberus gaap adempasmemberus gaap salesmembermrk bayeragmemberus gaap adempasmemberus gaap salesmembermrk bayeragmemberus gaap adempasmemberus gaap salesmembermrk bayeragmemberus gaap verquvomemberus gaap salesmembermrk bayeragmemberus gaap verquvomemberus gaap salesmembermrk bayeragmemberus gaap verquvomemberus gaap salesmembermrk bayeragmemberus gaap bayeragmemberus gaap costofsalesmemberus gaap bayeragmemberus gaap costofsalesmemberus gaap bayeragmemberus gaap costofsalesmemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk bayeragmemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk bayeragmemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk bayeragmemberus gaap gaap researchanddevelopmentexpensemembermrk bayeragmemberus gaap gaap researchanddevelopmentexpensemembermrk bayeragmemberus gaap gaap researchanddevelopmentexpensemembermrk bayeragmemberus gaap gaap othercurrentassetsmembermrk bayeragmemberus gaap gaap othercurrentassetsmembermrk bayeragmemberus gaap gaap accountspayableandaccruedliabilitiesmembermrk bayeragmemberus gaap gaap accountspayableandaccruedliabilitiesmembermrk bayeragmemberus gaap gaap salesmembermrk ridgebackbiotherapeuticslpmemberus gaap collaborativearrangementmembermrk gaap salesmembermrk ridgebackbiotherapeuticslpmemberus gaap collaborativearrangementmembermrk ridgebackbiotherapeuticslpmemberus gaap costofsalesmemberus gaap ridgebackbiotherapeuticslpmemberus gaap costofsalesmemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk ridgebackbiotherapeuticslpmemberus gaap gaap sellinggeneralandadministrativeexpensesmembermrk ridgebackbiotherapeuticslpmemberus gaap gaap researchanddevelopmentexpensemembermrk ridgebackbiotherapeuticslpmemberus gaap gaap researchanddevelopmentexpensemembermrk ridgebackbiotherapeuticslpmemberus gaap gaap accountspayableandaccruedliabilitiesmembermrk ridgebackbiotherapeuticslpmemberus gaap gaap accountspayableandaccruedliabilitiesmembermrk ridgebackbiotherapeuticslpmemberus gaap gaap costofsalesmemberus gaap accelerateddepreciationmemberus gaap gaap costofsalesmemberus gaap gaap gaap sellinggeneralandadministrativeexpensesmemberus gaap accelerateddepreciationmemberus gaap gaap sellinggeneralandadministrativeexpensesmemberus gaap gaap gaap researchanddevelopmentexpensememberus gaap accelerateddepreciationmemberus gaap gaap researchanddevelopmentexpensememberus gaap gaap gaap restructuringchargesmemberus gaap accelerateddepreciationmemberus gaap gaap restructuringchargesmemberus gaap gaap gaap gaap gaap costofsalesmemberus gaap accelerateddepreciationmemberus gaap gaap costofsalesmemberus gaap gaap gaap sellinggeneralandadministrativeexpensesmemberus gaap accelerateddepreciationmemberus gaap gaap sellinggeneralandadministrativeexpensesmemberus gaap gaap gaap researchanddevelopmentexpensememberus gaap accelerateddepreciationmemberus gaap gaap researchanddevelopmentexpensememberus gaap gaap restructuringchargesmemberus gaap accelerateddepreciationmemberus gaap gaap restructuringchargesmemberus gaap gaap gaap gaap gaap costofsalesmemberus gaap accelerateddepreciationmemberus gaap gaap costofsalesmemberus gaap gaap gaap sellinggeneralandadministrativeexpensesmemberus gaap accelerateddepreciationmemberus gaap gaap sellinggeneralandadministrativeexpensesmemberus gaap gaap gaap researchanddevelopmentexpensememberus gaap accelerateddepreciationmemberus gaap gaap researchanddevelopmentexpensememberus gaap gaap gaap restructuringchargesmemberus gaap accelerateddepreciationmemberus gaap gaap restructuringchargesmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap designatedashedginginstrumentmembersrt maximummemberus gaap gaap gaap gaap gaap othernonoperatingincomeexpensememberus gaap gaap othernonoperatingincomeexpensememberus gaap gaap othernonoperatingincomeexpensememberus gaap eurodominatednotesmemberus gaap eurodominatednotesmemberus gaap eurodominatednotesmemberus gaap gaap gaap gaap interestrateswapmembermrk gaap gaap interestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap interestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap interestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap interestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap otherassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap otherassetsmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap othercurrentliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap othernoncurrentliabilitiesmemberus gaap gaap designatedashedginginstrumentmemberus gaap othernoncurrentliabilitiesmemberus gaap gaap gaap gaap nondesignatedmemberus gaap othercurrentassetsmemberus gaap gaap nondesignatedmemberus gaap othercurrentassetsmemberus gaap gaap othercurrentliabilitiesmemberus gaap nondesignatedmemberus gaap gaap othercurrentliabilitiesmemberus gaap nondesignatedmemberus gaap gaap gaap gaap interestrateswapmemberus gaap gaap interestrateswapmemberus gaap gaap interestrateswapmemberus gaap gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmemberus gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmemberus gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap accumulatedgainlosscashflowhedgeincludingnoncontrollinginterestmemberus gaap reclassificationoutofaccumulatedothercomprehensiveincomememberus gaap gaap gaap gaap gaap salesmemberus gaap gaap salesmemberus gaap gaap salesmemberus gaap gaap interestratecontractmemberus gaap gaap interestratecontractmemberus gaap gaap interestratecontractmemberus gaap gaap researchanddevelopmentexpensememberus gaap gaap researchanddevelopmentexpensememberus gaap gaap researchanddevelopmentexpensememberus gaap gaap gaap gaap gaap gaap gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap equitysecuritiesmemberus gaap gaap gaap equitysecuritiesmemberus gaap gaap gaap equitysecuritiesmemberus gaap gaap gaap equitysecuritiesmemberus gaap gaap equitysecuritiesmemberus gaap gaap gaap equitysecuritiesmemberus gaap gaap gaap equitysecuritiesmemberus gaap gaap gaap equitysecuritiesmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap gaap gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap gaap gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap usgovernmentagenciesdebtsecuritiesmemberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap corporatedebtsecuritiesmemberus gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap corporatedebtsecuritiesmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap foreignexchangeoptionmemberus gaap gaap gaap gaap foreignexchangeoptionmemberus gaap gaap gaap foreignexchangeoptionmemberus gaap gaap foreignexchangeoptionmemberus gaap gaap foreignexchangeoptionmemberus gaap gaap gaap gaap foreignexchangeoptionmemberus gaap gaap gaap foreignexchangeoptionmemberus gaap gaap foreignexchangeoptionmemberus gaap gaap interestratecontractmemberus gaap gaap gaap interestratecontractmemberus gaap gaap gaap interestratecontractmemberus gaap gaap gaap interestratecontractmemberus gaap gaap interestratecontractmemberus gaap gaap gaap interestratecontractmemberus gaap gaap gaap interestratecontractmemberus gaap gaap gaap interestratecontractmemberus gaap gaap gaap sanofipasteurmemberus gaap gaap accountsreceivablememberus gaap customerconcentrationriskmembermrk gaap accountsreceivablememberus gaap customerconcentrationriskmembermrk gaap accountsreceivablememberus gaap customerconcentrationriskmembermrk gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap reblozylmemberus gaap zerbaxamemberus gaap gaap gaap developedtechnologyrightsmembermrk dificidmemberus gaap sivextromemberus gaap simponimemberus gaap gaap tradenamesmembermrk sotaterceptmemberus gaap nemtabrutinibmemberus gaap gefapixantmemberus gaap gaap valuationtechniquediscountedcashflowmembermrk nemtabrutinibmemberus gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap gaap gaap federalmembermrk otherstatecourtmembermrk januviamembermrk gaap gaap gaap gaap gaap gaap gaap gaap gaap usus gaap usus gaap usus gaap gaap foreignplanmemberus gaap gaap foreignplanmemberus gaap gaap foreignplanmemberus gaap gaap gaap gaap usus gaap usus gaap gaap foreignplanmemberus gaap gaap foreignplanmemberus gaap gaap gaap usus gaap gaap foreignplanmemberus gaap gaap gaap gaap gaap gaap gaap gaap usus gaap pensionplansdefinedbenefitmemberus gaap gaap usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap pensionplansdefinedbenefitmemberus gaap usus gaap pensionplansdefinedbenefitmemberus gaap gaap usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap pensionplansdefinedbenefitmemberus gaap usmrk developedmarketsequitiesinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap developedmarketsequitiesinvestmentfundsmemberus gaap usus gaap developedmarketsequitiesinvestmentfundsmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharemembermrk developedmarketsequitiesinvestmentfundsmemberus gaap usmrk developedmarketsequitiesinvestmentfundsmemberus gaap usmrk developedmarketsequitiesinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap developedmarketsequitiesinvestmentfundsmemberus gaap usus gaap developedmarketsequitiesinvestmentfundsmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharemembermrk developedmarketsequitiesinvestmentfundsmemberus gaap usmrk developedmarketsequitiesinvestmentfundsmemberus gaap usmrk emergingmarketsequitiesinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap usus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharemembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap usmrk emergingmarketsequitiesinvestmentfundsmemberus gaap usmrk emergingmarketsequitiesinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap usus gaap emergingmarketsequitiesinvestmentfundsmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharemembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap usmrk emergingmarketsequitiesinvestmentfundsmemberus gaap usmrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap usmrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap gaap usus gaap fairvaluemeasuredatnetassetvaluepersharemembermrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap usmrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap usmrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap usmrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap gaap usus gaap fairvaluemeasuredatnetassetvaluepersharemembermrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap usmrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap usmrk developedmarketsequitysecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap developedmarketsequitysecuritiesmemberus gaap usus gaap developedmarketsequitysecuritiesmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharemembermrk developedmarketsequitysecuritiesmemberus gaap usmrk developedmarketsequitysecuritiesmemberus gaap usmrk developedmarketsequitysecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap developedmarketsequitysecuritiesmemberus gaap usus gaap developedmarketsequitysecuritiesmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharemembermrk developedmarketsequitysecuritiesmemberus gaap usmrk developedmarketsequitysecuritiesmemberus gaap usus gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap pensionplansdefinedbenefitmembermrk usus gaap pensionplansdefinedbenefitmembermrk usus gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap pensionplansdefinedbenefitmembermrk usus gaap pensionplansdefinedbenefitmembermrk usmrk corporateobligationsfixedincomesecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap corporateobligationsfixedincomesecuritiesmemberus gaap usus gaap corporateobligationsfixedincomesecuritiesmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharemembermrk corporateobligationsfixedincomesecuritiesmemberus gaap usmrk corporateobligationsfixedincomesecuritiesmemberus gaap usmrk corporateobligationsfixedincomesecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap corporateobligationsfixedincomesecuritiesmemberus gaap usus gaap corporateobligationsfixedincomesecuritiesmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharemembermrk corporateobligationsfixedincomesecuritiesmemberus gaap usmrk corporateobligationsfixedincomesecuritiesmemberus gaap usus gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap pensionplansdefinedbenefitmembermrk usus gaap pensionplansdefinedbenefitmembermrk usus gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap pensionplansdefinedbenefitmembermrk usus gaap pensionplansdefinedbenefitmembermrk usus gaap pensionplansdefinedbenefitmemberus gaap otherinvestmentsmemberus gaap usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap pensionplansdefinedbenefitmemberus gaap usus gaap pensionplansdefinedbenefitmemberus gaap otherinvestmentsmemberus gaap usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap pensionplansdefinedbenefitmemberus gaap usus gaap pensionplansdefinedbenefitmemberus gaap usus gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap usus gaap gaap usus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap usus gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap usus gaap gaap usus gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap gaap gaap foreignplanmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap gaap foreignplanmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap gaap foreignplanmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap gaap gaap foreignplanmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap gaap foreignplanmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap foreignplanmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap foreignplanmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap gaap foreignplanmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap foreignplanmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap foreignplanmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap gaap foreignplanmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap foreignplanmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk realestateinvestmentfundsmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk realestateinvestmentfundsmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmembermrk developedmarketsequitysecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk developedmarketsequitysecuritiesmemberus gaap gaap gaap foreignplanmembermrk developedmarketsequitysecuritiesmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk developedmarketsequitysecuritiesmemberus gaap gaap foreignplanmembermrk developedmarketsequitysecuritiesmemberus gaap gaap foreignplanmembermrk developedmarketsequitysecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk developedmarketsequitysecuritiesmemberus gaap gaap gaap foreignplanmembermrk developedmarketsequitysecuritiesmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk developedmarketsequitysecuritiesmemberus gaap gaap foreignplanmembermrk developedmarketsequitysecuritiesmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap foreignplanmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap otherinvestmentsmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap otherinvestmentsmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap gaap gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap gaap gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap usus gaap insurancecontractsotherinvestmentsmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap insurancecontractsotherinvestmentsmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap usus gaap insurancecontractsotherinvestmentsmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap usus gaap insurancecontractsotherinvestmentsmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembermrk usus gaap gaap pensionplansdefinedbenefitmemberus gaap usus gaap gaap usus gaap insurancecontractsotherinvestmentsmemberus gaap usus gaap gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap gaap gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap gaap gaap foreignplanmembermrk insurancecontractsotherinvestmentsmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembermrk gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk developedmarketsequitiesinvestmentfundsmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk emergingmarketsequitiesinvestmentfundsmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk governmentandagencyobligationsinvestmentfundsmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk mortgageandassetbackedsecuritiesinvestmentfundsmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk developedmarketsequitysecuritiesmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk corporateobligationsfixedincomesecuritiesmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmembermrk gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap ussrt minimummemberus gaap ussrt maximummemberus gaap usus gaap definedbenefitplanequitysecuritiesnonusmembersrt usus gaap definedbenefitplanequitysecuritiesnonusmembersrt usus gaap fixedincomeinvestmentsmembersrt usus gaap fixedincomeinvestmentsmembersrt usmrk definedbenefitplancashandotherinvestmentsmembersrt ussrt minimummembersrt ussrt ussrt gaap gaap gaap gaap gaap gaap internalrevenueserviceirsmemberus gaap gaap internalrevenueserviceirsmemberus gaap segmentcontinuingoperationsmemberus gaap gaap internalrevenueserviceirsmemberus gaap domesticcountrymemberus gaap gaap internalrevenueserviceirsmemberus gaap gaap internalrevenueserviceirsmemberus gaap domesticcountrymemberus gaap gaap internalrevenueserviceirsmemberus gaap segmentcontinuingoperationsmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap keytrudamemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry keytrudamemberus gaap operatingsegmentsmembermrk internationalmembermrk keytrudamemberus gaap operatingsegmentsmembermrk keytrudamemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry keytrudamemberus gaap operatingsegmentsmembermrk internationalmembermrk keytrudamemberus gaap operatingsegmentsmembermrk keytrudamemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry keytrudamemberus gaap operatingsegmentsmembermrk internationalmembermrk keytrudamemberus gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk alliancerevenuelynparzamembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk alliancerevenuelynparzamembermrk internationalmembermrk gaap operatingsegmentsmembermrk alliancerevenuelynparzamembermrk gaap operatingsegmentsmembermrk alliancerevenuelynparzamembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk alliancerevenuelynparzamembermrk internationalmembermrk gaap operatingsegmentsmembermrk alliancerevenuelynparzamembermrk gaap operatingsegmentsmembermrk alliancerevenuelynparzamembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk alliancerevenuelynparzamembermrk internationalmembermrk gaap operatingsegmentsmembermrk alliancerevenuelynparzamembermrk gaap operatingsegmentsmembermrk lenvimamembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk lenvimamembermrk gaap operatingsegmentsmembermrk lenvimamembermrk gaap operatingsegmentsmembermrk lenvimamembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk lenvimamembermrk gaap operatingsegmentsmembermrk lenvimamembermrk gaap operatingsegmentsmembermrk lenvimamembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk lenvimamembermrk gaap operatingsegmentsmembermrk lenvimamembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk proquadmmriivarivaxmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk proquadmmriivarivaxmembermrk internationalmembermrk gaap operatingsegmentsmembermrk proquadmmriivarivaxmembermrk gaap operatingsegmentsmembermrk proquadmmriivarivaxmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk proquadmmriivarivaxmembermrk internationalmembermrk gaap operatingsegmentsmembermrk proquadmmriivarivaxmembermrk gaap operatingsegmentsmembermrk proquadmmriivarivaxmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk proquadmmriivarivaxmembermrk internationalmembermrk gaap operatingsegmentsmembermrk proquadmmriivarivaxmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk gaap operatingsegmentsmembermrk rotateqmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry rotateqmemberus gaap operatingsegmentsmembermrk internationalmembermrk rotateqmemberus gaap operatingsegmentsmembermrk rotateqmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry rotateqmemberus gaap operatingsegmentsmembermrk internationalmembermrk rotateqmemberus gaap operatingsegmentsmembermrk rotateqmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry rotateqmemberus gaap operatingsegmentsmembermrk internationalmembermrk rotateqmemberus gaap operatingsegmentsmembermrk vaqtamemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry vaqtamemberus gaap operatingsegmentsmembermrk internationalmembermrk vaqtamemberus gaap operatingsegmentsmembermrk vaqtamemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry vaqtamemberus gaap operatingsegmentsmembermrk internationalmembermrk vaqtamemberus gaap operatingsegmentsmembermrk vaqtamemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry vaqtamemberus gaap operatingsegmentsmembermrk internationalmembermrk vaqtamemberus gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usmrk gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usmrk gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usmrk gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk prevymismembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk prevymismembermrk gaap operatingsegmentsmembermrk prevymismembermrk gaap operatingsegmentsmembermrk prevymismembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk prevymismembermrk gaap operatingsegmentsmembermrk prevymismembermrk gaap operatingsegmentsmembermrk prevymismembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk prevymismembermrk gaap operatingsegmentsmembermrk prevymismembermrk gaap operatingsegmentsmembermrk primaxinmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk primaxinmembermrk gaap operatingsegmentsmembermrk primaxinmembermrk gaap operatingsegmentsmembermrk primaxinmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk primaxinmembermrk gaap operatingsegmentsmembermrk primaxinmembermrk gaap operatingsegmentsmembermrk primaxinmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk primaxinmembermrk gaap operatingsegmentsmembermrk primaxinmembermrk noxafilmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry noxafilmemberus gaap operatingsegmentsmembermrk internationalmembermrk noxafilmemberus gaap operatingsegmentsmembermrk noxafilmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry noxafilmemberus gaap operatingsegmentsmembermrk internationalmembermrk noxafilmemberus gaap operatingsegmentsmembermrk noxafilmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry noxafilmemberus gaap operatingsegmentsmembermrk internationalmembermrk noxafilmemberus gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk cancidasmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk cancidasmembermrk gaap operatingsegmentsmembermrk cancidasmembermrk gaap operatingsegmentsmembermrk cancidasmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk cancidasmembermrk gaap operatingsegmentsmembermrk cancidasmembermrk gaap operatingsegmentsmembermrk cancidasmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk cancidasmembermrk gaap operatingsegmentsmembermrk cancidasmembermrk gaap operatingsegmentsmembermrk invanzmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk invanzmembermrk internationalmembermrk gaap operatingsegmentsmembermrk invanzmembermrk gaap operatingsegmentsmembermrk invanzmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk invanzmembermrk internationalmembermrk gaap operatingsegmentsmembermrk invanzmembermrk gaap operatingsegmentsmembermrk invanzmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk invanzmembermrk internationalmembermrk gaap operatingsegmentsmembermrk invanzmembermrk gaap operatingsegmentsmembermrk zerbaxamembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk zerbaxamembermrk gaap operatingsegmentsmembermrk zerbaxamembermrk gaap operatingsegmentsmembermrk zerbaxamembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk zerbaxamembermrk gaap operatingsegmentsmembermrk zerbaxamembermrk gaap operatingsegmentsmembermrk zerbaxamembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk zerbaxamembermrk gaap operatingsegmentsmembermrk zerbaxamembermrk gaap operatingsegmentsmembermrk simponimembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk simponimembermrk gaap operatingsegmentsmembermrk simponimembermrk gaap operatingsegmentsmembermrk simponimembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk simponimembermrk gaap operatingsegmentsmembermrk simponimembermrk gaap operatingsegmentsmembermrk simponimembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk simponimembermrk gaap operatingsegmentsmembermrk simponimembermrk remicadememberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry remicadememberus gaap operatingsegmentsmembermrk internationalmembermrk remicadememberus gaap operatingsegmentsmembermrk remicadememberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry remicadememberus gaap operatingsegmentsmembermrk internationalmembermrk remicadememberus gaap operatingsegmentsmembermrk remicadememberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry remicadememberus gaap operatingsegmentsmembermrk internationalmembermrk remicadememberus gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk belsomramembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk belsomramembermrk internationalmembermrk gaap operatingsegmentsmembermrk belsomramembermrk gaap operatingsegmentsmembermrk belsomramembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk belsomramembermrk internationalmembermrk gaap operatingsegmentsmembermrk belsomramembermrk gaap operatingsegmentsmembermrk belsomramembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk belsomramembermrk internationalmembermrk gaap operatingsegmentsmembermrk belsomramembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usmrk gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usmrk gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usmrk gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk isentressisentresshdmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry isentressisentresshdmemberus gaap operatingsegmentsmembermrk internationalmembermrk isentressisentresshdmemberus gaap operatingsegmentsmembermrk isentressisentresshdmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry isentressisentresshdmemberus gaap operatingsegmentsmembermrk internationalmembermrk isentressisentresshdmemberus gaap operatingsegmentsmembermrk isentressisentresshdmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry isentressisentresshdmemberus gaap operatingsegmentsmembermrk internationalmembermrk isentressisentresshdmemberus gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usmrk gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usmrk gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry usmrk gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk adempasmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry adempasmemberus gaap operatingsegmentsmembermrk internationalmembermrk adempasmemberus gaap operatingsegmentsmembermrk adempasmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry adempasmemberus gaap operatingsegmentsmembermrk internationalmembermrk adempasmemberus gaap operatingsegmentsmembermrk adempasmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry adempasmemberus gaap operatingsegmentsmembermrk internationalmembermrk adempasmemberus gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk januviamembercountry gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk januviamembercountry gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk januviamembercountry gaap operatingsegmentsmembermrk internationalmembermrk pharmaceuticalsegmentmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembermrk janumetmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry janumetmemberus gaap operatingsegmentsmembermrk internationalmembermrk janumetmemberus gaap operatingsegmentsmembermrk janumetmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry janumetmemberus gaap operatingsegmentsmembermrk internationalmembermrk janumetmemberus gaap operatingsegmentsmembermrk janumetmemberus gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry janumetmemberus gaap operatingsegmentsmembermrk internationalmembermrk janumetmemberus gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk otherpharmaceuticalmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk otherpharmaceuticalmembermrk internationalmembermrk gaap operatingsegmentsmembermrk otherpharmaceuticalmembermrk gaap operatingsegmentsmembermrk otherpharmaceuticalmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk otherpharmaceuticalmembermrk internationalmembermrk gaap operatingsegmentsmembermrk otherpharmaceuticalmembermrk gaap operatingsegmentsmembermrk otherpharmaceuticalmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk otherpharmaceuticalmembermrk internationalmembermrk gaap operatingsegmentsmembermrk otherpharmaceuticalmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk gaap operatingsegmentsmembermrk gaap operatingsegmentsmembermrk pharmaceuticalsegmentmembercountry gaap operatingsegmentsmembermrk internationalmembermrk gaap operatingsegmentsmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembermrk livestockmembercountry animalhealthsegmentmemberus gaap operatingsegmentsmembermrk livestockmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembermrk livestockmembercountry animalhealthsegmentmemberus gaap operatingsegmentsmembermrk livestockmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembermrk livestockmembercountry animalhealthsegmentmemberus gaap operatingsegmentsmembermrk livestockmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembermrk companionanimalsmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembercountry companionanimalsmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembermrk companionanimalsmembermrk animalhealthsegmentmemberus gaap companionanimalsmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembercountry companionanimalsmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembermrk companionanimalsmembermrk animalhealthsegmentmemberus gaap companionanimalsmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembercountry companionanimalsmembermrk animalhealthsegmentmemberus gaap operatingsegmentsmembermrk companionanimalsmembermrk animalhealthsegmentmemberus gaap animalhealthsegmentmemberus gaap operatingsegmentsmembercountry animalhealthsegmentmemberus gaap operatingsegmentsmembermrk animalhealthsegmentmemberus gaap animalhealthsegmentmemberus gaap operatingsegmentsmembercountry animalhealthsegmentmemberus gaap operatingsegmentsmembermrk animalhealthsegmentmemberus gaap animalhealthsegmentmemberus gaap operatingsegmentsmembercountry animalhealthsegmentmemberus gaap operatingsegmentsmembermrk animalhealthsegmentmemberus gaap gaap allothersegmentsmemberus gaap operatingsegmentsmembercountry gaap allothersegmentsmemberus gaap operatingsegmentsmembermrk gaap allothersegmentsmemberus gaap gaap allothersegmentsmemberus gaap operatingsegmentsmembercountry gaap allothersegmentsmemberus gaap operatingsegmentsmembermrk gaap allothersegmentsmemberus gaap gaap allothersegmentsmemberus gaap operatingsegmentsmembercountry gaap allothersegmentsmemberus gaap operatingsegmentsmembermrk gaap allothersegmentsmemberus gaap gaap operatingsegmentsmembercountry gaap operatingsegmentsmembermrk gaap gaap operatingsegmentsmembercountry gaap operatingsegmentsmembermrk gaap gaap operatingsegmentsmembercountry gaap operatingsegmentsmembermrk gaap gaap corporatenonsegmentmembercountry gaap corporatenonsegmentmembermrk gaap gaap corporatenonsegmentmembercountry gaap corporatenonsegmentmembermrk gaap gaap corporatenonsegmentmembercountry gaap corporatenonsegmentmembermrk gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap filed with the security and exchange commission on february united statessecurities and exchange commissionwashington mark one annual report pursuant to section or of the security exchange act of the fiscal year ended december or transition report pursuant to section or of the security exchange act of the transition period from to commission file no _________________________________merck co inc galloping hill roadkenilworthnew new state or other jurisdiction of incorporation employer identification no security registered pursuant to section of the act title of each classtrading symbol name of each exchange on which registeredcommon stock par value mrknew york stock note due york stock note due york stock note due york stock note due york stock exchangenumber of share of common stock par value outstanding of january aggregate market value of common stock par value held by non affiliate on june based on closing price on june indicate by check mark if the registrant is well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is not required to file report pursuant to section or section of the act yes no indicate by check mark whether the registrant filed all report required to be filed by section or of the security exchange act of the preceding month or for shorter period that the registrant required to file such report and ha been subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of this chapter during the preceding month or for such shorter period that the registrant wa required to submit such file yes no indicate by check mark whether the registrant is large accelerated filer an accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act check one large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying with any new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant ha filed report on and attestation to it management assessment of the effectiveness of it internal control over financial reporting section of the sarbanes oxley act by the registered public accounting firm that prepared or issued it audit report indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no document incorporated by reference document part of form kproxy statement for the annual meeting of shareholder to be held may to be filed with the security and exchange commission within day the close of the fiscal year covered by this report part iiitable of contentstable of content pagepart iitem risk factor that may affect future unresolved staff legal mine safety officer of the iiitem market for registrant common equity related stockholder matter and issuer purchase of equity management discussion and analysis of financial condition and result of quantitative and qualitative disclosure about market financial statement and supplementary financial to consolidated financial of independent registered public accounting supplementary data change in and disagreement with accountant on accounting and financial control and other disclosure regarding foreign jurisdiction that prevent iiiitem director executive officer and corporate executive security ownership of certain beneficial owner and management and relatedstockholder certain relationship and related transaction and director principal accountant fee and ivitem exhibit and financial statement form of contentspart item business merck co inc merck or the company is global health care company that delivers innovative health solution through it prescription medicine vaccine biologic therapy and animal health product the company operation are principally managed on product basis and include two operating segment which are the pharmaceutical and animal health segment both of which are reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the company previously healthcare service segment that provided service and solution focused on engagement health analytics and clinical service to improve the value of care delivered to patient the company divested the remaining business in this segment in the first quarter of all product or service mark appearing in type form different from that of the surrounding text are trademark or service mark owned licensed to promoted or distributed by merck it subsidiary or affiliate except noted all other trademark or service mark are those of respective owner spin off of organon co on june merck completed the spin off the spin off of product from it woman health biosimilars and established brand business into new independent publicly traded company named organon co organon through distribution of organon publicly traded stock to company shareholder the established brand included in the transaction consisted of dermatology non opioid pain management respiratory select cardiovascular product well the rest of merck diversified brand franchise merck existing research pipeline program continue to be owned and developed within merck planned of contentsproduct salestotal company sale including sale of the company top pharmaceutical product well sale of animal health product follows in million sale gardasil gardasil januvia proquad ii alliance revenue lynparza pneumovax isentress isentress alliance revenue lenvima animal companion other revenue alliance revenue represents merck share of profit which are product sale net of cost of sale and commercialization cost other revenue are primarily comprised of third party manufacturing sale and miscellaneous corporate revenue including revenue hedging activity pharmaceuticalthe pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder human health vaccine product consist of preventive pediatric adolescent and adult vaccine certain of the product within the company franchise are follows oncologykeytruda pembrolizumab the company anti pd programmed death receptor therapy monotherapy for the treatment of certain patient with cervical cancer classical hodgkin lymphoma chl cutaneous squamous cell carcinoma cscc esophageal or gastroesophageal junction gej carcinoma head and neck squamous cell carcinoma hnscc hepatocellular carcinoma hcc non small cell lung cancer nsclc melanoma merkel cell carcinoma microsatellite instability high msi or mismatch repair deficient dmmr cancer solid tumor including msi dmmr colorectal cancer crc primary mediastinal large cell lymphoma pmbcl tumor mutational burden high tmb cancer solid tumor and urothelial carcinoma including non muscle invasive bladder cancer keytruda is also approved for the treatment of certain patient in combination with chemotherapy for metastatic squamous and non squamous nsclc in combination with chemotherapy for hnscc in combination with trastuzumab fluoropyrimidine and platinum containing chemotherapy for human epidermal growth factor positive gastric or gej adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy for esophageal or gej carcinoma in combination with chemotherapy with or without bevacizumab for cervical cancer in combination with chemotherapy for triple negative breast cancer tnbc in combination with axitinib for advanced renal cell carcinoma rcc and in combination with lenvatinib for endometrial carcinoma or rcc keytruda is also approved for certain patient with high risk early stage tnbc in combination with chemotherapy neoadjuvant treatment and continued single agent adjuvant treatment after surgery keytruda is also approved monotherapy for the adjuvant treatment of certain patient with rcc in addition the company recognizes alliance revenue related to sale of lynparza olaparib an oral poly adp ribose polymerase parp inhibitor for certain type of advanced ovarian breast pancreatic and prostate cancer and lenvima lenvatinib for certain type of of contentsthyroid cancer hepatocellular carcinoma in combination with everolimus for certain patient with rcc and in combination with keytruda for certain patient with endometrial carcinoma or rcc vaccinesgardasil human papillomavirus quadrivalent type and vaccine recombinant gardasil human papillomavirus valent vaccine recombinant vaccine to help prevent certain disease caused by certain type of human papillomavirus hpv proquad measles mumps rubella and varicella virus vaccine live pediatric combination vaccine to help protect measles mumps rubella and varicella ii measles mumps and rubella virus vaccine live vaccine to help prevent measles mumps and rubella varivax varicella virus vaccine live vaccine to help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine to help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine to help protect against rotavirus gastroenteritis in infant and child and vaqta hepatitis vaccine inactivated indicated for the prevention of disease caused by hepatitis virus in person month of age and older hospital acute carebridion sugammadex injection medication for the reversal of two type of neuromuscular blocking agent used during surgery prevymis letermovir for the prophylaxis of cytomegalovirus cmv reactivation and disease in adult cmv seropositive recipient of an allogeneic hematopoietic stem cell transplant primaxin imipenem and cilastatin for injection an antibiotic for the treatment of certain bacterial infection noxafil posaconazole an antifungal agent for the prevention of certain invasive fungal infection cancidas caspofungin acetate for injection an anti fungal agent for the treatment of certain fungal infection invanz ertapenem for injection an antibiotic for the treatment of certain bacterial infection and zerbaxa ceftolozane and tazobactam for injection combination antibacterial and beta lactamase inhibitor for the treatment of certain bacterial infection immunologysimponi golimumab once monthly subcutaneous treatment for certain inflammatory disease and remicade infliximab treatment for inflammatory disease both of which the company market in europe russia and turkey neurosciencebelsomra suvorexant an orexin receptor antagonist indicated for the treatment of insomnia characterized by difficulty with sleep onset and or sleep maintenance virologymolnupiravir an investigational oral antiviral covid medicine isentress isentress hd raltegravir an hiv integrase inhibitor for use in combination with other antiretroviral agent for the treatment of hiv infection cardiovascularadempas riociguat cardiovascular drug for the treatment of pulmonary arterial hypertension verquvo vericiguat medicine to reduce the risk of cardiovascular death and heart failure hospitalization following hospitalization for heart failure or need for outpatient intravenous diuretic in certain adult with symptomatic chronic heart failure and reduced ejection fraction diabetesjanuvia sitagliptin and janumet sitagliptin metformin hcl for the treatment of type diabetes animal healththe animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical vaccine and health management solution and service well an extensive suite of digitally connected identification traceability and monitoring product principal product in this segment include livestock productsnuflor florfenicol antibiotic range for use in cattle and swine bovilis vista vaccine line for infectious disease in cattle banamine flunixin meglumine bovine and swine anti inflammatory estrumate cloprostenol sodium for the treatment of fertility disorder in cattle matrix altrenogest fertility management for swine resflor florfenicol and flunixin meglumine combination broad spectrum antibiotic and non steroidal anti inflammatory of contentsdrug for bovine respiratory disease zuprevo tildipirosin for bovine respiratory disease zilmax zilpaterol hydrochloride and revalor trenbolone acetate and estradiol to improve production efficiency in beef cattle safe guard fenbendazole de wormer for cattle pac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin and circumvent porcine circovirus vaccine type killed baculovirus vector vaccine line for infectious disease in swine nobilis innovax live marek disease vector vaccine line for poultry paracox and coccivac coccidiosis vaccine exzolt systemic treatment for poultry red mite infestation slice emamectin benzoate parasiticide for sea louse in salmon aquavac avirulent live culture norvax vaccine against bacterial and viral disease in fish compact pd vaccine for salmon aquaflor florfenicol antibiotic for farm raised fish and allflex livestock intelligence solution for animal identification monitoring and traceability companion animal productsbravecto line of oral and topical parasitic control product including the original bravecto fluralaner product for dog and cat that last to week bravecto fluralaner one month monthly product for dog and bravecto plus fluralaner moxidectin two month product for cat sentinel line of oral parasitic product for dog including sentinel spectrum milbemycin oxime lufenuron and praziquantel and sentinel flavor tab milbemycin oxime lufenuron optimmune cyclosporine an ophthalmic ointment nobivac vaccine line for flexible dog and cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp and clotrimazole usp ointment mometamax gentamicin sulfate usp mometasone furoate monohydrate and clotrimazole usp otic suspension posatex orbifloxacin mometasone furoate monohydrate and posaconazole suspension ear ointment for acute and chronic otitis caninsulin vetsulin porcine insulin zinc suspension diabetes mellitus treatment for dog and cat panacur fenbendazole safeguard fenbendazole broad spectrum anthelmintic de wormer for use in many animal regumate altrenogest fertility management for horse prestige vaccine line for horse scalibor deltamethrin exspot for protecting against bite from flea tick mosquito and sandfly and sure petcare product for companion animal identification and well including the microchip and pet recovery system home for further discussion of sale of the company product see item management discussion and analysis of financial condition and result of operation below product approval and authorizationsset forth below is summary of significant product approval and authorization received by the company in productdateapprovalkeytrudajanuary commission ec approved keytruda monotherapy for the first line treatment of adult patient with msi or dmmr crc march approved keytruda monotherapy for the treatment of adult and pediatric patient aged year and older with relapsed or refractory chl have failed autologous stem cell transplant asct or following at least two prior therapy when asct is not treatment option march food and drug administration fda approved keytruda in combination with platinum and fluoropyrimidine based chemotherapy for the treatment of patient with locally advanced or metastatic esophageal or gej tumor with epicenter to centimeter the gej carcinoma that is not amenable to surgical resection or definitive chemoradiation may approved keytruda in combination with trastuzumab fluoropyrimidine and platinum containing chemotherapy for the first line treatment of patient with locally advanced unresectable or metastatic positive gastric or gej adenocarcinoma june national medical product administration nmpa approved keytruda monotherapy for the first line treatment of patient with unresectable or metastatic msi or dmmr crc that is kras nra and braf all wild type of contentskeytrudajune approved keytruda in combination with platinum and fluoropyrimidine based chemotherapy for the first line treatment of patient with locally advanced unresectable or metastatic carcinoma of the esophagus or negative gej adenocarcinoma in adult whose tumor express pd combined positive score cps july approved keytruda monotherapy for the treatment of patient with locally advanced cscc that is not curable by surgery or radiation july approved keytruda plus lenvima for the treatment of patient with advanced endometrial carcinoma that is not msi or dmmr who have disease progression following prior systemic therapy in any setting and are not candidate for curative surgery or radiation july approved keytruda for the treatment of patient with high risk early stage tnbc in combination with chemotherapy neoadjuvant treatment then continued single agent adjuvant treatment after surgery august approved keytruda for the treatment of patient with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum containing chemotherapy august pharmaceutical and medical device agency pmda approved keytruda for the treatment of patient with pd positive hormone receptor negative and negative inoperable or recurrent breast cancer august approved keytruda for the treatment of patient with unresectable advanced or recurrent msi crc august approved keytruda plus lenvima for the first line treatment of adult patient with advanced rcc september approved keytruda in combination with platinum and fluoropyrimidine based chemotherapy for first line treatment of patient with locally advanced unresectable or metastatic carcinoma of the esophageal or gej october approved keytruda in combination with chemotherapy with or without bevacizumab for the treatment of patient with persistent recurrent or metastatic cervical cancer whose tumor express pd cps determined by an fda approved test october approved keytruda in combination with chemotherapy for the first line treatment of locally recurrent unresectable or metastatic tnbc in adult whose tumor express pd cps and who have not received prior chemotherapy for metastatic disease november approved keytruda for the adjuvant treatment of patient with rcc at intermediate high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesion november approved keytruda plus lenvima first line treatment for adult patient with advanced rcc of contentskeytrudanovember approved keytruda plus lenvima for the treatment of advanced or recurrent endometrial carcinoma in adult who have disease progression on or following prior treatment with platinum containing therapy in any setting and who are not candidate for curative surgery or radiation november approved keytruda in combination with chemotherapy fluorouracil plus cisplatin for the first line treatment of patient with radically unresectable advanced or recurrent esophageal carcinoma december approved keytruda monotherapy for the adjuvant treatment of adult and pediatric year and older patient with stage iib or iic melanoma following complete resection the fda also expanded the indication for keytruda adjuvant treatment for stage iii melanoma following complete resection to include pediatric patient year and older december ministry of health labor and welfare mhlw approved keytruda in combination with lenvima for the treatment of patient with unresectable advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy lynparza june approved lynparza monotherapy for the treatment of adult patient with germline or somatic brca mutated metastatic castration resistant prostate cancer who have progressed following prior treatment that included new hormonal agent abiraterone enzalutamide molnupiravir december granted emergency use authorization eua for molnupiravir to treat mild to moderate covid in adult with positive result of direct sars cov viral testing and who are at high risk for progression to severe covid including hospitalization or death and for alternative covid treatment option authorized by the fda are not accessible or clinically appropriate december granted molnupiravir special approval for emergency for the treatment of infectious disease caused by sars cov vaxneuvancejuly approved vaxneuvance for active immunization for the prevention of invasive disease caused by streptococcus pneumoniae serotypes and in adult year of age and older december approved vaxneuvance for active immunization for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individual year of age and older verquvo january approved verquvo to reduce the risk of cardiovascular death and heart failure hf hospitalization following hospitalization for heart failure or need for outpatient intravenous iv diuretic in adult with symptomatic chronic hf and ejection fraction le july approved verquvo for the treatment of symptomatic chronic heart failure in adult patient with reduced ejection fraction who are stabilized after recent decompensation event requiring iv therapy weliregaugust approved welireg for adult patient with von hippel lindau vhl disease who require therapy for associated rcc central nervous system hemangioblastomas or pancreatic neuroendocrine tumor not requiring immediate surgery being jointly developed and commercialized in worldwide collaboration with astrazeneca being jointly developed and commercialized in worldwide collaboration with ridgeback biopharmaceuticals lp molnupiravir ha not been approved by the fda but ha been authorized for emergency use being jointly developed and commercialized in worldwide collaboration with bayer ag of contentscompetition and the health care environmentcompetitionthe market in which the company conduct it business and the pharmaceutical industry in general are highly competitive and highly regulated the company competitor include other worldwide research based pharmaceutical company smaller research company with more limited therapeutic focus generic drug manufacturer and animal health care company the company operation may be adversely affected by generic and biosimilar competition the company product mature well technological advance of competitor industry consolidation patent granted to competitor competitive combination product new product of competitor the generic availability of competitor branded product and new information from clinical trial of marketed product or post marketing surveillance in addition patent right are increasingly being challenged by competitor and the outcome can be highly uncertain an adverse result in patent dispute can preclude commercialization of product or negatively affect sale of existing product and could result in the payment of royalty or in the recognition of an impairment charge with respect to intangible asset associated with certain product pharmaceutical competition involves rigorous search for technological innovation and the ability to market these innovation effectively with it long standing emphasis on research and development the company is well positioned to compete in the search for technological innovation the company is active in acquiring and marketing product through external alliance such licensing arrangement and collaboration and ha been refining it sale and marketing effort to address changing industry condition however the introduction of new product and process by competitor may result in price reduction and product displacement even for product protected by patent for example the number of compound available to treat particular disease typically increase over time and can result in slowed sale growth or reduced sale for the company product in that therapeutic category the highly competitive animal health business is affected by several factor including regulatory and legislative issue scientific and technological advance product innovation the quality and price of the company product well competitor product effective promotional effort and the frequent introduction of generic product by competitor health care environment and government regulationglobal effort toward health care cost containment continue to exert pressure on product pricing and market access change to the health care system part of health care reform enacted in prior year well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary have contributed to pricing pressure in several international market government mandated pricing action have reduced price of generic and patented drug in addition the company revenue performance in wa negatively affected by other cost reduction measure taken by government and other third party to lower health care cost in the the biden administration and congress continue to discus legislation designed to control health care cost including the cost of drug the company anticipates all of these action and additional action in the future will continue to negatively affect revenue performance united statesthe company face increasing pricing pressure from managed care organization government agency and program that could negatively affect the company sale and profit margin including through practice of managed care organization federal and state exchange and institutional and governmental purchaser and ii federal law and regulation related to medicare and medicaid including the medicare prescription drug improvement and modernization act of and the patient protection and affordable care act aca in the federal and state government for many year have pursued method to reduce the cost of drug and vaccine for which they pay for example federal and state law require the company to pay specified rebate for medicine reimbursed by medicaid and to provide discount for medicine purchased by certain state and federal entity such the department of defense veteran affair public health service entity and hospital serving disproportionate share of low income or uninsured patient of contentsadditionally in the consolidation and integration among health care provider is major factor in the competitive marketplace for pharmaceutical product health plan and pharmacy benefit manager pbms have been consolidating into fewer larger entity thus enhancing their purchasing strength and importance private third party insurer well government employ formulary to control cost by negotiating discounted price in exchange for formulary inclusion failure to obtain timely or adequate pricing or formulary placement for merck product or obtaining such placement at unfavorable pricing could adversely affect revenue in addition to formulary tier co pay differential private health insurance company and self insured employer have been increasing the cost sharing required from beneficiary particularly for branded pharmaceutical and biotechnology product private health insurance company also are increasingly imposing utilization management tool such clinical protocol requiring prior authorization for branded product or requiring the patient to first fail on one or more generic product permitting access to branded medicine these management tool are also used in treatment area in which the payor ha taken the position that multiple branded product are therapeutically comparable the payor market concentrate further pharmaceutical company may face greater pricing pressure from private third party payors in order to provide information about the company pricing practice the company annually post on it website it pricing transparency report for the the report provides the company average annual list price net price increase and average discount across the company portfolio dating back to in the company gross sale were reduced by result of rebate discount and return legislative changesin congress actively considered multiple version of drug pricing legislation that could significantly impact branded pharmaceutical manufacturer this legislation would implement government negotiation plan for certain product covered by medicare part and institute financial penalty for price increase above inflation and redesign the medicare part program to include cap on patient of pocket cost and realign the liability for cost of the benefit among manufacturer health plan and the government it is unclear when or if this legislation will be passed by congress and it remains uncertain to other proposal if any may be included part of future federal legislative proposal that would directly or indirectly affect the company also in congress passed the american rescue plan act of which included provision that eliminates the statutory cap on rebate drug manufacturer pay to medicaid beginning in january these rebate act discount off the list price and eliminating the cap mean that manufacturer discount paid to medicaid can increase prior to this change manufacturer have not been required to pay more than of the average manufacturer price amp in rebate to state medicaid program for medicaid covered drug result of this provision beginning in it is possible that manufacturer may have to pay state medicaid program more in rebate than they received on sale of particular product this change could present risk to merck in the future for drug that have high medicaid utilization and rebate exposure that is more than of the amp the company also face increasing pricing pressure in the state which are looking to exert greater influence over the price of prescription drug number of state have passed pharmaceutical price and cost transparency law these law typically require manufacturer to report certain product price information or other financial data to the state law also require manufacturer to provide advance notification of price increase the company expects that state will continue their focus on pharmaceutical pricing and will increasingly shift to more aggressive price control tool such prescription drug affordability board that have the authority to conduct affordability review and establish upper payment limit regulatory changesin february the center for medicare medicaid service cm issued the medicaid rebate final rule that implemented provision of the aca effective april the rule provides comprehensive guidance on the calculation of amp and best price two metric used to determine the rebate drug manufacturer are required to pay to state medicaid program on december cm issued final rule making significant change to these requirement effective january this final rule change the way that manufacturer must calculate best price in relation to certain patient support program including coupon phrma pharmaceutical industry trade group of which the company is member filed complaint challenging this rule invalid asserting that it conflict of contentswith the plain language of the medicaid drug rebate statute this legal challenge fail the impact of this and other provision in this final rule could adversely impact the company business cash flow result of operation financial condition and prospect in november the department of health and human service office of inspector general issued final rule that would effective january eliminate the anti kickback statute safe harbor for rebate paid to medicare part plan or to pbms on behalf of such plan the company can not anticipate the effect of this change to the way it currently contract this new framework could significantly alter the way it doe business with part plan sponsor and pbms on behalf of such plan this rulemaking also established effective january new safe harbor for point of sale discount at the pharmacy counter and new safe harbor for certain service arrangement pharmaceutical manufacturer and pbms congress ha delayed implementation of this final rule january and pending federal legislation would repeal it entirely the pharmaceutical industry also could be considered potential source of saving via other legislative and administrative proposal that have been debated but not enacted these type of revenue generating or cost saving proposal include additional direct price control european unionefforts toward health care cost containment remain intense in the european union eu the company face competitive pricing pressure resulting from generic and biosimilar drug in addition majority of country in the eu attempt to contain drug cost by engaging in reference pricing in which authority examine pre determined market for published price of drug reference pricing may either compare product price in other market external reference pricing or compare product price with those of other product in national class internal reference pricing the authority then use the price data to set new local price for brand name drug including the company drug guideline for examining reference pricing are usually set in local market and can be changed pursuant to local regulation some eu member state have established free pricing system but regulate the pricing for drug through profit control plan others seek to negotiate or set price based on the cost effectiveness of product or an assessment of whether it offer therapeutic benefit over other product in the relevant class the downward pressure on health care cost in general particularly prescription drug ha become intense result increasingly high barrier are being erected to the entry of new product in some eu member state cross border import from low priced market also exert competitive pressure that may reduce pricing within an eu member state additionally eu member state have the power to restrict the range of pharmaceutical product for which their national health insurance system provide reimbursement in the eu pricing and reimbursement plan vary widely from member state to member state some eu member state provide that drug product may be marketed only after reimbursement price ha been agreed some eu member state may require the completion of additional study that compare the cost effectiveness of particular product candidate to already available therapy or called health technology assessment hta in order to obtain reimbursement or pricing approval the hta of pharmaceutical product is becoming an increasingly common part of the pricing and reimbursement procedure in eu member state the hta process which is governed by the national law of these country involves the assessment of the cost effectiveness public health impact therapeutic impact and or the economic and social impact of use of given pharmaceutical product in the national health care system of the individual country in which it is conducted ultimately hta measure the added value of new health technology compared to existing one the outcome of htas regarding specific pharmaceutical product will often influence the pricing and reimbursement status granted to these pharmaceutical product by the regulatory authority of individual eu member state negative hta of one of the company product may mean that the product is not reimbursable or may force the company to reduce it reimbursement price or offer discount or rebate negative hta by leading and recognized hta body could also undermine the company ability to obtain reimbursement for the relevant product outside jurisdiction for example eu member state that have not yet developed hta mechanism may rely to some extent on the hta performed in other country with developed hta framework to inform their pricing and reimbursement decision hta procedure require additional data review and administrative process all of which increase the complexity timing and cost of obtaining product reimbursement and exert downward pressure on available reimbursement of contentsto obtain reimbursement or pricing approval in some eu member state the company may be required to conduct study that compare the cost effectiveness of the company product candidate to other therapy that are considered the local standard of care there can be no assurance that any eu member state will allow favorable pricing reimbursement and market access condition for any of the company product or that it will be feasible to conduct additional cost effectiveness study if required brexitin the united kingdom uk held referendum in which voter approved an exit from the eu commonly referred to brexit result of that referendum and subsequent negotiation the uk left the eu on january transitional period applied from january until december and during this period the eu and uk operated if the uk wa an eu member state and the uk continued to participate in the eu custom union allowing for the freedom of movement for people and good it wa announced on december that the eu and the uk agreed to trade and cooperation agreement tca the tca set out the new arrangement for trade of good including medicine and vaccine which allows good to continue to flow between the eu and the uk the tca wa signed on december wa applied provisionally of january and entered into force on may result of the tca the company belief that it operation will not be materially adversely affected by brexit japanin japan the pharmaceutical industry is subject to government mandated annual price reduction of pharmaceutical product and certain vaccine furthermore the government can order pricing for specific product if it determines that use of such product will exceed certain threshold defined under applicable re pricing rule the next government mandated price reduction will occur in april chinathe company business in china ha grown rapidly in the past few year and the importance of china to the company overall pharmaceutical and vaccine business ha increased accordingly continued growth of the company business in china is dependent upon ongoing development of favorable environment for innovative pharmaceutical product and vaccine sustained access for the company current in line product and the absence of trade impediment or adverse pricing control in recent year the chinese government ha introduced and implemented number of structural reform to accelerate the shift to innovative product and reduce cost since there have been multiple new policy introduced by the government to improve access to new innovation reduce the complexity of regulatory filing and accelerate the review and approval process this ha led to significant increase in the number of new product being approved each year while the mechanism for drug being added to the government national reimbursement drug list nrdl evolves inclusion may require price negotiation which could impact the outlook in the market for selected brand in drug were added to the nrdl with an average of more than price reduction while pricing pressure ha always existed in china health care reform ha increased this pressure in part due to the acceleration of generic substitution through volume based procurement vbp in the government implemented the vbp program through tendering process for mature product which have generic substitute with generic quality consistency evaluation approval mature product that have entered into the last five round of vbp had on average price reduction of more than the company expects vbp to be semi annual process that will have significant impact on mature product moving forward emerging marketsthe company focus on emerging market in addition to china ha continued government in many emerging market are also focused on constraining health care cost and have enacted price control and measure impacting intellectual property including in exceptional case threat of compulsory license especially for covid vaccine and drug that aim to put pressure on the price of innovative pharmaceutical or result in constrained market access to innovative medicine the company anticipates that pricing pressure and market access challenge will continue in the future to varying degree in the emerging market beyond pricing and market access challenge other condition in emerging market country can affect the company effort to continue to grow in these market including potential political instability change in trade sanction and embargo significant currency fluctuation and control financial crisis limited or changing of contentsavailability of funding for health care credit worthiness of health care partner such hospital due to covid and other development that may adversely impact the business environment for the company further the company may engage third party agent to assist in operating in emerging market country which may affect it ability to realize continued growth and may also increase the company risk exposure in addressing global cost containment pressure the company engages in public policy advocacy with policymakers and continues to work to demonstrate that it medicine provide value to patient and to those who pay for health care the company advocate with government policymakers to encourage long term approach to sustainable health care financing that ensures access to innovative medicine and doe not disproportionately target pharmaceutical source of budget saving in market with historically low rate of health care spending the company encourages those government to increase their investment and adopt market reform in order to improve their citizen access to appropriate health care including medicine operating condition have become more challenging under the global pressure of competition industry regulation and cost containment effort although no one can predict the effect of these and other factor on the company business the company continually take measure to evaluate adapt and improve the organization and it business practice to better meet customer need and belief that it is well positioned to respond to the evolving health care environment and market force regulationthe pharmaceutical industry is also subject to regulation by regional country state and local agency around the world focused on standard and process for determining drug safety and effectiveness well condition for sale or reimbursement of particular importance is the fda in the which administers requirement covering the testing approval safety effectiveness manufacturing labeling and marketing of prescription pharmaceutical in some case the fda requirement and practice have increased the amount of time and resource necessary to develop new product and bring them to market in the at the same time the fda ha committed to expediting the development and review of product bearing the breakthrough therapy designation which ha accelerated the regulatory review process for medicine with this designation the fda ha also undertaken effort to bring generic competition to market more efficiently and in more timely manner the eu ha adopted directive and other legislation concerning the classification approval for marketing labeling advertising manufacturing wholesale distribution integrity of the supply chain pharmacovigilance and safety monitoring of medicinal product for human use these provide mandatory standard throughout the eu which may be supplemented or implemented with additional regulation by the eu member state in particular eu regulator may approve product subject to number of post authorization condition example of typical post authorization commitment include additional pharmacovigilance the conduct of clinical trial the establishment of patient registry physician or patient education and controlled distribution and prescribing arrangement non compliance with post authorization condition pharmacovigilance and other obligation can lead to regulatory action including the variation suspension or withdrawal of the marketing authorization or other enforcement or regulatory action including the imposition of financial penalty the company policy and procedure are already consistent with the substance of these directive consequently it is believed that they will not have any material effect on the company business the company belief that it will continue to be able to conduct it operation including launching new drug in this regulatory environment see research and development below for discussion of the regulatory approval process access to medicinesas global health care company merck primary role is to discover and develop innovative medicine and vaccine the company also recognizes that in collaboration with key stakeholder it ha role to play in helping to ensure that it science advance health care and it product are accessible and affordable the company is committed to ensuring reliable safe global supply of it quality medicine and vaccine and to developing testing and implementing innovative solution that address barrier to access and affordability of it medicine and vaccine the company approach is designed to enable it to serve the greatest number of patient today while of contentsmeeting the need of patient in the future the company effort in this regard are wide ranging and include set of principle that the company strives to embed into it operation and business strategy to guide the company worldwide approach to expanding access to health care in addition through innovative social investment including philanthropic program and impact investing merck is also helping to strengthen health system and build capacity particularly in under resourced community the merck patient assistance program provides medicine and adult vaccine for free to people in the who not have prescription drug or health insurance coverage and who without the company assistance can not afford their merck medicine and vaccine merck ha funded merck for mother long term effort with global health partner to end preventable death from complication of pregnancy and childbirth merck ha also provided fund to the merck foundation an independent grantmaking organization which ha partnered with variety of organization dedicated to improving global health privacy and data protectionthe company is subject to significant number of privacy and data protection law and regulation globally many of which place restriction on the company ability to transfer access and use personal data across it business the legislative and regulatory landscape for privacy and data protection continues to evolve there ha been increased attention to privacy and data protection issue in both developed and emerging market with the potential to affect directly the company business including the eu general data protection regulation gdpr which went into effect in may and imposes penalty of up to of global revenue the gdpr and related implementing law in individual eu member state govern the collection and use of personal health data and other personal data in the eu the gdpr increased responsibility and liability in relation to personal data that the company process it also imposes number of strict obligation and restriction on the ability to process which includes collection analysis and transfer of personal data including health data from clinical trial and adverse event reporting the gdpr also includes requirement relating to the consent of the individual to whom the personal data relates the information provided to the individual prior to processing their personal data or personal health data notification of data processing obligation to the national data protection authority and the security and confidentiality of the personal data further the gdpr prohibits the transfer of personal data to country outside of the eu that are not considered by the ec to provide an adequate level of data protection including to the except if the data controller meet very specific requirement following the schrems ii decision of the court of justice of the eu on july there is considerable uncertainty to the permissibility of international data transfer under the gdpr in light of the implication of this decision the company may face difficulty regarding the transfer of personal data from the eu to third country failure to comply with the requirement of the gdpr and the related national data protection law of the eu member state may result in significant monetary fine and other administrative penalty well civil liability claim from individual whose personal data wa processed data protection authority from the different eu member state may still implement certain variation enforce the gdpr and national data protection law differently and introduce additional national regulation and guideline which add to the complexity of processing personal data in the eu guidance developed at both the eu level and at the national level in individual eu member state concerning implementation and compliance practice is often updated or otherwise revised there is moreover growing trend towards required public disclosure of clinical trial data in the eu which add to the complexity of obligation relating to processing health data from clinical trial failing to comply with these obligation could lead to government enforcement action and significant penalty against the company harm to it reputation and adversely impact it business and operating result the uncertainty regarding the interplay between different regulatory framework further add to the complexity that the company face with regard to data protection regulation on august china national people congress passed the personal information protection law pipl that aim to standardize the handling of personal information in china which became effective on november the pipl currently applies to the processing of personal information of natural person in china the processing of personal information outside china the purpose is to provide product and service in china and to analyze the activity of individual in china while similar to the gdpr the pipl contains unique requirement not found in the gdpr of contentsthe company ha developed and implemented comprehensive plan to ensure compliance with the pipl with those relating to data localization and cross border transfer yet to be completed pending forthcoming guidance from the cyberspace administration of china additional law and regulation enacted in the such the california consumer privacy act europe asia and latin america have increased enforcement and litigation activity in the and other developed market well increased regulatory cooperation among privacy authority globally the company ha adopted comprehensive global privacy program to manage these evolving requirement and risk and to facilitate the transfer of personal information across international border distributionthe company sell it human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pbms and other institution human health vaccine are sold primarily to physician wholesaler physician distributor and government entity the company professional representative communicate the effectiveness safety and value of the company pharmaceutical and vaccine product to health care professional in private practice group practice hospital and managed care organization the company sell it animal health product to veterinarian distributor and animal producer patent trademark and licensespatent protection is considered in the aggregate to be of material importance to the company marketing of it product in the and in most major foreign market patent may cover product per se pharmaceutical formulation process for or intermediate useful in the manufacture of product or the us of product protection for individual product extends for varying period in accordance with the legal life of patent in the various country the protection afforded which may also vary from country to country depends upon the type of patent and it scope of coverage the food and drug administration modernization act includes pediatric exclusivity provision that may provide an additional six month of market exclusivity in the for indication of new or currently marketed drug if certain agreed upon pediatric study are completed by the applicant current patent law provides additional patent term for period when the patented product wa under regulatory review by the fda the eu also provides an additional six month of pediatric market exclusivity attached to product supplementary protection certificate spc japan provides the additional term for pediatric study attached to market exclusivity unrelated to patent term patent portfolio developed for product introduced by the company normally provide market exclusivity the company ha the following key patent protection in the the eu japan and china including the potential for patent term extension pte and spcs where indicated for the following marketed product of contentsproductyear of expiration year of expiration eu year of expiration japan year of expiration china an lenvima spcs with pending pte patent spcs agardasil patent spcs with pending pte patent spcs patent spcs with pending pte aadempas with pending pte patent spcs asegluromet with pending pte patent spcs with pending pte patent spcs with pending pte patent spcs with pending pte with pending pte no patentn an with pending pte patent spcs with pending pte patent spcs with pending pte an an with pending pte an an anote compound patent unless otherwise noted certain of the product listed may be the subject of patent litigation see item financial statement and supplementary data note contingency and environmental liability below currently no marketing approval the eu date represents the expiration date for the following four country france germany italy and spain major eu market if spc application have been filed but have not been granted in all major eu market both the patent expiry date and the spc expiry date are listed the pte system in japan allows for patent to be extended more than once provided the later approval is directed to different indication from that of the previous approval this may result in multiple pte approval for given patent each with it expiration date eligible for month pediatric exclusivity expiry date reflects the approved product and includes granted pte for the mg tablet in japan the company ha no marketing right in the japan or china the distribution agreement with janssen pharmaceutical inc expires on october part of global strategic oncology collaboration with eisai co ltd part of global strategic oncology collaboration with astrazeneca being commercialized in worldwide collaboration with bayer ag the company ha no marketing right in the being commercialized and promoted in worldwide except japan collaboration with pfizer inc the company ha no marketing right in japan the company ha no marketing right in the eu japan or china of contentsthe company ha the following key patent protection for drug candidate under review in the by the fda additional patent term may be provided for these pipeline candidate based on patent term restoration and pediatric exclusivity under review in the currently anticipatedyear of expiration in the mk gefapixant company also ha the following key patent protection for drug candidate in phase development phase drug candidatecurrently anticipatedyear of expiration in the mk islatravir sotatercept doravirine islatravir pending pte for doravirine mk quavonlimab pembrolizumab vibostolimab pembrolizumab favezelimab pembrolizumab clesrovimab molnupiravir received emergency use authorization from the fda for the treatment of high risk adult with mild to moderate covid unless otherwise noted the patent in the above chart are compound patent each patent may be subject to future patent term restoration of up to five year and six month pediatric market exclusivity either or both of which may be available in addition depending on the circumstance surrounding any final regulatory approval of the compound there may be other listed patent or patent application pending that could have relevance to the product finally approved the relevance of any such application would depend upon the claim that ultimately may be granted and the nature of the final regulatory approval of the product also regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and in some case may provide more effective or longer lasting marketing exclusivity than compound patent estate in the the data protection generally run five year from first marketing approval of new chemical entity extended to seven year for an orphan drug indication and year from first marketing approval of biological product while the expiration of compound patent normally result in loss of market exclusivity for the covered pharmaceutical product commercial benefit may continue to be derived from later expiring patent on process and intermediate related to the most economical method of manufacture of the active ingredient of such product ii patent relating to the use of such product iii patent relating to novel composition and formulation and iv in the and certain other country market exclusivity that may be available under relevant law the effect of product patent expiration on pharmaceutical product also depends upon many other factor such the nature of the market and the position of the product in it the growth of the market the complexity and economics of the process for manufacture of the active ingredient of the product and the requirement of new drug provision of the federal food drug and cosmetic act or similar law and regulation in other country addition to market exclusivity are sought in the and other country through all relevant law including law increasing patent life some of the benefit of increase in patent life have been partially offset by an increase in the number of incentive for and use of generic product additionally improvement in intellectual property law are sought in the and other country through reform of patent and other relevant law and implementation of international treaty for further information with respect to the company patent see item risk factor and item financial statement and supplementary data note contingency and environmental liability below worldwide all of the company important product are sold under trademark that are considered in the aggregate to be of material importance trademark protection continues in some country long used in other country long registered registration is for fixed term and can be renewed indefinitely of contentsroyalty income in on patent and know license and other right amounted to million merck also incurred royalty expense amounting to billion in under patent and know how license it hold research and developmentthe company business is characterized by the introduction of new product or new us for existing product through strong research and development program at december approximately people were employed in the company research activity the company prioritizes it research and development effort and focus on candidate that it belief represent breakthrough science that will make difference for patient and payer the company maintains number of long term exploratory and fundamental research program in biology and chemistry well research program directed toward product development the company research and development model is designed to increase productivity and improve the probability of success by prioritizing the company research and development resource on candidate the company belief are capable of providing unambiguous promotable advantage to patient and payer and delivering the maximum value of it approved medicine and vaccine through new indication and new formulation merck is pursuing emerging product opportunity independent of therapeutic area or modality small molecule biologics and vaccine and is building it biologics capability the company is committed to ensuring that externally sourced program remain an important component of it pipeline strategy with focus on supplementing it internal research with licensing and external alliance strategy focused on the entire spectrum of collaboration from early research to late stage compound well access to new technology the company clinical pipeline includes candidate in multiple disease area including cancer cardiovascular disease metabolic disease infectious disease neuroscience respiratory disease and vaccine in the development of human health product industry practice and government regulation in the and most foreign country provide for the determination of effectiveness and safety of new chemical compound through pre clinical test and controlled clinical evaluation before new drug or vaccine may be marketed in the recorded data on pre clinical and clinical experience are included in the new drug application nda for drug or the biologics license application bla for vaccine or biologic submitted to the fda for the required approval once the company scientist discover new small molecule compound or biologic that they believe ha promise to treat medical condition the company commences pre clinical testing with that compound pre clinical testing includes laboratory testing and animal safety study to gather data on chemistry pharmacology immunogenicity and toxicology pending acceptable pre clinical data the company will initiate clinical testing in accordance with established regulatory requirement the clinical testing begin with phase study which are designed to ass safety tolerability pharmacokinetics and preliminary pharmacodynamic activity of the compound in human if favorable additional larger phase study are initiated to determine the efficacy of the compound in the affected population define appropriate dosing for the compound well identify any adverse effect that could limit the compound usefulness in some situation the clinical program incorporates adaptive design methodology to use accumulating data to decide how to modify aspect of the ongoing clinical study it continues without undermining the validity and integrity of the trial one type of adaptive clinical trial is an adaptive phase trial design two stage trial design consisting of phase proof of concept stage and phase dose optimization finding stage if data from the phase trial are satisfactory the company commences large scale phase trial to confirm the compound efficacy and safety another type of adaptive clinical trial is an adaptive phase trial design study that includes an interim analysis and an adaptation that change the trial from feature common in phase study multiple dose group to design similar to phase trial an adaptive phase trial design reduces timeline by eliminating activity which would be required to start separate study upon completion of phase trial if satisfactory the company submits regulatory filing with the appropriate regulatory agency around the world to have the product candidate approved for marketing there can be no assurance that compound that is the result of any particular program will obtain the regulatory approval necessary for it to be marketed of contentsvaccine development follows the same general pathway for drug pre clinical testing focus on the vaccine safety and ability to elicit protective immune response immunogenicity pre marketing vaccine clinical trial are typically done in three phase initial phase clinical study are conducted in normal subject to evaluate the safety tolerability and immunogenicity of the vaccine candidate phase study are dose ranging study finally phase trial provide the necessary data on effectiveness and safety if successful the company submits regulatory filing with the appropriate regulatory agency in the the fda review process begin once complete nda or bla is submitted received and accepted for review by the agency within day after receipt the fda determines if the application is sufficiently complete to permit substantive review the fda also ass at that time whether the application will be granted priority review or standard review pursuant to the prescription drug user fee act pdufa the fda review period target for ndas or original blas is either six month for priority review or ten month for standard review from the time the application is deemed sufficiently complete once the review timeline are determined the fda will generally act upon the application within those timeline unless major amendment ha been submitted either at the company own initiative or the fda request to the pending application if this occurs the fda may extend the review period to allow for review of the new information but by no more than three month extension to the review period are communicated to the company the fda can act on an application either by issuing an approval letter or by issuing complete response letter crl stating that the application will not be approved in it present form and describing all deficiency that the fda ha identified should the company wish to pursue an application after receiving crl it can resubmit the application with information that address the question or issue identified by the fda in order to support approval resubmissions are subject to review period target which vary depending on the underlying submission type and the content of the resubmission the fda ha four program designation fast track breakthrough therapy accelerated approval and priority review to facilitate and expedite development and review of new drug to address unmet medical need in the treatment of serious or life threatening condition the fast track designation provides pharmaceutical manufacturer with opportunity for frequent interaction with fda reviewer during the product development and the ability for the manufacturer to do rolling submission of the nda bla rolling submission allows completed portion of the application to be submitted and reviewed by the fda on an ongoing basis the breakthrough therapy designation provides manufacturer with all of the feature of the fast track designation well intensive guidance on implementing an efficient development program for the product and commitment by the fda to involve senior manager and experienced staff in the review the accelerated approval designation allows the fda to approve product based on an effect on surrogate or intermediate endpoint that is reasonably likely to predict product clinical benefit and generally requires the manufacturer to conduct required post approval confirmatory trial to verify the clinical benefit the priority review designation mean that the fda goal is to take action on the nda bla within six month compared to ten month under standard review more than one of these special designation can be granted for given application product designated breakthrough therapy may also be eligible for priority review due to the covid public health crisis the secretary of health and human service ha exercised statutory authority to determine that public health emergency exists and declared these circumstance justify the emergency use of drug and biological product authorized by the fda while in effect this declaration enables the fda to issue emergency use authorization euas permitting distribution and use of specific medical product absent nda bla submission or approval including product to treat or prevent disease or condition caused by the sars cov virus subject to the term of any such euas the fda must make certain finding to grant an eua including that it is reasonable to believe based on the totality of evidence that the drug or biologic may be effective and that known or potential benefit when used under the term of the eua outweigh known or potential risk additionally the fda must find that there is no adequate approved and available alternative to the emergency use the fda may revise or revoke an eua if the circumstance justifying it issuance no longer exist the criterion for it issuance are no longer met or other circumstance make revision or revocation appropriate to protect the public health or safety the primary method the company us to obtain marketing authorization of pharmaceutical product in the eu is through the centralized procedure this procedure is compulsory for certain pharmaceutical product in particular those using biotechnological process and is also available for certain new chemical compound and product company seeking to market an innovative pharmaceutical product through the centralized procedure of contentsmust file complete set of safety data and efficacy data part of marketing authorization application maa with the european medicine agency ema after the ema evaluates the maa it provides recommendation to the ec and the ec then approves or denies the maa it is also possible for new chemical product to obtain marketing authorization in the eu through mutual recognition procedure in which an application is made to single member state and if the member state approves the pharmaceutical product under national procedure the applicant may submit that approval to the mutual recognition procedure of some or all other eu member state outside of the and the eu the company submits marketing application to national regulatory authority example of such are the ministry of health labour and welfare in japan the national medical product administration in china health canada agncia nacional de vigilncia sanatria in brazil korea food and drug administration in south korea and the therapeutic good administration in australia each country ha separate and independent review process and timeline in many market approval time can be longer the regulatory authority requires approval in major market such the or the eu and issuance of certificate of pharmaceutical product from that market before initiating their local review process research and development updatethe company currently ha several candidate under regulatory review in the and internationally or in late stage clinical development mk molnupiravir is an investigational oral antiviral medicine for the treatment of mild to moderate covid in adult who are at risk for progressing to severe disease merck is developing molnupiravir in collaboration with ridgeback biotherapeutics lp the fda granted emergency use authorization eua for molnupiravir in december updated in february to authorize molnupiravir for the treatment of mild to moderate covid in adult with positive result of direct sars cov viral testing and who are at high risk for progression to severe covid including hospitalization or death and for whom alternative covid treatment option approved or authorized by the fda are not accessible or clinically appropriate the authorization is based on the phase move out trial molnupiravir is not approved for any use in the and is authorized only for the duration of the declaration that circumstance exist justifying the authorization of it emergency use under the food drug and cosmetic act unless the authorization is terminated or revoked sooner molnupiravir ha also received conditional marketing authorization in the uk and special approval for emergency in japan in november the ema issued positive scientific opinion for molnupiravir which is intended to support national decision making on the possible use of molnupiravir prior to marketing authorization in october the ema initiated rolling review for molnupiravir for the treatment of covid in adult merck plan to work with the committee for medicinal product for human use of the ema to complete the rolling review process to facilitate initiating the formal review of the maa application to other regulatory body worldwide are underway molnupiravir is also being evaluated for post exposure prophylaxis in the phase move ahead trial which is evaluating the efficacy and safety of molnupiravir for the prevention of covid in adult who reside with person with covid previously announced data from the move in clinical trial indicated that molnupiravir is unlikely to demonstrate clinical benefit in hospitalized patient who generally had longer duration of symptom prior to study entry therefore the decision wa made not to proceed to phase mk gefapixant is an investigational orally administered selective receptor antagonist for the treatment of refractory chronic cough or unexplained chronic cough in adult under review by the fda the nda for gefapixant is based on result from the cough and cough clinical trial in january the fda issued complete response letter crl regarding merck nda for gefapixant in the crl the fda requested additional information related to measurement of efficacy the crl wa not related to the safety of gefapixant merck is reviewing the letter and considering next step gefapixant is also under review in the eu although the review period ha been extended pending the receipt of additional information from the company is an investigational valent pneumococcal conjugate vaccine under review in japan for use in adult wa approved in the in for use in adult where it is marketed vaxneuvance vaxneuvance is also under priority review by the fda for the prevention of invasive pneumococcal disease in child week through year of age the fda grant priority review to medicine and vaccine that if approved would provide significant improvement in the safety or effectiveness of the treatment or prevention of serious condition the fda set pdufa date of april the supplemental bla is supported by result from phase and phase clinical study in pediatric population including infant child and adolescent of contentsmk keytruda is an anti pd therapy approved for the treatment of many cancer that is in clinical development for expanded indication these approval were the result of broad clinical development program that currently consists of more than clinical trial including more than trial that combine keytruda with other cancer treatment these study encompass more than cancer type including biliary estrogen receptor positive breast cancer cervical colorectal cutaneous squamous cell endometrial esophageal gastric glioblastoma head and neck hepatocellular hodgkin lymphoma non hodgkin lymphoma non small cell lung small cell lung melanoma mesothelioma ovarian prostate renal triple negative breast and urothelial many of which are currently in phase clinical development further trial are being planned for other cancer keytruda is under review in the eu for the adjuvant treatment of adult and pediatric year and older patient with stage iib or iic melanoma following complete resection based on data from the phase keynote trial keytruda is under review in japan for the adjuvant treatment of patient with rcc at intermediate high or high risk of recurrence following nephrectomy surgical removal of kidney based on data from the phase keynote trial keytruda is under review by the fda for the treatment of patient with advanced endometrial cancer that is msi or dmmr who have disease progression following prior systemic therapy in any setting and are not candidate for curative surgery or radiation this submission is based on data from the keynote trial the fda set pdufa date of march keytruda is under review in the eu for the treatment of unresectable or metastatic msi or dmmr colorectal endometrial gastric small intestine biliary or pancreatic cancer in adult who have received prior therapy the proposed indication is based on the result from the keynote and keynote trial keytruda in combination with chemotherapy is under review in the eu and japan for the treatment of patient with high risk early stage tnbc neoadjuvant treatment and then single agent adjuvant treatment after surgery based on data from the keynote trial keytruda is under review in japan for treatment of adult patient with advanced or recurrent tmb solid tumor that have progressed after chemotherapy limited to use when difficult to treat with standard of care based on the keynote trial keytruda in combination with chemotherapy with or without bevacizumab is also under review in the eu and japan for the first line treatment of patient with persistent recurrent or metastatic cervical cancer based on the keynote trial in january merck the european organisation for research and treatment of cancer and the european thoracic oncology platform announced that the phase keynote trial investigating keytruda met one of it dual primary endpoint of disease free survival dfs for the adjuvant treatment of patient with stage ib iiia nsclc following surgical resection regardless of pd expression based on an interim analysis review conducted by an independent data monitoring committee adjuvant treatment with keytruda resulted in statistically significant and clinically meaningful improvement in dfs compared with placebo in the all comer population of patient with stage ib iiia nsclc at the interim analysis there wa also an improvement in dfs for patient whose tumor express pd tumor proportion score tps treated with keytruda compared to placebo however this dual primary endpoint not meet statistical significance per the pre specified statistical plan the trial will continue to analyze dfs in patient whose tumor express high level of pd tps and evaluate overall survival key secondary endpoint result will be presented at an upcoming medical meeting and will be submitted to regulatory authority mk lynparza is an oral parp inhibitor currently approved for certain type of advanced ovarian breast pancreatic and prostate cancer being co developed for multiple cancer type part of collaboration with astrazeneca plc in november the fda accepted for priority review supplemental nda for lynparza for the adjuvant treatment of patient with brca mutated human epidermal growth factor receptor negative high risk early stage breast cancer who have already been treated with chemotherapy either before or after surgery based on the result from the phase olympia trial the fda set pdufa date during the first quarter of of contentsthis indication is also under review in the eu lynparza is also under review in the eu for the treatment of certain patient with metastatic castration resistant prostate cancer based on the propel clinical trial mk lenvima is an oral receptor tyrosine kinase inhibitor being developed part of collaboration with eisai co ltd eisai merck and eisai are studying the keytruda plus lenvima combination through the leap lenvatinib and pembrolizumab clinical program that includes phase study across different tumor type biliary cancer crc endometrial carcinoma esophageal cancer gastric cancer glioblastoma hcc hnscc melanoma pancreatic cancer prostate cancer nsclc sclc and rcc in july merck and eisai announced that the fda issued crl regarding merck and eisai application seeking accelerated approval for the first line treatment of patient with unresectable hcc based on the keynote study trial ahead of the pdufa action date of merck and eisai application another combination therapy wa approved based on randomized controlled trial that demonstrated improvement in overall survival versus standard of care treatment consequently the crl stated that merck and eisai application do not provide evidence that keytruda in combination with lenvima represents meaningful advantage over available therapy for the treatment of unresectable or metastatic hcc with no prior systemic therapy for advanced disease since the application for keynote study no longer meet the criterion for accelerated approval both company plan to work with the fda to take appropriate next step which include conducting well controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination such leap the phase trial evaluating the keytruda plus lenvima combination first line treatment for advanced hcc is currently underway and fully enrolled the crl doe not impact the current approved indication for keytruda or for lenvima merck and eisai have stopped leap the phase study evaluating the first line treatment of lenvima in combination with keytruda in participant with metastatic squamous or non squamous nsclc whose tumor are pd positive with no egfr or alk genomic tumor aberration the trial ha been discontinued following the recommendation of the external data monitoring committee edmc which met scheduled to ass safety and futility the edmc determined that the study had met the criterion for declaring futility and the benefit risk profile of the combination did not support continuing the trial merck and eisai have closed leap for further enrollment leap is phase study evaluating lenvima in combination with keytruda for the first line treatment of patient with platinum ineligible urothelial carcinoma enrollment wa closed following the recommendation of the edmc which met scheduled to ass safety and futility the edmc determined that the benefit risk profile of the combination did not support continuing the trial and improvement in outcome in favor of the combination were unlikely to be high initially hypothesized the company also ha several other program in phase clinical development mk is the coformulation of quavonlimab merck novel investigational anti ctla antibody with pembrolizumab being evaluated for the treatment of rcc subcutaneous mk pembrolizumab is being evaluated for comparability with the intravenous formulation in nsclc mk is the coformulation of favezelimab merck novel investigational anti therapy with pembrolizumab being evaluated for the treatment of crc mk welireg belzutifan is hypoxia inducible factor hif inhibitor being evaluated for supplemental indication for the treatment of patient with rcc mk tukysa is small molecule tyrosine kinase inhibitor for the treatment of positive cancer in development for the treatment of breast cancer in september seagen granted merck an exclusive license and entered into co development agreement with merck to accelerate the global reach of tukysa mk is the coformulation of vibostolimab an anti tigit therapy with pembrolizumab being evaluated for the treatment of nsclc in december merck announced that the fda had placed clinical hold on the investigational new drug application for the oral and implant formulation of islatravir mk for hiv pre exposure prophylaxis of content prep the injectable formulation of islatravir for hiv treatment and prophylaxis and the oral doravirine islatravir mk hiv once daily treatment regimen the fda clinical hold is based on observation of decrease in total lymphocyte and cell count in some participant receiving islatravir in clinical study merck previously announced it had stopped dosing in the phase imagine dr clinical trial of islatravir in combination with mk mk and paused enrollment in the once monthly phase prep study mk and mk with the fda clinical hold no new study may be initiated additionally merck and gilead have made the decision to stop all dosing of participant in the phase clinical study evaluating an oral weekly combination treatment regimen of islatravir and gilead investigational lenacapavir in people living with hiv who are virologically suppressed on antiretroviral therapy this decision follows the joint announcement on november of temporary hold on further enrollment and screening in the study which commenced in october the two company will ass whether different dosing of islatravir in combination with lenacapavir may provide once weekly oral therapy option for people living with hiv merck and gilead remain committed to their collaboration which aim to develop long acting new treatment option to address the unmet need for people living with hiv mk sotatercept is potentially first in class therapy for the treatment of pulmonary arterial hypertension pah sotatercept is in clinical trial an add on to current standard of care for the treatment of pah sotatercept wa obtained in connection with merck acquisition of acceleron pharma inc in mk clesrovimab is respiratory syncytial virus rsv monoclonal antibody that is being evaluated for the prevention of rsv medically attended lower respiratory tract infection in infant and certain child over year of age in april merck announced the discontinuation of development of mk which wa being evaluated for the treatment of hospitalized patient with covid merck obtained mk in december through it acquisition of oncoimmune privately held clinical stage biopharmaceutical company in merck received feedback from the fda that additional data would be needed to support potential eua application and therefore the company did not expect mk would become available until the first half of given this timeline and the technical clinical and regulatory uncertainty the availability of number of medicine for patient hospitalized with covid and the need to concentrate merck resource on accelerating the development and manufacture of the most viable therapeutic and vaccine merck decided to discontinue development of mk for the treatment of covid in september the fda approved updated labeling for steglatro steglujan and segluromet medicine for adult with type diabetes to include the primary efficacy and safety result from the vertis cv trial which assessed the effect of steglatro compared with placebo on cardiovascular outcome in adult patient with type diabetes and established atherosclerotic cardiovascular disease the fda issued crl concerning the company application for new indication based on additional result from the vertis cv trial to reduce the risk of hospitalization for heart failure the company ha determined not to pursue the indication the chart below reflects the company research pipeline of february candidate shown in phase include specific product and the date such candidate entered into phase development candidate shown in phase include the most advanced compound with specific mechanism or if listed compound have the same mechanism they are each currently intended for commercialization in given therapeutic area small molecule and biologics are given mk number designation and vaccine candidate are given number designation except otherwise noted candidate in phase additional indication in the same therapeutic area other than with respect to cancer and additional claim line extension or formulation for in line product are not shown of contentsphase phase entry date under reviewcancermk non small cell lungmk nemtabrutinib hematological malignanciesmk quavonlimab non small cell lungmk quavonlimab pembrolizumab advanced solid tumor colorectalhepatocellular melanomasmall cell lungmk zilovertamab vedotin breasthematological malignanciesnon small cell lungmk keytrudaadvanced solid tumorsmk favezelimab hematological malignanciesnon small cell lungmk favezelimab pembrolizumab renal cellsmall cell lungmk non small cell lungrenal cellsmall cell lungmk non small cell lungsmall cell lungmk ladiratuzumab vedotin breastesophagealgastrichead and neckmelanomanon small cell lungprostatesmall cell lungmk welireg biliarycolorectalhepatocellularpancreaticrare cancersvon hippel lindau disease associated tumor eu mk tukysa advanced solid tumorsbiliarybladdercervicalcolorectalendometrialgastricnon small cell lungmk lynparza advanced solid tumorsmk vibostolimab melanoma mk vibostolimab pembrolizumab biliarybreastcervicalendometrialesophagealhead and neckhematological malignancieshepatocellularprostatemk lenvima biliaryglioblastomapancreaticprostatesmall cell squamous cellhead and neckmelanomasolid tumorscardiovascularmk virus infectionmk islatravir mk mk islatravir lenacapavir nonalcoholic steatohepatitis nash mk syndromemk miransertib pneumococcal vaccine arterial hypertensionmk resistant depressionmk covid molnupiravir may cancermk quavonlimab pembrolizumab renal cell april mk keytruda biliary september cutaneous squamous cell august eu gastric may eu hepatocellular may eu mesothelioma may ovarian december prostate may small cell lung may mk pembrolizumab subcutaneous non small cell lung august mk favezelimab pembrolizumab colorectal november mk welireg renal cell february mk tukysa breast october mk lynparza colorectal august non small cell lung june small cell lung december mk vibostolimab pembrolizumab non small cell lung april mk lenvima colorectal april esophageal july gastric december head and neck february melanoma march non small cell lung march hiv infection mk doravirine islatravir february hiv preventionmk islatravir february pulmonary arterial hypertensionmk sotatercept january respiratory syncytial virusmk clesrovimab november new molecular entity vaccinesantiviral covid molnupiravir eu coughmk gefapixant eu pneumococcal vaccine jpn certain supplemental filingscancermk keytruda adjuvant treatment of stage iib or iic melanoma keynote eu adjuvent renal cell cancer keynote jpn msi or dmmr endometrial cancer keynote msi or dmmr six tumor basket keynote eu high risk early stage triple negative breast cancer keynote eu jpn tumor mutational burden high keynote jpn cervical cancer keynote eu jpn mk lynparza brca mutated negative adjuvant breast cancer olympia eu first line metastatic prostate cancer propel eu mk lenvima first line metastatic hepatocellular carcinoma keynote advanced unresectable renal cell carcinoma keynote jpn footnote being developed in collaboration being developed in combination with keytruda being developed monotherapy and or in combination with keytruda on fda clinical hold available in the under emergency use authorization in january the fda issued crl merck is reviewing the crl and considering next step in july the fda issued crl for merck and eisai application merck and eisai intend to submit additional data when available to the fda approved on february of contentshuman capitalas of december the company had approximately employee worldwide with approximately employed in the including puerto rico and additionally approximately third party contractor globally approximately of the company employee are full time employee woman and individual from underrepresented ethnic group comprise approximately and of it workforce the company defines workforce it employee in the respectively woman comprise of the member of the board of director additionally the company executive team is made up of woman approximately of the company employee are represented by various collective bargaining group the company voluntary turnover rate wa approximately and respectively in and the company recognizes that it employee are critical to meet the need of it patient and customer and that it ability to excel depends on the integrity skill and diversity of it employee third party contractor include the company temporary worker independent contractor and freelancer who are viewed full time equivalent employee they exclude outsourced service provider talent acquisition the company us comprehensive approach to ensure recruiting retention and leadership development goal are systematically executed throughout the company and that it hire talented leader to achieve improved gender parity and representation across all dimension of diversity the company provides training to it manager and external recruiting organization on strategy to mitigate unconscious bias in the candidate selection and hiring process in addition the company utilizes comprehensive communication strategy employee branding and marketing outreach social medium and strategic alliance partnership to reach broad pool of talent in it critical business area in the company hired approximately employee across the globe through various channel including the company external career site direct passive candidate sourcing diversity partnership employee referral university and other external source global diversity and inclusion diversity and inclusion are fundamental to the company success and core to future innovation the company foster globally diverse and inclusive workforce for it employee by creating an environment of belonging engagement equity and empowerment the company is proactive and intentional about diversity hiring and development program to advance talent the company creates competitive advantage by leveraging diversity and inclusion to accelerate business performance this includes fostering global supplier diversity integrating diversity and inclusion into the company commercialization strategy and leveraging employee insight to improve performance in addition to these effort the company ha ten employee business resource group that provide opportunity for employee to take an active part in contributing to the company inclusive culture through their work in talent acquisition and development business and customer insight and social and community outreach the company diversity goal include increasing representation in senior management role by of woman globally to up from in ii black african american in the to up from in and iii hispanic latino in the to up from in at december representation in senior management role at the company for woman globally wa ii black african american in the wa and iii hispanic latino in the wa in addition by the company seek to maintain or exceed both it current inclusion index score and it current employee engagement index score senior management role is defined an individual holding either vice president or senior vice president title the inclusion index is the average favorability score for employee response to three item in the employee pulse survey manager support inclusion sense of belonging leader value perspective the employee engagement index is the average favorability score for employee response to item in the employee survey of contentsgender and ethnicity performance data in the woman in the workforce in the woman on the board of woman in executive role woman in management role member of underrepresented ethnic group on the board of member of underrepresented ethnic group in executive role member of underrepresented ethnic group in the workforce member of underrepresented ethnic group in management role new hire that were new hire that were member of underrepresented ethnic group of self identified to the company prior period data ha not been restated to adjust for the organon spin off executive role is defined an individual holding an executive vice president title management role is defined all manager with direct report other than executive defined in note compensation and benefitsthe company provides valuable total reward package reflecting it commitment to attract retain and motivate it talent and support it employee and their family in every stage of life the company continuously monitor and adjusts it compensation and benefit program to ensure they are competitive contemporary helpful and engaging and that they support strategic imperative such diversity and inclusion equity flexibility quality security and affordability for example the company added personal health care concierge service to assist employee participating in the company medical plan with their health care need aligned with it business and in support of it cancer care strategy the company also improved cancer screening benefit added resource and provided immediate access to leading cancer center of excellence for employee globally the company implemented minimum standard of week of paid parental leave which inclusively applies to all parent in the the company benefit rank in the top quartile of fortune company under the aon benefit index the company ha been included in seramount previously the working mother best company ranking for consecutive year and wa named seramount top ten best company for dad in employee wellbeingthe company is committed to helping it employee and their family improve their own health and wellbeing the company culture of wellbeing is referred to live it which includes program to support preventive health emotional and financial wellbeing physical fitness and nutrition it is designed to inspire all employee to pursue enjoy and share healthy lifestyle live it wa launched in the in and today is available in every country in which the company ha employee in addition many of the company larger site offer onsite health clinic that provide an array of service to help it employee stay or get well including vaccination cancer and biometric screening travel medicine and advice diagnosis and treatment of non occupational illness or injury health counseling and referral the company overall employee wellbeing program wa recognized for excellence in health and wellbeing by receiving the most recent highest level award from the business group on health and the american heart association covid responsethe company recognizes that it ha unique responsibility to help in response to the covid pandemic and is committed to supporting and protecting it employee and their family ensuring that it supply of medicine and vaccine reach it patient contributing it scientific expertise to the development of antiviral approach and supporting it health care provider and the community in which they serve the company continues to provide employee with easy and regular access to information including detail regarding the company tracking process guidance around hygiene measure and travel and best practice for working from home example of pandemic support resource and program available to the company employee include pay continuation for worker who have been sick or exposed volunteer policy adjustment to enable employee with of contentsmedical background to volunteer in sars cov related activity resource to prioritize physical and mental wellness adjustment to medical plan to cover of covid related diagnosis testing and treatment backup childcare and more engaging employeesthe company strives to foster employee engagement by promoting safe positive diverse and inclusive work environment that provides numerous opportunity for two way communication with employee some of the company key program and initiative include promoting global employee engagement survey ongoing pulse check to the organization for interim feedback on specific topic fostering professional networking and collaboration identifying and providing opportunity for volunteering and establishing positive cooperative business relation with designated employee representative talent management and developmentas the company pursues it goal of becoming the world premier research based biopharmaceutical company there is consistent focus on the importance of continuously developing it diverse and talented people the company current talent management system support company wide performance management leadership development talent review and succession planning annual performance review help further the professional development of the company employee and ensure that the company workforce is aligned with the company objective the company seek to continuously build the skill and capability of it workforce to accelerate talent improve performance and mitigate risk through relevant continuous learning experience this includes but is not limited to building leadership and management skill well providing technical and functional training to all employee environmental mattersenvironmental sustainabilitythe company strives to be strong environmental steward and realizes that it strategy and effort need to continuously improve for the company to excel in an increasingly resource constrained world the company environmental sustainability strategy ha three area of focus driving efficiency in operation designing new product to minimize environmental impact and reducing any impact in the company upstream and downstream value chain the company ha recently adopted set of new climate goal to address the rising expectation of it customer investor external stakeholder and employee regarding the environmental impact of it operation and supply chain these goal include achieving carbon neutrality for greenhouse gas emission across operation scope and by reducing scope and greenhouse gas emission by from baseline reducing value chain scope greenhouse gas emission by by from baseline and sourcing renewable energy for purchased electricity by the company absolute greenhouse gas reduction target have been verified by the science based target initiative other environmental sustainability initiative of the company include global water use and stewardship the company global water strategy aim to achieve sustainable water management within it operation and it supply chain well address water related risk access to clean water is critical for human health and water is key input to the company manufacturing operation the company site employ variety of technology and technique such closed loop cooling system and reused reverse osmosis reject water to reduce the company water footprint and improve operational performance waste management and diversion the company continuously strives to reduce the amount of operational waste it generates and to maximize the use of environmentally beneficial disposal method such recycling composting and waste to energy product stewardship and green and sustainable science the company product stewardship program focus on identifying and either preventing or minimizing potential safety and environmental hazard throughout product life cycle the company is also committed to of contentsunderstanding managing and reducing the environmental impact of it product and the material associated with discovering and producing them the company green and sustainable science program us green by design approach by using more efficient and innovative processing method and technology the company is reducing the amount of energy water and raw material the company us to make the company product thereby reducing the amount of waste the company generates and lowering the company production cost animal conservation the company is leading worldwide supplier of individual identification real time data access and advanced analytics for the animal conservation community this enables the company to produce actionable insight that inform recovery action on global scale for specie ranging from wild fish to penguin the company also provides wild fish conservation monitoring equipment and real time video monitoring technology to advance fish health and welfare together these technology help to promote biodiversity and support the global need for reliable and safe source of protein management doe not believe that expenditure related to these initiative should have material adverse effect on the company financial condition result of operation liquidity or capital resource for any year in december the company completed it inaugural issuance of billion sustainability bond which wa part of an billion underwritten bond offering the company intends to use the net proceeds from the sustainability bond offering to support project and partnership in the company priority environmental social and governance esg area and contribute to the advancement of the united nation sustainable development goal merck belief that climate change could present risk to it business some of the potential impact of climate change to it business include increased operating cost due to additional regulatory requirement physical risk to the company facility water limitation and disruption to it supply chain these potential risk are integrated into the company business planning including investment in reducing energy usage water use and greenhouse gas emission environmental regulation and remediationthe company belief that there are no compliance issue associated with applicable environmental law and regulation that would have material adverse effect on the company the company is also remediating environmental contamination resulting from past industrial activity at certain of it site expenditure for remediation and environmental liability were million in and are estimated to be million in the aggregate for the year through these amount do not consider potential recovery from other party the company ha taken an active role in identifying and accruing for these cost and in management opinion the liability for all environmental matter that are probable and reasonably estimable have been accrued and totaled million and million at december and respectively although it is not possible to predict with certainty the outcome of these matter or the ultimate cost of remediation management doe not believe that any reasonably possible expenditure that may be incurred in excess of the liability accrued should exceed approximately million in the aggregate management also doe not believe that these expenditure should have material adverse effect on the company financial condition result of operation liquidity or capital resource for any year geographic area informationthe company operation outside the are conducted primarily through subsidiary sale worldwide by subsidiary outside the percentage of total company sale were in and were in both and the company worldwide business is subject to risk of currency fluctuation governmental action and other governmental proceeding abroad the company doe not regard these risk deterrent to further expansion of it operation abroad however the company closely review it method of operation and adopts strategy responsive to changing economic and political condition of contentsmerck ha operation in country located in latin america the middle east africa eastern europe and asia pacific business in these developing area while sometimes le stable offer important opportunity for growth over time available informationthe company internet website address is merck com the company will make available free of charge at the investor portion of it website it annual report on form quarterly report on form current report on form and all amendment to those report filed or furnished pursuant to section or of the security exchange act of amended soon reasonably practicable after such report are electronically filed with or furnished to the security and exchange commission sec the address of that website is sec gov in addition the company will provide without charge copy of it annual report on form including financial statement and schedule upon the written request of any shareholder to the office of the secretary merck co inc galloping hill road kenilworth nj the company corporate governance guideline and the charter of the board of director four standing committee are available on the company website at merck com company overview leadership and all such information is available in print to any shareholder who request it from the company the company environmental social governance esg progress report which provides enhanced esg disclosure is available on the company website at merck com company overview responsibility information in the company esg progress report is not incorporated by reference into this form item risk factor summary risk factorsthe company is subject to number of risk that if realized could materially adversely affect it business result of operation cash flow financial condition or prospect the following is summary of the principal risk factor facing the company the company is dependent on it patent right and if it patent right are invalidated or circumvented it business could be materially adversely affected the company product lose market exclusivity the company generally experience significant and rapid loss of sale from those product key product generate significant amount of the company profit and cash flow and any event that adversely affect the market for it leading product could have material adverse effect on the company result of operation and financial condition the company research and development effort may not succeed in developing commercially successful product and the company may not be able to acquire commercially successful product in other way in consequence the company may not be able to replace sale of successful product that lose patent protection the company success is dependent on the successful development and marketing of new product which are subject to substantial risk the company face continued pricing pressure with respect to it product unfavorable or uncertain economic condition together with cost reduction measure being taken by certain government could negatively affect the company operating result the company face intense competition from lower cost generic product the company face intense competition from competitor product in and covid related disruption had an adverse impact on the company business operation and financial performance the company is unable to predict the full extent to which the of contentscovid pandemic or any future pandemic epidemic or similar public health threat will adversely impact it business operation financial performance result of operation and financial condition the company ha significant global operation which expose it to additional risk and any adverse event could have material adverse effect on the company result of operation and financial condition climate change or legal regulatory or market measure to address climate change may negatively affect the company business result of operation cash flow and prospect environmental social and governance esg matter may impact the company business and reputation failure to attract and retain highly qualified personnel could affect the company ability to successfully develop and commercialize product the company may experience difficulty and delay in manufacturing certain of it product including vaccine the company may not be able to realize the expected benefit of it investment in emerging market the company is exposed to market risk from fluctuation in currency exchange rate and interest rate pharmaceutical product can develop unexpected safety or efficacy concern reliance on third party relationship and outsourcing arrangement could materially adversely affect the company business negative event in the animal health industry could have material adverse effect on future result of operation and financial condition biologics and vaccine carry unique risk and uncertainty which could have material adverse effect on the company future result of operation and financial condition the health care industry in the ha been and will continue to be subject to increasing regulation and political action the company product including product in development can not be marketed unless the company obtains and maintains regulatory approval development following regulatory approval may adversely affect sale of the company product the company is subject to variety of and international law and regulation the company is subject to evolving and complex tax law which may result in additional liability that may affect result of operation and financial condition adverse outcome in current or future legal matter could negatively affect merck business product liability insurance for product may be limited cost prohibitive or unavailable the company is increasingly dependent on sophisticated software application and computing infrastructure in the company experienced network cyber attack that led to disruption of it worldwide operation including manufacturing research and sale operation the company could be target of future cyber attack social medium and mobile messaging platform present risk and challenge the above list is not exhaustive and the company face additional challenge and risk investor should carefully consider all of the information set forth in this form including the following risk factor before deciding to invest in any of the company security of contentsrisk factor the risk below are not the only one the company face additional risk not currently known to the company or that the company presently deems immaterial may also impair it business operation the company business financial condition result of operation cash flow or prospect could be materially adversely affected by any of these risk this form also contains forward looking statement that involve risk and uncertainty the company result could materially differ from those anticipated in these forward looking statement result of certain factor including the risk it face described below and elsewhere see cautionary factor that may affect future result below risk related to the company businessthe company is dependent on it patent right and if it patent right are invalidated or circumvented it business could be materially adversely affected patent protection is considered in the aggregate to be of material importance to the company marketing of human health and animal health product in the and in most major foreign market patent covering product that it ha introduced normally provide market exclusivity which is important for the successful marketing and sale of it product the company seek patent covering each of it product in each of the market where it intends to sell the product and where meaningful patent protection is available even if the company succeeds in obtaining patent covering it product third party or government authority may challenge or seek to invalidate or circumvent it patent and patent application it is important for the company business to successfully assert and defend the patent right that provide market exclusivity for it product the company is often involved in patent dispute relating to challenge to it patent or claim by third party of infringement against the company the company asserts and defends it patent both within and outside the including by filing claim of infringement against other party see item financial statement and supplementary data note contingency and environmental liability below in particular manufacturer of generic pharmaceutical product from time to time file abbreviated ndas with the fda seeking to market generic form of the company product prior to the expiration of relevant patent owned or licensed by the company the company normally responds by asserting it patent with lawsuit alleging patent infringement patent litigation and other challenge to the company patent are costly and unpredictable and may deprive the company of market exclusivity for patented product or in some case third party patent may prevent the company from marketing and selling product in particular geographic area additionally certain foreign government have indicated that compulsory license to patent may be granted in the case of national emergency or in other circumstance which could diminish or eliminate sale and profit from those region and negatively affect the company result of operation further court decision relating to other company patent potential legislation in both the and certain foreign market relating to patent well regulatory initiative may result in more general weakening of intellectual property protection if one or more important product lose patent protection in profitable market sale of those product are likely to decline significantly result of generic version of those product becoming available the company result of operation may be adversely affected by the lost sale unless and until the company ha launched commercially successful product that replace the lost sale in addition if product that were measured at fair value and capitalized in connection with acquisition experience difficulty in the market that negatively affect product cash flow the company may recognize material non cash impairment charge with respect to the value of those product chart listing the patent protection for certain of the company marketed product and patent protection for candidate in phase clinical development is set forth above in item business patent trademark and license the company product lose market exclusivity the company generally experience significant and rapid loss of sale from those product the company depends upon patent to provide it with exclusive marketing right for it product for some period of time loss of patent protection for one of the company product typically lead to significant and of contentsrapid loss of sale for that product lower priced generic version of that drug become available in the case of product that contribute significantly to the company sale the loss of market exclusivity can have material adverse effect on the company business cash flow result of operation financial condition and prospect januvia and janumet will lose market exclusivity in the in january januvia and janumet will lose market exclusivity in the eu in september and in china in july the company anticipates sale of januvia and janumet in these market will decline substantially after the loss of exclusivity key product generate significant amount of the company profit and cash flow and any event that adversely affect the market for it leading product could have material adverse effect on the company result of operation and financial condition the company ability to generate profit and operating cash flow depends largely upon the continued profitability of the company key product such keytruda gardasil gardasil lynparza bravecto and bridion in particular in the company oncology portfolio led by keytruda represented substantial portion of the company revenue growth result of the company dependence on key product any event that adversely affect any of these product or the market for any of these product could have significant adverse impact on result of operation and financial condition these event could include loss of patent protection increased cost associated with manufacturing generic or over the counter availability of the company product or competitive product the discovery of previously unknown side effect result of post approval trial increased competition from the introduction of new more effective treatment and discontinuation or removal from the market of the product for any reason such event could have material adverse effect on the sale of any such product the company research and development effort may not succeed in developing commercially successful product and the company may not be able to acquire commercially successful product in other way in consequence the company may not be able to replace sale of successful product that lose patent protection in order to remain competitive the company like other major pharmaceutical company must continue to launch new product expected decline in sale of product after the loss of market exclusivity mean that the company future success is dependent on it pipeline of new product including new product that it may develop through collaboration and joint venture and product that it is able to obtain through license or acquisition to accomplish this the company commits substantial effort fund and other resource to research and development both through it own dedicated resource and through various collaboration with third party there is high rate of failure inherent in the research and development process for new drug and vaccine result there is high risk that fund invested by the company in research program will not generate financial return this risk profile is compounded by the fact that this research ha long investment cycle to bring pharmaceutical compound from the discovery phase to market may take decade or more and failure can occur at any point in the process including later in the process after significant fund have been invested for description of the research and development process see item business research and development above each phase of testing is highly regulated and during each phase there is substantial risk that the company will encounter serious obstacle or will not achieve it goal therefore the company may abandon product in which it ha invested substantial amount of time and resource some of the risk encountered in the research and development process include the following pre clinical testing of new compound may yield disappointing result competing product from other manufacturer may reach the market first clinical trial of new drug may not be successful new drug may not be effective or may have harmful side effect new drug may not be approved by the regulator for it intended use it may not be possible to obtain patent for new drug payer may refuse to cover or reimburse the new product or sale of new product may be disappointing the company can not state with certainty when or whether any of it product under development will be approved or launched whether it will be able to develop license or otherwise acquire compound product candidate or product or whether any product once launched will be commercially successful the company must maintain continuous flow of successful new product and successful new indication for existing product sufficient both to cover it substantial research and development cost and to replace sale that are lost profitable product lose market exclusivity or are displaced by competing product or therapy failure to do so in the short of contentsterm or long term would have material adverse effect on the company business result of operation cash flow financial condition and prospect the company success is dependent on the successful development and marketing of new product which are subject to substantial risk product that appear promising in development may fail to reach the market or fail to succeed for numerous reason including the following finding of ineffectiveness superior safety or efficacy of competing product or harmful side effect in clinical or pre clinical testing failure to receive the necessary regulatory approval including delay in the approval of new product and new indication or the anticipated labeling and uncertainty about the time required to obtain regulatory approval and the benefit risk standard applied by regulatory agency in determining whether to grant approval failure in certain market to obtain reimbursement commensurate with the level of innovation and clinical benefit presented by the product lack of economic feasibility due to manufacturing cost or other factor and preclusion from commercialization by the proprietary right of others in the future if certain pipeline program are cancelled or if the company belief that their commercial prospect have been reduced the company may recognize material non cash impairment charge for those program that were measured at fair value and capitalized in connection with acquisition or certain collaboration failure to successfully develop and market new product in the short term or long term would have material adverse effect on the company business result of operation cash flow financial condition and prospect the company face continued pricing pressure with respect to it product the company face continued pricing pressure globally and particularly in mature market from managed care organization government agency and program that could negatively affect the company sale and profit margin in the these include practice of managed care group and institutional and governmental purchaser ii federal law and regulation related to medicare and medicaid including the medicare prescription drug improvement and modernization act of and the aca and iii state activity aimed at increasing price transparency including new law noted above in item competition and the health care environment change to the health care system enacted part of health care reform in the well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary could result in further pricing pressure in addition in the larger customer have received higher rebate on drug in certain highly competitive category the company must also compete to be placed on formulary of managed care organization exclusion of product from formulary can lead to reduced usage in the managed care organization in order to provide information about the company pricing practice the company annually post on it website it pricing transparency report for the the report provides the company average annual list price and net price increase across the company portfolio dating back to in the company gross sale were reduced by result of rebate discount and return outside the numerous major market including the eu japan and china have pervasive government involvement in funding health care and in that regard fix the pricing and reimbursement of pharmaceutical and vaccine product consequently in those market the company is subject to government decision making and budgetary action with respect to it product in japan the pharmaceutical industry is subject to government mandated annual price reduction of pharmaceutical product and certain vaccine furthermore the government can order re pricing for specific product if it determines that use of such product will exceed certain threshold defined under applicable re pricing rule of contentsthe company expects pricing pressure to continue in the future unfavorable or uncertain economic condition together with cost reduction measure being taken by certain government could negatively affect the company operating result the company business may be adversely affected by local and global economic condition including with respect to inflation interest rate and cost of raw material and packaging uncertainty in global economic and geopolitical condition may result in slowdown to the global economy that could affect the company business by reducing the price that drug wholesaler and retailer hospital government agency and managed health care provider may be able or willing to pay for the company product or by reducing the demand for the company product which could in turn negatively impact the company sale and result in material adverse effect on the company business cash flow result of operation financial condition and prospect discussed above in competition and the health care environment global effort toward health care cost containment continue to exert pressure on product pricing and market access worldwide change to the health care system part of health care reform well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary have contributed to pricing pressure in several international market government mandated pricing action have reduced price of generic and patented drug in addition the company revenue performance in wa negatively affected by other cost reduction measure taken by government and other third party to lower health care cost the company anticipates all of these action and additional action in the future will continue to negatively affect revenue performance if credit and economic condition worsen the resulting economic and currency impact in the affected market and globally could have material adverse effect on the company result in addition the covid pandemic ha caused some disruption and volatility in the company global supply chain network and the company may experience disruption in availability and delay in shipment of raw material and packaging well related cost inflation any such disruption delay or cost may result in the company inability to meet demand for the company product the company face intense competition from lower cost generic product in general the company face increasing competition from lower cost generic product the patent right that protect it product are of varying strength and duration in addition in some country patent protection is significantly weaker than in the or in the eu in the and the eu political pressure to reduce spending on prescription drug ha led to legislation and other measure that encourage the use of generic and biosimilar product although it is the company policy to actively protect it patent right generic challenge to the company product can arise at any time and the company patent may not prevent the emergence of generic competition for it product loss of patent protection for product typically is followed promptly by generic substitute reducing the company sale of that product availability of generic substitute for the company drug may adversely affect it result of operation and cash flow in addition proposal emerge from time to time in the and other country for legislation to further encourage the early and rapid approval of generic drug any such proposal that is enacted into law could worsen this substantial negative effect on the company sale and potentially it business cash flow result of operation financial condition and prospect the company face intense competition from competitor product the company product face intense competition from competitor product this competition may increase new product enter the market in such an event the competitor product may be safer or more effective more convenient to use have better insurance coverage or reimbursement level or be more effectively marketed and sold than the company product alternatively in the case of generic competition including the generic availability of competitor branded product they may be equally safe and effective product that are sold at substantially lower price than the company product result if the company fails to maintain it competitive position this could have material adverse effect on it business cash flow result of operation financial condition and prospect in addition if product that were measured at fair value and capitalized in of contentsconnection with acquisition experience difficulty in the market that negatively impact product cash flow the company may recognize material non cash impairment charge with respect to the value of those product in and covid related disruption had an adverse impact on the company business operation and financial performance the company is unable to predict the full extent to which the covid pandemic or any future pandemic epidemic or similar public health threat will adversely impact it business operation financial performance result of operation and financial condition the company business and financial result were negatively impacted by covid related disruption in and the continued duration and severity of the covid pandemic is uncertain rapidly changing and difficult to predict the degree to which covid related disruption impact the company result in will depend on future development beyond the company knowledge or control including but not limited to the duration of the pandemic it severity the success of action taken to contain or prevent the virus or treat it impact and how quickly and to what extent normal economic and operating condition can resume in the covid pandemic impacted the company business in numerous way expected within the company human health business which is comprised largely of physician administered product revenue wa negatively impacted by social distancing measure and fewer well visit which negatively affected vaccine and oncology sale in particular the estimated negative impact of covid related disruption to merck revenue for the full year wa approximately billion attributable to the pharmaceutical segment merck belief that global health system and patient have largely adapted to the impact of covid however roughly of merck pharmaceutical segment revenue is comprised of physician administered product which could be adversely affected by the pandemic if it effect worsen despite the company effort to manage the impact of the covid pandemic their ultimate effect will also depend on factor beyond the company knowledge or control including the duration of the covid pandemic well governmental and third party action taken to contain or prevent the spread and treatment of the virus and mitigate it public health and economic effect in addition any future pandemic epidemic or similar public health threat could present similar risk to the company business cash flow result of operation financial condition and prospect the company ha significant global operation which expose it to additional risk and any adverse event could have material adverse effect on the company result of operation and financial condition the extent of the company operation outside the is significant risk inherent in conducting global business include change in medical reimbursement policy and program and pricing restriction in key market multiple regulatory requirement that could restrict the company ability to manufacture and sell it product in key market trade protection measure and import or export licensing requirement including the imposition of trade sanction or similar restriction by the or other government foreign exchange fluctuation diminished protection of intellectual property in some country and possible nationalization and expropriation in addition there may be change to the company business and political position if there is instability disruption or destruction in significant geographic region regardless of cause including war terrorism riot civil insurrection or social unrest and natural or man made disaster including famine flood fire earthquake storm or disease in particular in february armed conflict escalated between russia and ukraine it is not possible to predict the broader consequence of this conflict which could include sanction embargo regional instability geopolitical shift and adverse effect on macroeconomic condition currency exchange rate and financial market of contentsclimate change or legal regulatory or market measure to address climate change may negatively affect the company business result of operation cash flow and prospect the company belief that climate change ha the potential to negatively affect it business and result of operation cash flow and prospect the company is exposed to physical risk such extreme weather condition or rising sea level risk in transitioning to low carbon economy such additional legal or regulatory requirement change in technology market risk and reputational risk and social and human effect such population dislocation and harm to health and well being associated with climate change these risk can be either acute short term or chronic long term the adverse impact of climate change include increased frequency and severity of natural disaster and extreme weather event such hurricane tornado wildfire exacerbated by drought flooding and extreme heat extreme weather and sea level rise pose physical risk to the company facility well those of it supplier such risk include loss incurred result of physical damage to facility loss or spoilage of inventory and business interruption caused by such natural disaster and extreme weather event other potential physical impact due to climate change include reduced access to high quality water in certain region and the loss of biodiversity which could impact future product development these risk could disrupt the company operation and it supply chain which may result in increased cost new legal or regulatory requirement may be enacted to prevent mitigate or adapt to the implication of changing climate and it effect on the environment these regulation which may differ across jurisdiction could result in the company being subject to new or expanded carbon pricing or tax increased compliance cost restriction on greenhouse gas emission investment in new technology increased carbon disclosure and transparency upgrade of facility to meet new building code and the redesign of utility system which could increase the company operating cost including the cost of electricity and energy used by the company the company supply chain would likely be subject to these same transitional risk and would likely pas along any increased cost to the company environmental social and governance esg matter may impact the company business and reputation governmental authority non governmental organization customer investor external stakeholder and employee are increasingly sensitive to esg concern such diversity and inclusion climate change water use recyclability or recoverability of packaging and plastic waste this focus on esg concern may lead to new requirement that could result in increased cost associated with developing manufacturing and distributing the company product the company ability to compete could also be affected by changing customer preference and requirement such growing demand for more environmentally friendly product packaging or supplier practice or by failure to meet such customer expectation or demand while the company strives to improve it esg performance the company risk negative stockholder reaction including from proxy advisory service well damage to it brand and reputation if the company doe not act responsibly or if the company is perceived to not be acting responsibly in key esg area including equitable access to medicine and vaccine product quality and safety diversity and inclusion environmental stewardship support for local community corporate governance and transparency and addressing human capital factor in the company operation if the company doe not meet the esg expectation of it investor customer and other stakeholder the company could experience reduced demand for it product loss of customer and other negative impact on the company business and result of operation failure to attract and retain highly qualified personnel could affect the company ability to successfully develop and commercialize product the company success is largely dependent on it continued ability to attract and retain highly qualified scientific technical and management personnel well personnel with expertise in clinical research and development governmental regulation and commercialization competition for qualified personnel in the pharmaceutical industry both in the and internationally is intense the company can not be sure that it will be able to attract and retain quality personnel or that the cost of so will not materially increase of contentsthe company may experience difficulty and delay in manufacturing certain of it product including vaccine merck ha in the past experienced difficulty in manufacturing certain of it product including vaccine for example in the company issued product recall for zerbaxa following the identification of product sterility issue the company may in the future experience other difficulty and delay in manufacturing it product such failure of the company or any of it vendor or supplier to comply with current good manufacturing practice and other applicable regulation and quality assurance guideline that could lead to manufacturing shutdown product shortage and delay in product manufacturing ii delay related to the construction of new facility or the expansion of existing facility including those intended to support future demand for the company product and iii other manufacturing or distribution problem including supply chain delay shortage in raw material change in manufacturing production site and limit to manufacturing capacity due to regulatory requirement change in type of product produced or physical limitation that could impact continuous supply in addition the company could experience difficulty or delay in manufacturing it product caused by natural disaster such hurricane manufacturing difficulty can result in product shortage leading to lost sale and reputational harm to the company the company may not be able to realize the expected benefit of it investment in emerging market the company ha been taking step to increase it sale in emerging market however there is no guarantee that the company effort to expand sale in these market will succeed some country within emerging market may be especially vulnerable to period of global financial instability or may have very limited resource to spend on health care in order for the company to successfully implement it emerging market strategy it must attract and retain qualified personnel the company may also be required to increase it reliance on third party agent within le developed market which may affect it ability to realize continued growth and may also increase the company risk exposure in addition many of these country have currency that fluctuate substantially and if such currency devalue and the company can not offset the devaluation the company financial performance within such country could be adversely affected the company business in china ha grown rapidly in the past few year and the importance of china to the company overall pharmaceutical and vaccine business outside the ha increased accordingly continued growth of the company business in china is dependent upon ongoing development of favorable environment for innovative pharmaceutical product and vaccine sustained access for the company currently marketed product and the absence of trade impediment or adverse pricing control noted above in competition and the health care environment pricing pressure in china ha increased the chinese government ha been taking step to reduce cost including implementing health care reform that ha led to the acceleration of generic substitution where available while the mechanism for drug being added to the nrdl evolves inclusion may require price negotiation which could impact the outlook in the market for selected brand in drug were added to the nrdl with an average of more than price reduction while pricing pressure ha always existed in china health care reform ha increased this pressure in part due to the acceleration of generic substitution through the government vbp program in the government implemented the vbp program through tendering process for mature product which have generic substitute with generic quality consistency evaluation approval mature product that have entered into the last five round of vbp had on average price reduction of more than the company expects vbp to be semi annual process that will have significant impact on mature product moving forward in addition the company anticipates that the reported inquiry made by various governmental authority involving multinational pharmaceutical company in china may continue for all these reason sale within emerging market carry significant risk however at the same time macro economic growth of selected emerging market is expected to outpace europe and even the leading to significant increased health care spending in those country and access to innovative medicine for patient failure to maintain the company presence in emerging market could therefore have material adverse effect on the company business cash flow result of operation financial condition and prospect of contentsthe company is exposed to market risk from fluctuation in currency exchange rate and interest rate the company operates in multiple jurisdiction and virtually all sale are denominated in currency of the local jurisdiction additionally the company ha entered and will enter into business development transaction borrowing or other financial transaction that may give rise to currency and interest rate exposure since the company can not with certainty foresee and mitigate against such adverse fluctuation fluctuation in currency exchange rate interest rate and inflation could negatively affect the company business cash flow result of operation financial condition and prospect in order to mitigate against the adverse impact of these market fluctuation the company will from time to time enter into hedging agreement while hedging agreement such currency option and forward and interest rate swap may limit some of the exposure to exchange rate and interest rate fluctuation such attempt to mitigate these risk may be costly and not always successful certain of the company interest rate derivative and investment are based on the london interbank offered rate libor and portion of merck indebtedness bear interest at variable interest rate primarily based on libor libor is the subject of recent national international and other regulatory guidance and proposal for reform which will cause libor to cease to exist entirely in the future while the company ha begun to implement alternative reference rate alternative to libor the company can not predict the consequence and timing of any additional or unexpected development which could include an increase in interest expense and will also require the amendment of contract that reference libor pharmaceutical product can develop unexpected safety or efficacy concern unexpected safety or efficacy concern can arise with respect to marketed product whether or not scientifically justified leading to product recall withdrawal or declining sale well product liability consumer fraud and or other claim including potential civil or criminal governmental action reliance on third party relationship and outsourcing arrangement could materially adversely affect the company business the company depends on third party including supplier alliance with other pharmaceutical and biotechnology company and third party service provider for key aspect of it business including development manufacture and commercialization of it product and support for it information technology it system failure of these third party to meet their contractual regulatory and other obligation to the company or the development of factor that materially disrupt the relationship between the company and these third party could have material adverse effect on the company business negative event in the animal health industry could have material adverse effect on future result of operation and financial condition future sale of key animal health product could be adversely affected by number of risk factor including certain risk that are specific to the animal health business for example the outbreak of disease carried by animal such african swine fever could lead to their widespread death and precautionary destruction well the reduced consumption and demand for animal which could adversely affect the company result of operation also the outbreak of any highly contagious disease near the company main production site could require the company to immediately halt the manufacture of it animal health product at such site or force the company to incur substantial expense in procuring raw material or product elsewhere other risk specific to animal health include epidemic and pandemic government procurement and pricing practice weather and global agribusiness economic event in addition sale of bravecto represent significant portion of the company animal health segment sale any negative event with respect to bravecto could have material adverse effect on the company animal health sale the animal health segment of the company business becomes more significant the impact of any such event on future result of operation would also become more significant of contentsbiologics and vaccine carry unique risk and uncertainty which could have material adverse effect on the company future result of operation and financial condition the successful development testing manufacturing and commercialization of biologics and vaccine particularly human and animal health vaccine is long complex expensive and uncertain process there are unique risk and uncertainty related to biologics and vaccine including there may be limited access to and supply of normal and diseased tissue sample cell line pathogen bacteria viral strain and other biological material in addition government regulation in multiple jurisdiction such the and the eu could result in restricted access to or transport or use of such material if the company loses access to sufficient source of such material or if tighter restriction are imposed on the use of such material the company may not be able to conduct research activity planned and may incur additional development cost the development manufacturing and marketing of biologics and vaccine are subject to regulation by the fda the ema and other regulatory body these regulation are often more complex and extensive than the regulation applicable to other pharmaceutical product for example in the bla including both pre clinical and clinical trial data and extensive data regarding the manufacturing procedure is required for human vaccine candidate and fda approval is generally required for the release of each manufactured commercial human vaccine lot manufacturing biologics and vaccine especially in large quantity is often complex and may require the use of innovative technology to handle living micro organism each lot of an approved biologic and vaccine must undergo thorough testing for identity strength quality purity and potency manufacturing biologics requires facility specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedure are necessary slight deviation anywhere in the manufacturing process including filling labeling packaging storage and shipping and quality control and testing may result in lot failure product recall or spoilage when change are made to the manufacturing process the company may be required to provide pre clinical and clinical data showing the comparable identity strength quality purity or potency of the product before and after such change biologics and vaccine are frequently costly to manufacture production ingredient are derived from living animal or plant material and most biologics and vaccine can not be made synthetically in particular keeping up with the demand for vaccine may be difficult due to the complexity of producing vaccine the use of biologically derived ingredient can lead to variability in the manufacturing process and could lead to allegation of harm including infection or allergic reaction which allegation would be reviewed through standard investigation process that could lead to closure of product facility due to possible contamination any of these event could result in substantial cost risk relating to government regulation and legal proceedingsthe health care industry in the ha been and will continue to be subject to increasing regulation and political action discussed above in competition and the health care environment the company belief that the health care industry will continue to be subject to increasing regulation well political and legal action future proposal to reform the health care system are considered by the executive branch congress and state legislature in the center for medicare medicaid service cm issued the medicaid rebate final rule that implemented provision of the aca effective april the rule provides comprehensive guidance on the calculation of average manufacturer price and best price two metric utilized to determine the rebate drug manufacturer are required to pay to state medicaid program on december the cm issued final rule making significant change to these requirement effective january this final rule also change the way that manufacturer must calculate best price in relation to certain patient support program including coupon phrma pharmaceutical industry trade group of which the company is member filed complaint challenging this rule invalid asserting that it conflict with the plain language of the medicaid drug rebate statute should this legal of contentschallenge fail the impact of this and other provision in this final rule could adversely impact the company business cash flow result of operation financial condition and prospect in congress passed the american rescue plan act of which included provision that eliminates the statutory cap on rebate drug manufacturer pay to medicaid beginning in january these rebate act discount off the list price and eliminating the cap mean that manufacturer discount paid to medicaid can increase prior to this change manufacturer have not been required to pay more than of the average manufacturer price amp in rebate to state medicaid program for medicaid covered drug result of this provision beginning in it is possible that manufacturer may have to pay state medicaid program more in rebate than they received on sale of particular product this change could present risk to merck in the future for drug that have high medicaid utilization and rebate exposure that is more than of the amp in the the biden administration and congress continue to discus legislation designed to control health care cost including the cost of drug the company can not predict what additional future change in the health care industry in general or the pharmaceutical industry in particular will occur however any change could have material adverse effect on the company business cash flow result of operation financial condition and prospect the company product including product in development can not be marketed unless the company obtains and maintains regulatory approval the company activity including research pre clinical testing clinical trial and the manufacturing and marketing of it product are subject to extensive regulation by numerous federal state and local governmental authority in the including the fda and by foreign regulatory authority including in the eu japan and china in the the fda administers requirement covering the testing approval safety effectiveness manufacturing labeling and marketing of prescription pharmaceutical in some case the fda requirement have increased the amount of time and resource necessary to develop new product and bring them to market in the regulation outside the also is primarily focused on drug safety and effectiveness and in many case reduction in the cost of drug the fda and foreign regulatory authority including in the eu japan and china have substantial discretion to require additional testing to delay or withhold registration and marketing approval and to otherwise preclude distribution and sale of product even if the company is successful in developing new product it will not be able to market any of those product unless and until it ha obtained all required regulatory approval in each jurisdiction where it proposes to market the new product once obtained the company must maintain approval long it plan to market it new product in each jurisdiction where approval is required the company failure to obtain approval significant delay in the approval process or it failure to maintain approval in any jurisdiction will prevent it from selling the product in that jurisdiction the company would not be able to realize revenue for those new product in any jurisdiction where it doe not have approval development following regulatory approval may adversely affect sale of the company product even after product reach the market certain development following regulatory approval may decrease demand for the company product including the following result in post approval phase trial or other study the re review of product that are already marketed the recall or loss of marketing approval of product that are already marketed changing government standard or public expectation regarding safety efficacy quality or labeling change scrutiny of advertising and promotion and the withdrawal of indication granted pursuant to accelerated approval in the past clinical trial and post marketing surveillance of certain marketed drug of the company and of competitor within the industry have raised concern that have led to recall withdrawal or adverse labeling of of contentsmarketed product clinical trial and post marketing surveillance of certain marketed drug also have raised concern among some prescribers and patient relating to the safety or efficacy of pharmaceutical product in general that have negatively affected the sale of such product in addition increased scrutiny of the outcome of clinical trial ha led to increased volatility in market reaction further these matter often attract litigation and even where the basis for the litigation is groundless considerable resource may be needed to respond in addition following in the wake of product withdrawal and other significant safety issue health authority such the fda the ema japan pmda and china nmpa have increased their focus on safety when assessing the benefit risk balance of drug some health authority appear to have become more cautious when making decision about approvability of new product or indication if previously unknown side effect are discovered or if there is an increase in negative publicity regarding known side effect of any of the company product it could significantly reduce demand for the product or require the company to take action that could negatively affect sale including removing the product from the market restricting it distribution or applying for labeling change further in the current environment in which all pharmaceutical company operate the company is at risk for product liability and consumer protection claim and civil and criminal governmental action related to it product research and or marketing activity in addition dissemination of promotional material through evolving digital channel serf to increase visibility and scrutiny in the marketplace the company is subject to variety of and international law and regulation the company is currently subject to number of government law and regulation and in the future could become subject to new government law and regulation the cost of compliance with such law and regulation or the negative result of non compliance could adversely affect the business cash flow result of operation financial condition and prospect of the company these law and regulation include additional health care reform initiative in the or in other country including additional mandatory discount or fee ii the foreign corrupt practice act or other anti bribery and corruption law iii new law regulation and judicial or other governmental decision affecting pricing drug reimbursement and access or marketing within or across jurisdiction iv change in intellectual property law change in accounting standard vi new and increasing data privacy regulation and enforcement particularly in the eu the and china vii legislative mandate or preference for local manufacturing of pharmaceutical or vaccine product viii emerging and new global regulatory requirement for reporting payment and other value transfer to health care professional ix environmental regulation and the potential impact of importation restriction embargo trade sanction and legislative and or other regulatory change the company is subject to evolving and complex tax law which may result in additional liability that may affect result of operation and financial condition the company is subject to evolving and complex tax law in the jurisdiction in which it operates significant judgment is required for determining the company tax liability and the company tax return are routinely examined by various tax authority in connection with the organization for economic cooperation and development oecd base erosion and profit shifting project company are required to disclose more information to tax authority on operation around the world which may lead to greater audit scrutiny of profit earned in other country the company belief that it accrual for tax contingency is adequate for all open year based on past experience interpretation of tax law and judgment about potential action by tax authority however due to the complexity of tax contingency the ultimate resolution of any tax matter may result in payment greater or le than amount accrued in addition the company may be negatively affected by change in tax law or new tax law affecting for example tax rate and or revised tax law interpretation in domestic or foreign jurisdiction including among others any potential change to the existing tax law by the current presidential administration and congress well any change in tax law resulting from the implementation of the oecd two pillar solution to reform the international tax landscape the company ha taken the position based on the opinion of tax counsel that it distribution of organon common stock in connection with the spin off of organon qualifies transaction that is tax free for federal income tax purpose if any fact assumption representation and undertaking from the company and organon regarding the past and future conduct of their respective business and other matter are of contentsincorrect or not otherwise satisfied the spin off may not qualify for tax free treatment which could result in significant federal income tax liability for the company and it shareholder adverse outcome in current or future legal matter could negatively affect merck business current or future litigation claim proceeding and government investigation could preclude or delay the commercialization of merck product or could adversely affect merck business result of operation cash flow prospect and financial condition such legal matter may include but are not limited to intellectual property dispute ii adverse decision in litigation including product safety and liability consumer protection and commercial case iii anti bribery regulation such the foreign corrupt practice act including compliance with ongoing reporting obligation to the government resulting from any settlement iv recall or withdrawal of pharmaceutical product or forced closing of manufacturing plant product pricing and promotional matter vi lawsuit claim and administrative proceeding asserting or investigation into violation of security antitrust federal and state pricing consumer protection data privacy and other law and regulation vii environmental health safety and sustainability matter including regulatory action in response to climate change and viii tax liability resulting from assessment from tax authority see item financial statement and supplementary data note contingency and environmental liability for more information on the company legal matter in merck informed the department of health and human service health resource and service administration hhs that merck wa implementing an update to it section program integrity initiative pursuant to which merck required all hospital covered entity to provide claim data for all claim originating from contract pharmacy for those entity that declined to submit such claim data merck new initiative provided that it would no longer voluntarily honor discount or chargebacks for contract pharmacy transaction except for single contract pharmacy of the hospital covered entity choice also in hhs sent letter to numerous drug manufacturer stating that it had determined that those manufacturer action restricting contract pharmacy transaction were in violation of the statute and further stating that if those manufacturer did not cease their restriction hhs might seek both repayment of overcharge well civil monetary penalty those manufacturer are now in litigation with the government seeking to confirm the legality of the restriction merck did not receive similar letter from hhs however hhs could seek to implement administrative proceeding to recover overcharge and or impose civil monetary penalty against merck if such proceeding were implemented against merck negative outcome could have material adverse effect on merck business result of operation cash flow prospect and financial condition product liability insurance for product may be limited cost prohibitive or unavailable result of number of factor product liability insurance ha become le available while the cost of such insurance ha increased significantly the company is subject to substantial number of product liability claim see item financial statement and supplementary data note contingency and environmental liability below for more information on the company current product liability litigation with respect to product liability the company self insures substantially all of it risk the availability of commercial insurance ha become more restrictive the company ha evaluated it risk and ha determined that the cost of obtaining product liability insurance outweighs the likely benefit of the coverage that is available and such ha no insurance for most product liability the company will continually ass the most efficient mean to address it risk however there can be no guarantee that insurance coverage will be obtained or if obtained will be sufficient to fully cover product liability that may arise risk related to technologythe company is increasingly dependent on sophisticated software application and computing infrastructure in the company experienced network cyber attack that led to disruption of it worldwide operation including manufacturing research and sale operation the company could be target of future cyber attack the company is increasingly dependent on sophisticated software application complex information technology system computing infrastructure and cloud service provider collectively it system to conduct of contentscritical operation certain of these system are managed hosted provided or used by third party to assist in conducting the company business disruption degradation or manipulation of these it system through intentional or accidental mean by the company employee third party with authorized access or unauthorized third party could adversely affect key business process cyber attack against the company it system or third party provider it system such cloud based system could result in exposure of confidential information the modification of critical data and or the failure of critical operation misuse of any of these it system could result in the disclosure of sensitive personal information or the theft of trade secret intellectual property or other confidential business information the company continues to leverage new and innovative technology across the enterprise to improve the efficacy and efficiency of it business process including data acquisition the use of which can create new risk in the company experienced network cyber attack that led to disruption of it worldwide operation including manufacturing research and sale operation and resulting loss the company ha implemented variety of measure to further enhance and modernize it system to guard against similar attack in the future and also is pursuing an enterprise wide effort to enhance the company resiliency against future cyber attack including incident similar to the attack the objective of these effort is not only to protect against future cyber attack but also to improve the speed of the company recovery from such attack and enable continued business operation to the greatest extent possible during any recovery period although the aggregate impact of cyber attack and network disruption including the cyber attack on the company operation and financial condition ha not been material to date the company continues to be target of event of this nature and expects them to continue the company monitor it data information technology and personnel usage of company it system to reduce these risk and continues to do so on an ongoing basis for any current or potential threat there can be no assurance that the company effort to protect it data and it system or the effort of third party provider to protect their it system will be successful in preventing disruption to the company operation including it manufacturing research and sale operation such disruption have in the past and could in the future result in loss of revenue or the loss of critical or sensitive information from the company or the company third party provider database or it system and have in the past and could in the future also result in financial legal business or reputational harm to the company and substantial remediation cost social medium and mobile messaging platform present risk and challenge the inappropriate and or unauthorized use of certain social medium and mobile messaging channel could cause brand damage or information leakage or could lead to legal implication including from the improper collection and or dissemination of personally identifiable information in addition negative or inaccurate post or comment about the company or it product on any social networking platform could damage the company reputation brand image and goodwill further the disclosure of non public company sensitive information by the company workforce or others through external medium channel could lead to information loss although there are internal company social medium and mobile messaging policy that guide employee on appropriate personal and professional use of these platform for communication about the company the process in place may not completely secure and protect information identifying new point of entry new communication tool expand also present new challenge cautionary factor that may affect future result cautionary statement under the private security litigation reform act of this report and other written report and oral statement made from time to time by the company may contain so called forward looking statement all of which are based on management current expectation and are subject to risk and uncertainty which may cause result to differ materially from those set forth in the statement one can identify these forward looking statement by their use of word such anticipates expects plan will estimate forecast project and other word of similar meaning or negative variation of any of the foregoing one can also identify them by the fact that they do not relate strictly to historical or current fact these statement are likely to address the company growth strategy financial result product approval product potential development program environmental or other sustainability initiative and include of contentsstatements related to the expected impact of the covid pandemic one must carefully consider any such statement and should understand that many factor could cause actual result to differ materially from the company forward looking statement these factor include inaccurate assumption and broad variety of other risk and uncertainty including some that are known and some that are not no forward looking statement can be guaranteed and actual future result may vary materially the company doe not assume the obligation to update any forward looking statement the company caution you not to place undue reliance on these forward looking statement although it is not possible to predict or identify all such factor they may include the following competition from generic and or biosimilar product the company product lose patent protection increased brand competition in therapeutic area important to the company long term business performance the difficulty and uncertainty inherent in new product development the outcome of the lengthy and complex process of new product development is inherently uncertain drug candidate can fail at any stage of the process and one or more late stage product candidate could fail to receive regulatory approval new product candidate may appear promising in development but fail to reach the market because of efficacy or safety concern the inability to obtain necessary regulatory approval the difficulty or excessive cost to manufacture and or the infringement of patent or intellectual property right of others furthermore the sale of new product may prove to be disappointing and fail to reach anticipated level pricing pressure both in the and abroad including rule and practice of managed care group judicial decision and governmental law and regulation related to medicare medicaid and health care reform pharmaceutical reimbursement and pricing in general the impact of the global covid pandemic and any future pandemic epidemic or similar public health threat on the company business operation and financial performance change in government law and regulation including law governing intellectual property and the enforcement thereof affecting the company business efficacy or safety concern with respect to marketed product whether or not scientifically justified leading to product recall withdrawal or declining sale significant change in customer relationship or change in the behavior and spending pattern of purchaser of health care product and service including delaying medical procedure rationing prescription medication reducing the frequency of physician visit and foregoing health care insurance coverage legal factor including product liability claim antitrust litigation and governmental investigation including tax dispute environmental concern and patent dispute with branded and generic competitor any of which could preclude commercialization of product or negatively affect the profitability of existing product cyber attack on the company or third party provider information technology system which could disrupt the company operation lost market opportunity resulting from delay and uncertainty in the approval process of the fda and foreign regulatory authority increased focus on privacy issue in country around the world including the the eu and china the legislative and regulatory landscape for privacy and data protection continues to evolve and there ha been an increasing amount of focus on privacy and data protection issue with the potential to affect directly the company business including recently enacted law in majority of state in the requiring security breach notification change in tax law including change related to the taxation of foreign earnings change in accounting pronouncement promulgated by standard setting or regulatory body including the financial accounting standard board and the sec that are adverse to the company of content economic factor over which the company ha no control including change in inflation interest rate and foreign currency exchange rate this list should not be considered an exhaustive statement of all potential risk and uncertainty see risk factor above item unresolved staff comment none item property the company corporate headquarters is currently located in kenilworth new jersey the company ha previously announced that it intends to consolidate it new jersey campus into single corporate headquarters location in rahway new jersey by the end of the company also maintains operational or divisional headquarters in kenilworth new jersey madison new jersey and upper gwynedd pennsylvania principal research facility are located in rahway and kenilworth new jersey west point pennsylvania boston and cambridge massachusetts south san francisco california and elkhorn nebraska animal health principal research facility outside the are located in the united kingdom switzerland and china merck manufacturing operation are currently headquartered in whitehouse station new jersey the company also ha production facility for human health product at seven location in the and puerto rico outside the through subsidiary the company owns or ha an interest in manufacturing plant or other property in japan singapore south africa and other country in western europe central and south america and asia number of property were transferred to organon in the spin off capital expenditure were billion in billion in and billion in in the these amounted to billion in billion in and billion in abroad such expenditure amounted to billion in billion in and billion in the company and it subsidiary own their principal facility and manufacturing plant under title that they consider to be satisfactory the company belief that it property are in good operating condition and that it machinery and equipment have been well maintained the company belief that it plant for the manufacture of product are suitable for their intended purpose and have capacity and projected capacity including previously disclosed capital expansion project that will be adequate for current and projected need for existing company product some capacity of the plant is being converted with any needed modification to the requirement of newly introduced and future product item legal proceeding the information called for by this item is incorporated herein by reference to item financial statement and supplementary data note contingency and environmental liability item mine safety disclosure not applicable of contentsexecutive officer of the registrant age of february all officer listed below serve at the pleasure of the board of director none of these officer wa elected pursuant to any arrangement or understanding between the officer and any other person nameageoffices and business experiencerobert executive officer and president since july executive vice president global service and chief financial officer since april sanat vice president and president merck manufacturing division since march richard deluca jr vice president and president merck animal health since september cristal downing vice president and chief communication public affair officer since august vice president medical device global communication and public affair johnson johnson december august vice president financial communication johnson johnson january december prior to that senior director communication at johnson johnsonkenneth chairman since july prior to that chairman president and chief executive officerjulie vice president and chief patient officer population health and sustainability since july rita vice president finance global controller since march michael vice president chief strategy officer since july senior vice president cfo of merck and head of global portfolio and alliance management january june senior vice president of corporate strategy and planning and president of emerging business december january prior to that vice president global business and financial planninglisa lecointe vice president chief ethic and compliance officer since april executive director head of global investigation february april prior to that senior counsel litigation and government investigation bristol myers squibb companydean merck research laboratory since january senior vice president discovery science and translational medicine merck research laboratory november january vice president translational medicine march november prior to that chief scientific officer and associate vice president university of utah health sciencescaroline vice president and chief financial officer since april senior vice president corporate treasurer january march prior to that senior vice president global human health steven vice president chief human resource officer since december david vice president chief information and digital officer since august acting chief information and digital officer december august vice president and chief information officer merck animal health may december prior to that associate vice president and chief information officer merck animal healthjennifer vice president general counsel and corporate secretary since january executive vice president and general counsel april january prior to that partner covington burling of contentson february the company announced that arpa garay will lead human health global marketing and mr jannie oosthuizen will lead human health both garay and mr oosthuizen will become executive officer of the company effective february nameageoffices and business experiencearpa global oncology and digital since january president global pharmaceutical commercial analytics digital marketing march january senior vice president vaccine business unit june march prior to that managing director msd norwayjannie vice president and president merck human health since january senior vice president and head of global oncology commercial january december senior vice president and president of msd july december of contentspart ii item market for registrant common equity related stockholder matter and issuer purchase of equity security the principal market for trading of the company common stock is the new york stock exchange nyse under the symbol mrk of january there were approximately shareholder of record of the company common stock issuer purchase of equity security for the three month ended december were follows issuer purchase of equity security in million periodtotal numberof sharespurchased average pricepaid persharetotal number of share purchased part of publicly announced plan or programsapproximate dollar value of sharesthat may yet be purchasedunder the plan or program october october november december all share purchased during the period were made part of plan approved by the board of director in october to purchase up to billion in merck share for it treasury of contentsperformance graphthe following graph assumes investment on december and reinvestment of all dividend in each of the company common stock the index and composite peer group of major and european based pharmaceutical company which are abbvie inc amgen inc astrazeneca plc bristol myers squibb company johnson johnson eli lilly and company glaxosmithkline plc novartis ag pfizer inc roche holding ag and sanofi sa comparison of five year cumulative total returnmerck co inc composite peer group and indexend ofperiod merck peer group compound annual growth rate peer group average wa calculated on market cap weighted basis of december this performance graph will not be deemed to be incorporated by reference into any filing under the security act of or the security exchange act of except to the extent that the company specifically incorporates it by reference in addition the performance graph will not be deemed to be soliciting material or to be filed with the sec or subject to regulation or other than provided in regulation or to the liability of section of the security exchange act of except to the extent that the company specifically request that such information be treated soliciting material or specifically incorporates it by reference into filing under the security act or the exchange act of contentsitem management discussion and analysis of financial condition and result of operation description of merck businessmerck co inc merck or the company is global health care company that delivers innovative health solution through it prescription medicine vaccine biologic therapy and animal health product the company operation are principally managed on product basis and include two operating segment which are the pharmaceutical and animal health segment both of which are reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the company previously had healthcare service segment that provided service and solution focused on engagement health analytics and clinical service to improve the value of care delivered to patient the company divested the remaining business in this segment during the first quarter of spin off of organon co on june merck completed the spin off of product from it woman health biosimilars and established brand business into new independent publicly traded company named organon co organon through distribution of organon publicly traded stock to company shareholder the distribution is expected to qualify and ha been treated tax free to the company and it shareholder for federal income tax purpose the established brand included in the transaction consisted of dermatology non opioid pain management respiratory select cardiovascular product well the rest of merck diversified brand franchise merck existing research pipeline program continue to be owned and developed within merck planned the historical result of the business that were contributed to organon in the spin off have been reflected discontinued operation in the company consolidated financial statement through the date of the spin off see note to the consolidated financial statement of contentsoverviewfinancial highlight in million change change excluding change change excluding net income from continuing operation attributable to merck co inc gaap non gaap earnings per common share assuming dilution from continuing operation attributable to merck co inc common shareholder gaap non gaap calculation not meaningful non gaap net income and non gaap earnings per share eps exclude acquisition and divestiture related cost restructuring cost and certain other item for further discussion and reconciliation of gaap to non gaap net income and eps see non gaap income and non gaap eps below executive summaryduring merck delivered on it strategic priority by executing commercially to drive strong revenue and earnings growth in the year completing key business development transaction accelerating it broad pipeline and achieving notable regulatory milestone also on june merck completed the spin off of organon the historical result of the business that were contributed to organon in the spin off have been reflected discontinued operation in the company consolidated financial statement through the date of the spin off worldwide sale were billion in an increase of compared with or excluding the favorable effect of foreign exchange the sale increase wa driven primarily by growth in oncology vaccine hospital acute care and animal health additionally revenue in reflects the benefit of sale of molnupiravir an investigational oral antiviral covid treatment discussed below covid related disruption negatively affected sale in but to lesser extent than in which benefited year over year sale growth merck continues to execute scientifically compelling business development opportunity to augment it pipeline in november merck acquired acceleron pharma inc acceleron publicly traded biopharmaceutical company evaluating the transforming growth factor tgf beta superfamily of protein through the development of pulmonary and hematologic therapy in april merck acquired pandion therapeutic inc pandion clinical stage biotechnology company developing novel therapeutic designed to address the unmet need of patient living with autoimmune disease additionally merck entered into collaboration with gilead science inc gilead to jointly develop and commercialize long acting treatment in hiv in merck received over approval and filed over new drug application ndas and supplemental biologics license application blas across the the eu japan and china during the company received numerous regulatory approval within oncology keytruda received approval for additional indication in the and or internationally monotherapy in the therapeutic area of breast colorectal cutaneous squamous cell esophageal melanoma and renal cell cancer well in combination with chemotherapy in the therapeutic area of breast cervical gastric or gastroesophageal junction cancer keytruda wa also approved in combination with lenvima both for the treatment of certain adult patient with endometrial cancer and for the treatment of renal cell cancer lenvima is being developed in collaboration with eisai co ltd eisai lynparza which is being developed in collaboration with astrazeneca plc astrazeneca received approval in china monotherapy for the treatment of certain adult patient with metastatic castration resistant prostate cancer additionally the food and drug administration fda approved welireg belzutifan an oral hypoxia inducible factor alpha hif inhibitor for the treatment of adult patient with von hippel lindau vhl of contentsdisease who require therapy for associated renal cell carcinoma rcc central nervous system hemangioblastomas or pancreatic neuroendocrine tumor not requiring immediate surgery also in updated in february the fda granted emergency use authorization eua for molnupiravir an investigational oral antiviral covid treatment being developed in collaboration with ridgeback biotherapuetics lp ridgeback molnupiravir also received conditional marketing authorization in the united kingdom uk and special approval for emergency in japan also in the fda and the european commission ec approved vaxneuvance pneumococcal valent conjugate vaccine pneumococcal conjugate vaccine for use in adult additionally verquvo medicine to reduce the risk of cardiovascular death and heart failure hospitalization following hospitalization for heart failure or need for outpatient intravenous diuretic in adult wa approved in the the eu and japan verquvo is being jointly developed with bayer ag bayer in january the japan ministry of health labor and welfare mhlw approved lyfnua gefapixant for adult with refractory or unexplained chronic cough in addition to the recent regulatory approval discussed above the company advanced it late stage pipeline with several regulatory submission keytruda is under review in the and or internationally for supplemental indication for the treatment of certain patient with triple negative breast cervical endometrial melanoma renal cell and tumor mutation burden high tmbh cancer lynparza is under review for supplemental indication for the treatment of certain patient with breast and prostate cancer lenvima is under review in combination with keytruda for supplemental indication for the treatment of certain patient with hepatocellular carcinoma hcc mk molnupiravir is under rolling review by the european medicine agency ema mk gefapixant selective non narcotic orally administered investigational receptor antagonist being developed for the treatment of refractory chronic cough is under review in the and the eu and vaxneuvance valent pneumococcal conjugate vaccine is under priority review by the fda for the prevention of invasive pneumococcal disease in pediatric patient is also under review in japan for use in adult the company phase oncology program include keytruda in the therapeutic area of biliary cutaneous squamous cell gastric hepatocellular mesothelioma ovarian prostate and small cell lung cancer lynparza monotherapy for colorectal cancer and in combination with keytruda for non small cell lung and small cell lung cancer lenvima in combination with keytruda for colorectal esophageal gastric head and neck melanoma and non small cell lung cancer welireg for rcc mk the coformulation of quavonlimab merck novel investigational anti ctla antibody and pembrolizumab for rcc mk pembrolizumab subcutaneous for non small cell lung cancer nsclc mk tukysa tucatinib which is being developed in collaboration with seagen inc seagen for breast cancer mk the coformulation of favezelimab merck novel investigational anti therapy and pembrolizumab for colorectal cancer and mk the coformulation of vibostolimab an anti tigit therapy and pembrolizumab for nsclc additionally the company ha candidate in phase clinical development in several other therapeutic area including mk sotatercept for the treatment of pulmonary arterial hypertension pah which wa obtained in the acceleron acquisition mk clesrovimab for the prevention of respiratory syncytial virus mk islatravir an investigational nucleoside reverse transcriptase translocation inhibitor nrtti for the prevention of hiv infection which is on clinical hold of content mk islatravir in combination with doravirine for the treatment of hiv infection which is on clinical hold and mk molnupiravir which is reflected in phase development in the it remains investigational following eua the company is allocating resource to support it commercial opportunity in the near term while investing heavily in research to support future innovation and long term growth research and development expense in reflect higher clinical development spending and increased investment in discovery research and early drug development in november merck board of director approved an increase to the company quarterly dividend raising it to per share from per share on the company outstanding common stock during the company returned billion to shareholder through dividend and share repurchase in december the company completed it inaugural issuance of billion sustainability bond which wa part of an billion underwritten bond offering the company intends to use the net proceeds from the sustainability bond offering to support project and partnership in the company priority environmental social and governance esg area and contribute to the advancement of the united nation sustainable development goal covid updateduring the covid pandemic merck ha remained focused on protecting the safety of it employee ensuring that it supply of medicine and vaccine reach it patient contributing it scientific expertise to the development of an antiviral therapy supporting effort to expand manufacturing capacity and supply of sars cov covid medicine and vaccine see below and supporting health care provider and merck community although covid related disruption negatively affected result in and merck continues to experience strong global underlying demand across it business in merck sale were unfavorably affected by covid related disruption which resulted in an estimated negative impact to merck pharmaceutical segment sale of approximately billion roughly of merck pharmaceutical segment revenue is comprised of physician administered product which despite strong underlying demand have been affected by social distancing measure and fewer well visit merck sale were favorably affected by the authorization of molnupiravir in several market discussed further below which resulted in sale of million in in the estimated negative impact of covid related disruption to merck sale wa approximately billion of which approximately billion wa attributable to the pharmaceutical segment and approximately million wa attributable to the animal health segment in april merck announced it wa discontinuing the development of mk formerly known for the treatment of hospitalized patient with covid which wa obtained part of merck acquisition of oncoimmune see note to the consolidated financial statement this decision resulted in charge of million to cost of sale in in january the company announced the discontinuation of the development program for it covid vaccine candidate and following merck review of finding from phase clinical study for the vaccine in these study both and were generally well tolerated but the immune response were inferior to those seen following natural infection and those reported for other sars cov covid vaccine due to the discontinuation the company recorded charge of million in of which million wa reflected in cost of sale and the remaining million of cost were reflected in research and development expense operating expense reflect minor positive effect in investment in covid related research largely offset the favorable impact of lower spending in other area due to the covid pandemic operating expense were positively affected in by approximately million primarily due to lower promotional and selling cost well lower research and development expense net of investment in covid related antiviral and vaccine research program in addition the covid pandemic ha caused some disruption and volatility in the company global supply chain network and the company may in the future experience disruption in availability and delay in shipment of raw material and packaging well related cost inflation in december the fda granted eua for molnupiravir based on positive result from the phase move out clinical trial additionally in december japan mhlw granted special approval for of contentsemergency for molnupiravir in november the uk medicine and healthcare product regulatory agency granted conditional marketing authorization for molnupiravir in addition in october the ema initiated rolling review for molnupiravir merck plan to work with the committee for medicinal product for human use of the ema to complete the rolling review process to facilitate initiating the formal review of the marketing authorization application merck is developing molnupiravir in collaboration with ridgeback the company are actively working with other regulatory agency worldwide to submit application for emergency use or marketing authorization merck ha entered into advance purchase and supply agreement for molnupiravir in more than market see note to the consolidated financial statement for additional information related to the collaboration with ridgeback in march merck announced it had entered into multiple agreement to support effort to expand manufacturing capacity and supply of sars cov covid medicine and vaccine the biomedical advanced research and development authority barda division of the office of the assistant secretary for preparedness and response within the department of health and human service is providing merck with funding to adapt and make available number of existing manufacturing facility for the production of sars cov covid vaccine and medicine merck ha also entered into agreement to support the manufacturing and supply of johnson johnson sars cov covid vaccine merck is using certain of it facility in the to produce drug substance formulate and fill vial of johnson johnson vaccine pricingglobal effort toward health care cost containment continue to exert pressure on product pricing and market access worldwide change to the health care system part of health care reform enacted in prior year well increased purchasing power of entity that negotiate on behalf of medicare medicaid and private sector beneficiary have contributed to pricing pressure in several international market government mandated pricing action have reduced price of generic and patented drug in addition the company revenue performance in wa negatively affected by other cost reduction measure taken by government and other third party to lower health care cost in the the biden administration and congress continue to discus legislation designed to control health care cost including the cost of drug the company anticipates all of these action and additional action in the future will continue to negatively affect revenue performance operating resultssales in million change change excluding change change excluding state total worldwide sale grew in primarily due to higher sale in the oncology franchise largely driven by strong growth of keytruda and increased alliance revenue from lynparza and lenvima well higher sale in the vaccine franchise primarily attributable to growth in gardasil gardasil varivax and proquad also contributing to revenue growth in were higher sale in the virology franchise attributable to molnupiravir higher sale in the hospital acute care franchise reflecting growth in bridion and prevymis well higher sale of animal health product additionally sale in benefited from higher third party manufacturing sale and the achievement of milestone for an out licensed product that triggered contingent payment to merck discussed above covid related disruption unfavorably affected sale in but to lesser extent than in which benefited year over year sale growth sale growth in wa partially offset by lower sale of pneumovax the suspension of sale in of hospital acute care product zerbaxa and lower sale of virology product isentress isentress hd sale in the grew in primarily driven by higher sale of keytruda sale of molnupiravir higher sale of bridion gardasil varivax and proquad increased alliance revenue from lynparza and lenvima of contentsas well higher sale of animal health product lower sale of pneumovax januvia janumet and zerbaxa partially offset revenue growth in the in international sale increased in primarily due to growth in gardasil gardasil keytruda sale of molnupiravir increased alliance revenue from lynparza and lenvima well higher sale of januvia janumet bridion prevymis and animal health product international sale growth in wa partially offset by lower sale of noxafil zerbaxa and isentress isentress hd international sale represented and of total sale in and respectively worldwide sale increased in primarily due to higher sale in the oncology franchise well growth in certain hospital acute care product and animal health growth in these area wa largely offset by the negative effect of the covid pandemic discussed above competitive pressure in the virology franchise and pricing pressure in the diabetes franchise see note to the consolidated financial statement for detail on sale of the company product discussion of performance for select product in the franchise follows pharmaceutical segmentoncology in million change change excluding change change excluding alliance revenue lynparza alliance revenue lenvima alliance revenue represents merck share of profit which are product sale net of cost of sale and commercialization cost see note to the consolidated financial statement keytruda is an anti pd programmed death receptor therapy that ha been approved monotherapy for the treatment of certain patient with cervical cancer classical hodgkin lymphoma chl cutaneous squamous cell carcinoma cscc esophageal or gastroesophageal junction gej carcinoma head and neck squamous cell carcinoma hnscc hcc nsclc melanoma merkel cell carcinoma microsatellite instability high msi or mismatch repair deficient dmmr cancer solid tumor including msi dmmr colorectal cancer primary mediastinal large cell lymphoma tmb cancer solid tumor and urothelial carcinoma including non muscle invasive bladder cancer additionally keytruda is approved monotherapy for the adjuvant treatment of certain patient with rcc keytruda is also approved for the treatment of certain patient in combination with chemotherapy for metastatic squamous and nonsquamous nsclc in combination with chemotherapy with or without bevacizumab for cervical cancer in combination with chemotherapy for esophageal cancer in combination with chemotherapy for gastric cancer in combination with chemotherapy for hnscc in combination with chemotherapy for triple negative breast cancer tnbc in combination with axitinib for advanced rcc and in combination with lenvima for both endometrial carcinoma and rcc the keytruda clinical development program includes study across broad range of cancer type global sale of keytruda grew in driven by higher demand the company continues to launch keytruda with multiple new indication globally although the covid pandemic had dampening effect on growing demand by negatively affecting the number of new patient starting treatment sale in the continue to build across the multiple approved indication in particular for the treatment of advanced nsclc monotherapy and in combination with chemotherapy for both nonsquamous and squamous metastatic nsclc along with continued uptake in the tnbc rcc hnscc msi cancer and esophageal cancer indication keytruda sale growth in international market reflects continued uptake predominately for the nsclc hnscc and rcc indication particularly in europe sale growth in wa partially offset by lower pricing in europe china and japan global sale of keytruda grew in driven by higher demand globally particularly in the and europe although the covid pandemic had an unfavorable effect on growing demand sale growth in wa partially offset by lower pricing in japan and europe of contentskeytruda received numerous regulatory approval in summarized below dateapprovaljanuary approval first line treatment in adult patient with msi or dmmr colorectal cancer based on the keynote study march approval of an expanded label monotherapy for the treatment of adult and pediatric patient aged year and older with relapsed or refractory chl who have failed autologous stem cell transplant asct or following at least two prior therapy when asct is not treatment option based on the keynote and keynote trial march approval in combination with platinum and fluoropyrimidine based chemotherapy for the treatment of certain patient with locally advanced or metastatic esophageal or gej carcinoma that is not amenable to surgical resection or definitive chemoradiation based on the keynote trial may approval in combination with trastuzumab fluoropyrimidine and platinum containing chemotherapy for the first line treatment of patient with locally advanced unresectable or metastatic human epidermal growth factor receptor positive gastric or gej adenocarcinoma based on the keynote trial may approval of the mg every six week dosing regimen to indication where keytruda is administered in combination with other anticancer agent june national medical product administration nmpa approval first line treatment of adult patient with msi or dmmr colorectal cancer that is kras nra and braf all wild type based on the keynote study june approval in combination with chemotherapy for the first line treatment of patient with locally advanced unresectable or metastatic carcinoma of the esophagus or negative gej adenocarcinoma in adult whose tumor express pd based on the keynote trial july approval monotherapy for the treatment of patient with locally advanced cscc that is not curable by surgery or radiation based on the keynote trial july approval of keytruda plus lenvima for the treatment of patient with advanced endometrial carcinoma that is not msi or dmmr who have disease progression following prior systemic therapy in any setting and are not candidate for curative surgery or radiation based on the keynote study trial july approval of keytruda for treatment of patient with high risk early stage tnbc in combination with chemotherapy neoadjuvant treatment and then continued single agent adjuvant treatment after surgery based on the keynote trial august approval of keytruda plus lenvima for the first line treatment of adult patient with advanced rcc based on the keynote trial study trial august pharmaceutical and medical device agency pmda approval for the treatment of patient with unresectable advanced or recurrent msi colorectal cancer based on the keynote trial august pmda approval for the treatment of patient with pd positive hormone receptor negative and negative inoperable or recurrent breast cancer based on the keynote trial september nmpa approval in combination with chemotherapy for the first line treatment of patient with locally advanced unresectable or metastatic carcinoma of the esophagus or gej based on the keynote trial october approval in combination with chemotherapy with or without bevacizumab for the treatment of patient with persistent recurrent or metastatic cervical cancer based on the keynote trial october approval in combination with chemotherapy for the first line treatment of locally recurrent unresectable or metastatic tnbc in adult whose tumor express pd and who have not received prior chemotherapy for metastatic disease based on the keynote trial november approval for the adjuvant treatment of patient with rcc at intermediate high or high risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesion based on the keynote trial of contentsnovember approval of keytruda plus lenvima for the first line treatment of adult patient with advanced rcc based on the clear study keynote trial november approval of keytruda plus lenvima for the treatment of advanced or recurrent endometrial carcinoma in adult who have disease progression on or following prior treatment with platinum containing therapy in any setting and who are not candidate for curative surgery or radiation based on the keynote study trial november pmda approval in combination with chemotherapy fluorouracil plus cisplatin for the first line treatment of patient with radically unresectable advanced or recurrent esophageal carcinoma in combination with chemotherapy based on the keynote trial december approval for the adjuvant treatment of adult and pediatric year and older patient with stage iib or iic melanoma following complete resection based on the keynote trial fda expanded the indication for the adjuvant treatment of stage iii melanoma following complete resection to include pediatric patient year and older december mhlw approval of keytruda in combination with lenvima for the treatment of patient with unresectable advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy based on the keynote study trial in march merck announced it wa voluntarily withdrawing the indication for keytruda for the treatment of patient with metastatic small cell lung cancer with disease progression on or after platinum based chemotherapy and at least one other prior line of therapy the withdrawal of this indication wa done in consultation with the fda and doe not affect other indication for keytruda announced in january keynote the confirmatory phase trial for this indication met one of it dual primary endpoint of progression free survival but did not reach statistical significance for the other primary endpoint of overall survival in merck initiated the withdrawal of the accelerated approval indication for keytruda for the treatment of patient with recurrent locally advanced or metastatic gastric or gej adenocarcinoma whose tumor express pd with disease progression on or after two or more prior line of therapy the decision wa made in consultation with the fda following the oncologic drug advisory committee evaluation of this third line gastric cancer indication for keytruda monotherapy because it failed to meet it post marketing requirement of demonstrating an overall survival benefit in phase study the withdrawal of this indication doe not affect other indication for keytruda the company is party to certain third party license agreement pursuant to which the company pay royalty on sale of keytruda under the term of the more significant of these agreement merck pay royalty of on worldwide sale of keytruda through to one third party this royalty will decline to for through and will terminate thereafter the company pay an additional royalty on worldwide sale of keytruda to another third party the termination date of which varies by country this royalty will expire in the in and in major european market in the royalty are included in cost of sale lynparza is an oral poly adp ribose polymerase parp inhibitor being developed part of collaboration with astrazeneca see note to the consolidated financial statement lynparza is approved for the treatment of certain type of advanced ovarian breast pancreatic and prostate cancer alliance revenue related to lynparza grew in and in due to continued uptake across the multiple approved indication in the europe japan and china in june lynparza wa granted conditional approval in china monotherapy for the treatment of certain previously treated adult patient with germline or somatic brca mutated metastatic castration resistant prostate cancer based on the result of the profound trial lenvima is an oral receptor tyrosine kinase inhibitor being developed part of collaboration with eisai see note to the consolidated financial statement lenvima is approved for the treatment of certain type of thyroid cancer hcc in combination with everolimus for certain patient with rcc and in combination with keytruda both for the treatment of certain patient with endometrial carcinoma and for the treatment of certain patient with rcc alliance revenue related to lenvima grew in and in primarily due to higher demand in the and china global sale of emend aprepitant for the prevention of certain chemotherapy induced nausea and vomiting declined in reflecting lower volume in europe and china worldwide sale of emend of contentsdecreased in primarily due to lower demand and pricing in the due to generic competition for emend for injection following patent expiry in september also contributing to the emend sale decline in wa lower demand in europe and japan result of generic competition for the oral formulation of emend following loss of market exclusivity in may and december respectively in june koselugo selumetinib wa granted conditional approval in the eu for the treatment of pediatric patient three year of age and older with neurofibromatosis type who have symptomatic inoperable plexiform neurofibroma based on positive result from the national cancer institute cancer therapy evaluation program sponsored sprint stratum trial koselugo wa approved by the fda in april koselugo is part of the same collaboration with astrazeneca referenced above that includes lynparza in august the fda approved welireg an oral hif inhibitor for the treatment of adult patient with vhl disease who require therapy for associated rcc central nervous system hemangioblastomas or pancreatic neuroendocrine tumor not requiring immediate surgery the approval wa based on result from the open label study trial welireg wa obtained part of merck acquisition of peloton therapeutic inc peloton see note to the consolidated financial statement vaccine in million change change excluding change change excluding gardasil pneumovax worldwide sale of gardasil gardasil vaccine to help prevent certain cancer and other disease caused by certain type of human papillomavirus hpv grew in driven primarily by strong global demand particularly in china well increased supply higher pricing in china and the also contributed to sale growth in sale growth in wa unfavorably affected by the replenishment in of dos borrowed from the center for disease control and prevention cdc pediatric vaccine stockpile which favorably affected sale by million in the timing of public sector purchase in the also partially offset sale growth in global sale of gardasil gardasil grew in primarily due to higher volume in china and the replenishment in of dos borrowed from the cdc pediatric vaccine stockpile in the replenishment resulted in the recognition of sale of million in which when combined with the reduction of sale of million in due to the borrowing resulted in favorable impact to sale of million in compared with lower demand in the and hong kong sar prc attributable to the covid pandemic partially offset the increase in sale of gardasil gardasil in the company is party to certain third party license agreement pursuant to which the company pay royalty on sale of gardasil gardasil under the term of the more significant of these agreement merck pay royalty on worldwide sale of gardasil gardasil to one third party royalty obligation under this agreement expire in december and an additional royalty on sale of gardasil gardasil in the to another third party these royalty obligation expire in december the royalty are included in cost of sale global sale of proquad pediatric combination vaccine to help protect against measles mumps rubella and varicella grew in due to higher sale in the reflecting higher demand driven by the ongoing covid pandemic recovery well higher pricing worldwide sale of proquad declined in driven primarily by lower demand in the resulting from fewer measles outbreak in compared with coupled with the unfavorable impact of the covid pandemic partially offset by higher pricing worldwide sale of ii vaccine to help protect against measles mumps and rubella grew in primarily due to higher sale in the reflecting the ongoing covid pandemic recovery inclusive of higher public sector mix of business lower demand in europe partially offset ii sale growth in global sale of ii declined in driven primarily by lower demand in the resulting from fewer of contentsmeasles outbreak in compared with coupled with the unfavorable impact of the covid pandemic lower demand in brazil also contributed to the ii sale decline in global sale of varivax vaccine to help prevent chickenpox varicella grew in primarily reflecting the ongoing covid pandemic recovery and higher pricing in the higher government tender in brazil also contributed to varivax sale growth in worldwide sale of varivax declined in driven primarily by lower demand in the resulting from the covid pandemic partially offset by higher pricing the varivax sale decline in wa also attributable to lower government tender in brazil worldwide sale of pneumovax vaccine to help prevent pneumococcal disease declined in primarily due to lower sale in the attributable to lower demand reflecting prioritization of covid vaccination partially offset by higher pricing global sale of pneumovax grew in primarily due to higher volume in europe and the attributable in part to heightened awareness of pneumococcal vaccination higher pricing in the also contributed to pneumovax sale growth in in july the fda approved vaxneuvance for active immunization for the prevention of invasive disease caused by streptococcus pneumoniae serotypes in adult year of age and older in december vaxneuvance wa approved by the ec these approval were based on data from seven clinical study assessing safety tolerability and immunogenicity in adult in october the cdc advisory committee on immunization practice acip voted to recommend vaccination either with sequential regimen of vaxneuvance followed by pneumovax or with single dose of valent pneumococcal conjugate vaccine both for adult year and older and for adult age to with certain underlying medical condition these recommendation subsequently were adopted by the director of the cdc and the department of health and human service and published in the cdc morbidity and mortality weekly report in september merck announced settlement and license agreement with pfizer inc pfizer resolving all worldwide patent infringement litigation related to the use of merck investigational and licensed pneumococcal conjugate vaccine pcv product including vaxneuvance under the term of the agreement merck will make certain regulatory milestone payment to pfizer well royalty payment on the worldwide sale of it pcv product the company will pay royalty of of net sale of all merck pcv product through and of net sale of all merck pcv product from through vaxelis diphtheria and tetanus toxoid and acellular pertussis inactivated poliovirus haemophilus conjugate and hepatitis vaccine developed part of based partnership between merck and sanofi pasteur is now available in the for active immunization of child six week through four year of age to help prevent diphtheria tetanus pertussis poliomyelitis hepatitis and invasive disease due to haemophilus influenzae type in february the cdc acip included vaxelis combination vaccine option in the cdc recommended child and adolescent immunization schedule sale of vaxelis in the are made through the based merck sanofi pasteur partnership the result of which are reflected in equity income from affiliate included in other income expense net supply sale to the partnership are recorded within sale vaxelis is also approved in the eu where it is marketed directly by merck and sanofi pasteur hospital acute care in million change change excluding change change excluding zerbaxa calculation not meaningful global sale of bridion for the reversal of two type of neuromuscular blocking agent used during surgery grew in due to higher demand globally particularly in the and europe attributable to the covid pandemic recovery well increased usage of neuromuscular blockade reversal agent and bridion growing share within the class bridion wa also approved by the fda in june for pediatric patient aged year and older undergoing surgery worldwide sale of bridion grew in due to higher demand globally of contentsparticularly in the however fewer elective surgery result of the covid pandemic unfavorably affected demand in worldwide sale of prevymis medicine for prophylaxis prevention of cytomegalovirus cmv infection and disease in adult cmv seropositive recipient of an allogenic hematopoietic stem cell transplant grew in and increased in due to continued uptake since launch in several market particularly in europe and the worldwide sale of noxafil an antifungal agent for the prevention of certain invasive fungal infection declined in primarily due to generic competition in europe partially offset by higher demand in china the patent that provided market exclusivity for noxafil in number of major european market expired in december result the company is experiencing lower demand for noxafil in these market due to generic competition and expects the decline to continue global sale of noxafil declined in due to generic competition in the and in europe the patent that provided market exclusivity for certain form of noxafil representing the majority of noxafil sale expired in july in december the company temporarily suspended sale of zerbaxa combination antibacterial and beta lactamase inhibitor for the treatment of certain bacterial infection and subsequently issued product recall following the identification of product sterility issue result the company recorded an intangible asset impairment charge in related to zerbaxa see note to the consolidated financial statement phased resupply of zerbaxa wa initiated in the fourth quarter of which the company expects to continue during immunology in million change change excluding change change excluding sale of simponi once monthly subcutaneous treatment for certain inflammatory disease marketed by the company in europe russia and turkey declined in and were nearly flat in sale of simponi are being unfavorably affected by biosimilar competition for competing product the company expects this competition will continue to unfavorably affect sale of simponi sale of remicade treatment for inflammatory disease marketed by the company in europe russia and turkey declined in and decreased in driven by ongoing biosimilar competition in the company marketing territory in europe the company lost market exclusivity for remicade in major european market in and no longer ha market exclusivity in any of it marketing territory the company is experiencing pricing and volume decline in these market result of biosimilar competition and expects the decline to continue the company marketing right with respect to these product will revert to janssen pharmaceutical inc on october virology in million change change excluding change change excluding isentress isentress molnupiravir is an investigational oral antiviral covid medicine being developed in collaboration with ridgeback see note to the consolidated financial statement the fda granted an eua for molnupiravir in december updated in february to authorize molnupiravir for the treatment of mild to moderate covid in high risk adult for whom alternative fda approved or authorized treatment option are not of contentsaccessible or clinically appropriate also in december japan mhlw granted special approval for emergency for molnupiravir to treat infectious disease caused by sars cov in november the uk mhra granted conditional marketing authorization for molnupiravir to treat mild to moderate covid in adult at risk of developing severe illness merck ha entered into advance purchase and supply agreement for molnupiravir in more than market and merck began shipping molnupiravir in the fourth quarter of to country where it is approved or authorized sale of molnupiravir were million in primarily consisting of sale in the the uk and japan worldwide sale of isentress isentress hd an hiv integrase inhibitor for use in combination with other antiretroviral agent for the treatment of hiv infection declined in and decreased in primarily due to competitive pressure particularly in europe and the the company expects competitive pressure for isentress isentress hd to continue global sale of zepatier treatment for adult patient with chronic hepatitis virus genotype gt or infection declined in primarily due to lower demand from competitive pressure in the and europe worldwide sale of zepatier declined in driven by lower demand globally due to competition and declining patient volume coupled with the impact of the covid pandemic cardiovascular in million change change excluding change change excluding revenue adempas verquvo alliance revenue represents merck share of profit from sale in bayer marketing territory which are product sale net of cost of sale and commercialization cost see note to the consolidated financial statement adempas and verquvo are part of worldwide collaboration with bayer to market and develop soluble guanylate cyclase sgc modulators see note to the consolidated financial statement adempas is approved for the treatment of certain type of pah verquvo wa approved in the in january to reduce the risk of cardiovascular death and heart failure hospitalization following hospitalization for heart failure or need for outpatient intravenous diuretic in adult with symptomatic chronic heart failure and reduced ejection fraction verquvo wa also approved in japan in june and in the eu in july these approval were based on the result of the victoria trial alliance revenue from the collaboration grew in and rose in revenue from the collaboration also includes sale of adempas and verquvo in merck marketing territory sale of adempas in merck marketing territory grew in primarily reflecting higher demand in europe diabetes in million change change excluding change change excluding janumet worldwide combined sale of januvia and janumet medicine that help lower blood sugar level in adult with type diabetes were nearly flat in and declined in sale performance in both period reflects continued pricing pressure and lower demand in the largely offset by higher demand in certain international market particularly in china the company expects pricing pressure to continue januvia and janumet will lose market exclusivity in the in january in the eu in september and in china in july the company anticipates sale of januvia and janumet in these market will decline substantially after the loss of exclusivity combined sale of januvia and janumet in the europe and china represented and respectively of total combined januvia and janumet sale in of contentsanimal health segment in million change change excluding change change excluding companion sale of livestock product grew in primarily due to higher demand for ruminant product including animal health intelligence solution for animal identification monitoring and traceability well higher demand for poultry and swine product sale of livestock product increased in predominantly due to an additional five month of sale in related to the april acquisition of antelliq leader in digital animal identification traceability and monitoring solution see note to the consolidated financial statement sale of companion animal product grew in and rose in primarily due to higher demand for parasiticides including the bravecto line of product well higher demand for companion animal vaccine cost expense and other in million of sale selling general and research and restructuring other income expense net calculation not meaningful cost of salescost of sale wa billion in both and and wa billion in cost of sale includes the amortization of intangible asset recorded in connection with acquisition collaboration and licensing arrangement which totaled billion in billion in and billion in cost in and also include charge of million and million respectively related to the discontinuation of covid development program see note to the consolidated financial statement additionally cost in and include intangible asset impairment charge of billion and million related to marketed product and other intangible see note to the consolidated financial statement the company may recognize additional impairment charge in the future related to intangible asset that were measured at fair value and capitalized in connection with business combination and such charge could be material cost in also include inventory write offs of million related to recall for zerbaxa see note to the consolidated financial statement also included in cost of sale are expense associated with restructuring activity which amounted to million in million in and million in primarily reflecting accelerated depreciation and asset write offs related to the planned sale or closure of manufacturing facility separation cost associated with manufacturing related headcount reduction have been incurred and are reflected in restructuring cost discussed below gross margin wa in compared with in the gross margin improvement in reflects lower impairment and amortization of intangible asset noted above well the favorable effect of product mix and lower inventory write offs partially offsetting the gross margin improvement in were higher manufacturing cost the impact of molnupiravir which ha lower gross margin due to profit sharing with ridgeback discussed in note to the consolidated financial statement and higher compensation and benefit cost gross margin wa in compared with in the gross margin decline in reflects the unfavorable effect of higher impairment and amortization of intangible asset pricing pressure charge related to the discontinuation of covid vaccine development program and higher inventory write offs related to the recall of zerbaxa noted above partially offset by the favorable effect of product mix and lower restructuring cost of contentsselling general and administrativeselling general and administrative sg expense were billion in an increase of compared with the increase wa primarily due to higher administrative cost including compensation and benefit higher promotional expense in support of the company key growth pillar and higher acquisition related cost including cost related to the acquisition of acceleron the covid pandemic drove lower spending in which contributed to the increase in sg expense in these increase were partially offset by the favorable effect of foreign exchange and contribution in to the merck foundation sg expense were billion in decline of compared with the decline wa driven primarily by lower administrative selling and promotional cost including lower travel and meeting expense due in part to the covid pandemic and the favorable effect of foreign exchange partially offset by contribution to the merck foundation research and developmentresearch and development expense were billion in decline of compared with primarily due to lower upfront payment related to acquisition and collaboration the decline wa partially offset by higher clinical development spending and increased investment in discovery research and early drug development net of the reimbursement of portion of molnupiravir development cost through the partnership with ridgeback higher compensation and benefit cost higher in process research and development ipr impairment charge well cost related to the acquisition of acceleron also partially offset the decline in expense in expense were billion in an increase of compared with the increase wa driven largely by higher upfront payment related to acquisition and collaboration higher clinical development spending and increased investment in discovery research and early drug development higher restructuring cost also contributed to the increase in expense in the increase in expense in wa partially offset by lower ipr impairment charge and lower cost resulting from the covid pandemic net of spending on covid related vaccine and antiviral research program expense are comprised of the cost directly incurred by merck research laboratory mrl the company research and development division that focus on human health related activity which were billion in billion in and billion in also included in expense are animal health research cost licensing cost and cost incurred by other division in support of activity including depreciation production and general and administrative which in the aggregate were billion in billion in and billion in additionally expense in include billion charge for the acquisition of pandion expense in include billion charge for the acquisition of velosbio inc million charge for the acquisition of oncoimmune and charge of million related to transaction with seagen expense in include million charge for the acquisition of peloton see note to the consolidated financial statement for more information on these transaction expense also include ipr impairment charge of million million and million in and respectively see note to the consolidated financial statement the company may recognize additional impairment charge in the future related to the cancellation or delay of other pipeline program that were measured at fair value and capitalized in connection with business combination and such charge could be material in addition expense in and include million and million respectively of cost associated with restructuring activity primarily relating to accelerated depreciation expense also include expense or income related to change in the estimated fair value measurement of liability for contingent consideration recorded in connection with business combination the company recorded million of expense in compared with net reduction in expense of million and million in and respectively related to change in these estimate restructuring costsin merck approved global restructuring program restructuring program part of worldwide initiative focused on further optimizing the company manufacturing and supply network well reducing it global real estate footprint this program is continuation of the company plant rationalization and build on prior restructuring program the action currently contemplated under the restructuring program are expected to be substantially completed by the end of with the cumulative pretax cost to be incurred by the company to implement the program estimated to be approximately billion the company expects to record charge of of contentsapproximately million in related to the restructuring program the company anticipates the action under the restructuring program will result in annual net cost saving of approximately million by the end of restructuring cost primarily representing separation and other related cost associated with these restructuring activity were million in million in and million in separation cost incurred were associated with actual headcount reduction well estimated expense under existing severance program for headcount reduction that were probable and could be reasonably estimated also included in restructuring cost are asset abandonment facility shut and other related cost well employee related cost such curtailment settlement and termination charge associated with pension and other postretirement benefit plan and share based compensation plan cost for segment reporting restructuring cost are unallocated expense additional cost associated with the company restructuring activity are included in cost of sale selling general and administrative expense and research and development cost the company recorded aggregate pretax cost of million in million in and million in related to restructuring program activity see note to the consolidated financial statement other income expense netother income expense net wa billion of income in compared with million of income in primarily due to higher income from investment in equity security net largely related to higher realized and unrealized gain on certain investment including the disposition in of the company ownership interest in preventice solution inc preventice result of the acquisition of preventice by boston scientific partially offset by higher foreign exchange loss and pension settlement cost other income and expense net wa million of income in compared with million of expense in primarily due to higher income from investment in equity security net largely related to moderna inc for detail on the component of other income expense net see note to the consolidated financial statement segment profit in million segment profit animal health segment other non reportable segment profit other income from continuing operation before tax pharmaceutical segment profit are comprised of segment sale le standard cost well sg expense directly incurred by the segment animal health segment profit are comprised of segment sale le all cost of sale well sg and expense directly incurred by the segment for internal management reporting presented to the chief operating decision maker merck doe not allocate the remaining cost of sale not included in segment profit described above expense incurred by mrl or general and administrative expense the cost of financing these activity separate division maintain responsibility for monitoring and managing these cost including depreciation related to fixed asset utilized by these division and therefore they are not included in segment profit also excluded from the determination of segment profit are cost related to restructuring activity and acquisition and divestiture related cost including the amortization of intangible asset and amortization of purchase accounting adjustment intangible asset impairment charge and expense or income related to change in the estimated fair value measurement of liability for contingent consideration additionally segment profit do not reflect other expense from corporate and manufacturing cost center and other miscellaneous income or expense these unallocated item are reflected in other in the above table also included in other are miscellaneous corporate profit loss well operating profit loss related to third party manufacturing sale beginning in the amortization of intangible asset previously included part of the calculation of of contentssegment profit is now included in unallocated non segment corporate expense prior period pharmaceutical and animal health segment profit have been recast to reflect this change on comparable basis pharmaceutical segment profit grew in primarily due to higher sale and the favorable effect of foreign exchange partially offset by higher administrative and promotional cost pharmaceutical segment profit increased in driven primarily by higher sale well lower selling and promotional cost animal health segment profit grew in reflecting higher sale partially offset by higher promotional selling and administrative cost animal health segment profit increased in driven primarily by higher sale and lower promotional and selling cost partially offset by higher cost and the unfavorable effect of foreign exchange tax on incomethe effective income tax rate from continuing operation were in in and in the full year effective income tax rate reflects favorable mix of income and expense well higher foreign tax credit from ordinary business operation that the company wa able to credit in the effective income tax rate from continuing operation in also reflects the beneficial impact of the settlement of foreign tax matter well net tax benefit of million related to the settlement of certain federal income tax matter see note to the consolidated financial statement the effective income tax rate from continuing operation in also reflects the unfavorable effect of charge for the acquisition of pandion for which no tax benefit wa recognized the effective income tax rate in reflects the unfavorable impact of charge for the acquisition of velosbio for which no tax benefit wa recognized the effective income tax rate in reflects the favorable impact of million net tax benefit related to the settlement of certain federal income tax matter see note to the consolidated financial statement and the reversal of tax reserve established in connection with the divestiture of merck consumer care mcc business due to the lapse in the statute of limitation in addition the effective income tax rate in reflects the unfavorable impact of charge for the acquisition of peloton for which no tax benefit wa recognized and charge of million related to the finalization of treasury regulation for the transition tax associated with the enactment of tax legislation known the tax cut and job act tcja see note to the consolidated financial statement net income loss attributable to noncontrolling interestsnet income loss attributable to noncontrolling interest wa million in million in and million in the loss in wa driven primarily by the portion of goodwill impairment charge related to certain business in the healthcare service segment that were attributable to noncontrolling interest non gaap income and non gaap eps from continuing operationsnon gaap income and non gaap eps are alternative view of the company performance that merck is providing because management belief this information enhances investor understanding of the company result it permit investor to understand how management ass performance non gaap income and non gaap eps exclude certain item because of the nature of these item and the impact that they have on the analysis of underlying business performance and trend the excluded item which should not be considered non recurring consist of acquisition and divestiture related cost restructuring cost income and loss from investment in equity security and certain other item these excluded item are significant component in understanding and assessing financial performance non gaap income and non gaap eps are important internal measure for the company senior management receives monthly analysis of operating result that includes non gaap eps management us these measure internally for planning and forecasting purpose and to measure the performance of the company along with other metric in addition senior management annual compensation is derived in part using non gaap pretax income since non gaap income and non gaap eps are not measure determined in accordance with gaap they have no standardized meaning prescribed by gaap and therefore may not be comparable to the calculation of similar measure of other company the information on non gaap income and non gaap eps should be considered in addition to but not substitute for or superior to net income and eps prepared in accordance with generally accepted accounting principle in the gaap of contentsa reconciliation between gaap financial measure and non gaap financial measure from continuing operation is follows in million except per share amount from continuing operation before tax reported under gaap increase decrease for excluded item acquisition and divestiture related cost restructuring income from investment in equity security net other item charge for the acquisition of charge for the discontinuation of covid development charge for the acquisition of velosbio charge for the formation of collaboration charge for the acquisition of oncoimmune charge for the acquisition of peloton other non gaap income from continuing operation before tax on income reported under estimated tax benefit on excluded item net tax benefit from the settlement of certain federal income tax adjustment to tax benefit recorded in conjunction with the cubist pharmaceutical inc acquisition tax benefit from the reversal of tax reserve related to the divestiture of mcc net tax charge related to the finalization of treasury regulation related to the enactment of the tcja non gaap tax on income from continuing non gaap net income from continuing le net income loss attributable to noncontrolling interest reported under acquisition and divestiture related cost attributable to noncontrolling interest non gaap net income from continuing operation attributable to noncontrolling non gaap net income attributable to merck co inc eps assuming dilution from continuing operation reported under gaap eps non gaap eps assuming dilution from continuing operation amount in includes billion intangible asset impairment charge related to zerbaxa amount in includes million intangible asset impairment charge related to sivextro see note to the consolidated financial statement includes million related to transaction with seagen see note to the consolidated financial statement the estimated tax impact on the excluded item is determined by applying the statutory rate of the originating territory of the non gaap adjustment acquisition and divestiture related costsnon gaap income and non gaap eps exclude the impact of certain amount recorded in connection with acquisition and divestiture these amount include the amortization of intangible asset and amortization of purchase accounting adjustment to inventory well intangible asset impairment charge and expense or income related to change in the estimated fair value measurement of liability for contingent consideration also excluded are integration transaction and certain other cost associated with acquisition and divestiture non gaap income and non gaap eps also exclude amortization of intangible asset related to collaboration and licensing arrangement of contentsrestructuring costsnon gaap income and non gaap eps exclude cost related to restructuring action see note to the consolidated financial statement these amount include employee separation cost and accelerated depreciation associated with facility to be closed or divested accelerated depreciation cost represent the difference between the depreciation expense to be recognized over the revised useful life of the asset based upon the anticipated date the site will be closed or divested or the equipment disposed of and depreciation expense determined utilizing the useful life prior to the restructuring action restructuring cost also include asset abandonment facility shut down and other related cost well employee related cost such curtailment settlement and termination charge associated with pension and other postretirement benefit plan and share based compensation cost income and loss from investment in equity securitiesnon gaap income and non gaap eps exclude realized and unrealized gain and loss from investment in equity security either owned directly or through ownership interest in investment fund certain other itemsnon gaap income and non gaap eps exclude certain other item these item are adjusted for after evaluating them on an individual basis considering their quantitative and qualitative aspect typically these consist of item that are unusual in nature significant to the result of particular period or not indicative of future operating result excluded from non gaap income and non gaap eps are charge for the acquisition of pandion velosbio oncoimmune and peloton well charge related to collaboration including transaction with seagen see note to the consolidated financial statement also excluded from non gaap income and non gaap eps are charge related to the discontinuation of covid development program see note to the consolidated financial statement additionally excluded from non gaap income and non gaap eps are certain tax item including net tax benefit related to the settlement of certain federal income tax matter an adjustment to tax benefit recorded in conjunction with the acquisition of cubist pharmaceutical inc tax benefit related to the reversal of tax reserve established in connection with the divestiture of mcc and net tax charge related to the finalization of treasury regulation related to the tcja see note to the consolidated financial statement research and developmentresearch pipelinethe company currently ha several candidate under regulatory review in the and internationally well in late stage clinical development chart reflecting the company current research pipeline of february and related discussion is set forth in item business research and development above acquisition research collaboration and license agreementsmerck continues to remain focused on pursuing opportunity that have the potential to drive both near and long term growth certain recent transaction are summarized below additional detail are included in note to the consolidated financial statement merck actively monitor the landscape for growth opportunity that meet the company strategic criterion in march merck and gilead entered into an agreement to jointly develop and commercialize long acting treatment in hiv that combine merck investigational nrtti islatravir and gilead investigational capsid inhibitor lenacapavir the collaboration will initially focus on long acting oral formulation and long acting injectable formulation of these combination product with other formulation potentially added to the collaboration mutually agreed there wa no upfront payment made by either party upon entering into the agreement in april merck acquired pandion clinical stage biotechnology company developing novel therapeutic designed to address the unmet need of patient living with autoimmune disease for total consideration of billion pandion is advancing pipeline of precision immune modulators targeting critical immune control node in november merck acquired acceleron publicly traded biopharmaceutical company for total consideration of billion acceleron is evaluating the tgf beta superfamily of protein that is known to play central role in the regulation of cell growth differentiation and repair acceleron lead therapeutic candidate of contentssotatercept mk ha novel mechanism of action with the potential to improve short term and or long term clinical outcome in patient with pah sotatercept is in phase trial an add on to current standard of care for the treatment of pah in addition to sotatercept acceleron portfolio includes reblozyl luspatercept first in class erythroid maturation recombinant fusion protein that is approved in the europe canada and australia for the treatment of anemia in certain rare blood disorder and is being evaluated in clinical trial for additional indication for hematology therapy reblozyl is being developed and commercialized through global collaboration with bristol myers squibb acquired in process research and developmentin connection with business combination the company ha recorded the fair value of in process research project which at the time of acquisition had not yet reached technological feasibility at december the balance of ipr wa billion see note to the consolidated financial statement the ipr project that remain in development are subject to the inherent risk and uncertainty in drug development and it is possible that the company will not be able to successfully develop and complete the ipr program and profitably commercialize the underlying product candidate the time period to receive approval from the fda and other regulatory agency are subject to uncertainty significant delay in the approval process or the company failure to obtain approval at all would delay or prevent the company from realizing revenue from these product additionally if the ipr program require additional clinical trial data than previously anticipated or if the program fail or are abandoned during development then the company will not realize the future cash flow it ha estimated and recorded ipr of the acquisition date if such circumstance were to occur the company future operating result could be adversely affected and the company may recognize impairment charge which could be material in and the company recorded ipr impairment charge within research and development expense of million million and million respectively see note to the consolidated financial statement additional research and development will be required before any of the remaining program reach technological feasibility the cost to complete the research project will depend on whether the project are brought to their final stage of development and are ultimately submitted to the fda or other regulatory agency for approval capital expenditurescapital expenditure were billion in billion in and billion in expenditure in the were billion in billion in and billion in the company plan to invest approximately billion in capital project from including expanding manufacturing capacity for oncology vaccine and animal health product depreciation expense wa billion in billion in and billion in of which billion in billion in and billion in related to location in the total depreciation expense in and included accelerated depreciation of million million and million respectively associated with restructuring activity see note to the consolidated financial statement analysis of liquidity and capital resourcesmerck strong financial profile enables it to fund research and development focus on external alliance support in line product and maximize upcoming launch while providing significant cash return to shareholder selected data in million capital total debt to total liability and cash provided by operating activity of continuing operation to total of contentsthe increase in working capital in compared with is primarily related to decreased short term debt cash provided by operating activity of continuing operation wa billion in compared with billion in and billion in the higher cash provided by operating activity of continuing operation in reflects stronger operating performance cash provided by operating activity of continuing operation includes upfront and milestone payment related to collaboration of million in billion in and million in cash provided by operating activity of continuing operation continues to be the company source of fund to finance operating need with excess cash serving the primary source of fund to finance capital expenditure treasury stock purchase and dividend paid to shareholder cash used in investing activity of continuing operation wa billion in compared with billion in the higher use of cash in investing activity of continuing operation wa primarily due to higher cash used for acquisition including for the acquisition of acceleron and lower proceeds from sale of security and other investment partially offset by the purchase of seagen common stock cash used in investing activity of continuing operation wa billion in compared with billion in the increase wa driven primarily by lower proceeds from the sale of security and other investment higher use of cash for acquisition higher capital expenditure and the purchase of seagen common stock partially offset by lower purchase of security and other investment cash provided by financing activity of continuing operation wa billion in compared with use of cash in financing activity of continuing operation of billion in the change wa primarily driven by the cash distribution received from organon in connection with the spin off see note to the consolidated financial statement higher proceeds from the issuance of debt see below and lower purchase of treasury stock partially offset by net decrease in short term borrowing in compared with net increase in short term borrowing in higher payment on debt see below and higher dividend paid to shareholder cash used in financing activity of continuing operation wa billion in compared with billion in the lower use of cash in financing activity of continuing operation wa driven primarily by net increase in short term borrowing in compared with net decrease in short term borrowing in well lower purchase of treasury stock partially offset by higher payment on debt see below lower proceeds from the issuance of debt see below higher dividend paid to shareholder and lower proceeds from the exercise of stock option in december the company issued billion principal amount of senior unsecured note consisting of billion of note due billion of note due billion of note due billion of note due and billion of note due merck used the net proceeds from the offering of the note the note the note and the note for general corporate purpose including the repayment of outstanding commercial paper borrowing including commercial paper borrowing in connection with merck acquisition of acceleron and other indebtedness merck allocated an amount equal to the net proceeds of the offering of the note due in to finance or refinance in whole or in part project and partnership in the company priority esg area in june the company issued billion principal amount of senior unsecured note consisting of billion of note due billion of note due billion of note due and billion of note due merck used the net proceeds from the offering for general corporate purpose including the repayment of outstanding commercial paper borrowing and other indebtedness in march the company issued billion principal amount of senior unsecured note consisting of million of note due billion of note due billion of note due and billion of note due the company used the net proceeds from the offering for general corporate purpose including the repayment of outstanding commercial paper borrowing in february the company billion note matured in accordance with their term and were repaid in the company billion note and the company billion note matured in accordance with their term and were repaid in the company billion note and million floating rate note matured in accordance with their term and were repaid of contentsthe company ha billion credit facility that matures in june the facility provides backup liquidity for the company commercial paper borrowing facility and is to be used for general corporate purpose the company ha not drawn funding from this facility the company expects foreseeable liquidity and capital resource requirement to be met through existing cash and cash equivalent and anticipated cash flow from operation well commercial paper borrowing and long term borrowing if needed merck belief that it source of financing will be adequate to meet it future requirement the company material cash requirement arising in the normal course of business primarily include debt obligation and interest payment see note to the consolidated financial statement for further detail of the company debt obligation and the timing of expected future principal and interest payment tax liability in connection with the enactment of the tcja the company is required to pay one time transition tax which the company ha elected to pay over period of eight year through permitted under the tcja additionally the company ha liability for unrecognized tax benefit including interest and penalty see note to the consolidated financial statement for further information pertaining to the transition tax and liability for unrecognized tax benefit operating lease see note to consolidated financial statement for further detail of the company lease obligation and the timing of expected future lease payment contingent milestone payment the company ha accrued liability for contingent sale based milestone payment related to collaboration with astrazeneca eisai and bayer where payment ha been deemed probable but remains subject to the achievement of the related sale milestone see note to the consolidated financial statement for additional information related to these sale based milestone purchase obligation purchase obligation are enforceable and legally binding obligation for purchase of good and service including minimum inventory contract research and development and advertising purchase obligation also include future inventory purchase the company ha committed to in connection with certain divestiture of december the company had total purchase obligation of billion of which billion is estimated to be payable in in march the company filed security registration statement with the security and exchange commission sec under the automatic shelf registration process available to well known seasoned issuer which is effective for three year effective of november the company executed full and unconditional guarantee of the then existing debt of it subsidiary merck sharp dohme corp msd and msd executed full and unconditional guarantee of the then existing debt of the company excluding commercial paper including for payment of principal and interest these guarantee do not extend to debt issued subsequent to that date the company belief it maintains conservative financial profile the company place it cash and investment in instrument that meet high credit quality standard specified in it investment policy guideline these guideline also limit the amount of credit exposure to any one issuer the company doe not participate in any off balance sheet arrangement involving unconsolidated subsidiary that provide financing or potentially expose the company to unrecorded financial obligation in november merck board of director increased the quarterly dividend declaring quarterly dividend of per share on the company outstanding common stock that wa paid in january in january the board of director declared quarterly dividend of per share on the company common stock for the second quarter of payable in april in october merck board of director authorized purchase of up to billion of merck common stock for it treasury the treasury stock purchase authorization ha no time limit and will be made over time in open market transaction block transaction on or off an exchange or in privately negotiated transaction in may merck restarted it share repurchase program which the company had temporarily suspended in march the company spent million to purchase million share of it common stock for it treasury during under this program of december the company remaining share repurchase of contentsauthorization wa billion the company purchased billion and billion of it common stock during and respectively under authorized share repurchase program financial instrument market risk disclosuresthe company manages the impact of foreign exchange rate movement and interest rate movement on it earnings cash flow and fair value of asset and liability through operational mean and through the use of various financial instrument including derivative instrument significant portion of the company revenue and earnings in foreign affiliate is exposed to change in foreign exchange rate the objective of and accounting related to the company foreign currency risk management program well it interest rate risk management activity are discussed below foreign currency risk managementthe company ha established revenue hedging balance sheet risk management and net investment hedging program to protect against volatility of future foreign currency cash flow and change in fair value caused by change in foreign exchange rate the objective of the revenue hedging program is to reduce the variability caused by change in foreign exchange rate that would affect the dollar value of future cash flow derived from foreign currency denominated sale primarily the euro japanese yen and chinese renminbi to achieve this objective the company will hedge portion of it forecasted foreign currency denominated third party and intercompany distributor entity sale forecasted sale that are expected to occur over it planning cycle typically no more than two year into the future the company will layer in hedge over time increasing the portion of forecasted sale hedged it get closer to the expected date of the forecasted sale the portion of forecasted sale hedged is based on assessment of cost benefit profile that consider natural offsetting exposure revenue and exchange rate volatility and correlation and the cost of hedging instrument the company manages it anticipated transaction exposure principally with purchased local currency put option forward contract and purchased collar option the fair value of these derivative contract are recorded either asset gain position or liability loss position in the consolidated balance sheet change in the fair value of derivative contract are recorded each period in either current earnings or other comprehensive income loss oci depending on whether the derivative is designated part of hedge transaction and if so the type of hedge transaction for derivative that are designated cash flow hedge the unrealized gain or loss on these contract are recorded in accumulated other comprehensive loss aocl and reclassified into sale when the hedged anticipated revenue is recognized for those derivative which are not designated cash flow hedge but serve economic hedge of forecasted sale unrealized gain or loss are recorded in sale each period the cash flow from both designated and non designated contract are reported operating activity in the consolidated statement of cash flow the company doe not enter into derivative for trading or speculative purpose because merck principally sell foreign currency in it revenue hedging program uniform weakening of the dollar would yield the largest overall potential loss in the market value of these hedge instrument the market value of merck hedge would have declined by an estimated million and million at december and respectively from uniform weakening of the dollar the market value wa determined using foreign exchange option pricing model and holding all factor except exchange rate constant although not predictive in nature the company belief that threshold reflects reasonably possible near term change in merck major foreign currency exposure relative to the dollar the company manages operating activity and net asset position at each local subsidiary in order to mitigate the effect of exchange on monetary asset and liability the company also us balance sheet risk management program to mitigate the exposure of net monetary asset that are denominated in currency other than subsidiary functional currency from the effect of volatility in foreign exchange in these instance merck principally utilizes forward exchange contract to offset the effect of exchange on exposure denominated in developed country currency primarily the euro japanese yen british pound canadian dollar and swiss franc for exposure in developing country currency including the chinese renminbi the company will enter into forward contract to offset the effect of exchange on exposure when it is deemed economical to do so based on cost benefit analysis that considers the magnitude of the exposure the volatility of the exchange rate and the cost of the of contentshedging instrument the cash flow from these contract are reported operating activity in the consolidated statement of cash flow monetary asset and liability denominated in currency other than the functional currency of given subsidiary are remeasured at spot rate in effect on the balance sheet date with the effect of change in spot rate reported in other income expense net the forward contract are not designated hedge and are marked to market through other income expense net accordingly fair value change in the forward contract help mitigate the change in the value of the remeasured asset and liability attributable to change in foreign currency exchange rate except to the extent of the spot forward difference these difference are not significant due to the short term nature of the contract which typically have average maturity at inception of le than one year sensitivity analysis to change in the value of the dollar on foreign currency denominated derivative investment and monetary asset and liability indicated that if the dollar uniformly weakened by against all currency exposure of the company at december and income from continuing operation before tax would have declined by approximately million and million in and respectively because the company wa in net short payable position relative to it major foreign currency after consideration of forward contract uniform weakening of the dollar will yield the largest overall potential net loss in earnings due to exchange this measurement assumes that change in one foreign currency relative to the dollar would not affect other foreign currency relative to the dollar although not predictive in nature the company belief that threshold reflects reasonably possible near term change in merck major foreign currency exposure relative to the dollar the cash flow from these contract are reported operating activity in the consolidated statement of cash flow the company also us forward exchange contract to hedge portion of it net investment in foreign operation against movement in exchange rate the forward contract are designated hedge of the net investment in foreign operation the unrealized gain or loss on these contract are recorded in foreign currency translation adjustment within oci and remain in aocl until either the sale or complete or substantially complete liquidation of the subsidiary the company excludes certain portion of the change in fair value of it derivative instrument from the assessment of hedge effectiveness excluded component change in fair value of the excluded component are recognized in oci the company recognizes in earnings the initial value of the excluded component on straight line basis over the life of the derivative instrument rather than using the mark to market approach the cash flow from these contract are reported investing activity in the consolidated statement of cash flow foreign exchange risk is also managed through the use of foreign currency debt the company senior unsecured euro denominated note have been designated and are effective economic hedge of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument are included in foreign currency translation adjustment within oci interest rate risk managementthe company may use interest rate swap contract on certain investing and borrowing transaction to manage it net exposure to interest rate change and to reduce it overall cost of borrowing the company doe not use leveraged swap and in general doe not leverage any of it investment activity that would put principal capital at risk at december the company wa party to nine pay floating receive fixed interest rate swap contract designated fair value hedge of fixed rate note in which the notional amount match the amount of the hedged fixed rate note detailed in the table below in million instrumentpar value of debtnumber of interest rate swap heldtotal swap notional note due note due these interest rate swap matured in february of contentsthe interest rate swap contract are designated hedge of the fair value change in the note attributable to change in the benchmark london interbank offered rate libor swap rate the fair value change in the note attributable to change in the libor swap rate are recorded in interest expense along with the offsetting fair value change in the swap contract see note to the consolidated financial statement for discussion of the pending discontinuation of libor part of reference rate reform the cash flow from these contract are reported operating activity in the consolidated statement of cash flow the company investment portfolio includes cash equivalent and short term investment the market value of which are not significantly affected by change in interest rate the market value of the company medium to long term fixed rate investment is modestly affected by change in interest rate change in medium to long term interest rate have more significant impact on the market value of the company fixed rate borrowing which generally have longer maturity sensitivity analysis to measure potential change in the market value of merck investment and debt from change in interest rate indicated that one percentage point increase in interest rate at december and would have positively affected the net aggregate market value of these instrument by billion and billion respectively one percentage point decrease at december and would have negatively affected the net aggregate market value by billion and billion respectively the fair value of merck debt wa determined using pricing model reflecting one percentage point shift in the appropriate yield curve the fair value of merck investment were determined using combination of pricing and duration model critical accounting estimatesthe company consolidated financial statement are prepared in conformity with gaap and accordingly include certain amount that are based on management best estimate and judgment estimate are used when accounting for amount recorded in connection with acquisition including initial fair value determination of asset and liability primarily ipr other intangible asset and contingent consideration well subsequent fair value measurement additionally estimate are used in determining such item provision for sale discount and return depreciable and amortizable life recoverability of inventory including those produced in preparation for product launch amount recorded for contingency environmental liability accrual for contingent sale based milestone payment and other reserve pension and other postretirement benefit plan assumption share based compensation assumption restructuring cost impairment of long lived asset including intangible asset and goodwill and investment and tax on income because of the uncertainty inherent in such estimate actual result may differ from these estimate application of the following accounting policy result in accounting estimate having the potential for the most significant impact on the financial statement acquisition and dispositionsto determine whether transaction should be accounted for acquisition or disposal of asset or business the company make certain judgment which include assessment of the input process and output associated with the acquired set of activity if the company determines that substantially all of the fair value of gross asset included in transaction is concentrated in single asset or group of similar asset the asset would not represent business to be considered business the asset in transaction need to include an input and substantive process that together significantly contribute to the ability to create output in business combination the acquisition method of accounting requires that the asset acquired and liability assumed be recorded of the date of the acquisition at their respective fair value with limited exception the fair value of intangible asset are determined utilizing information available near the acquisition date based on expectation and assumption that are deemed reasonable by management given the considerable judgment involved in determining fair value the company typically obtains assistance from third party valuation specialist for significant item asset acquired and liability assumed in business combination that arise from contingency are generally recognized at fair value if fair value can not be determined the asset or liability is recognized if probable and reasonably estimable if these criterion are not met no asset or liability is recognized fair value is defined the exchange price that would be received for an asset or paid to transfer liability an exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between market participant on the measurement date accordingly the company may be required to value asset at fair value measure that do not reflect the company intended use of those asset any excess of the purchase price consideration transferred of contentsover the estimated fair value of net asset acquired is recorded goodwill transaction cost and cost to restructure the acquired company are expensed incurred the operating result of the acquired business are reflected in the company consolidated financial statement after the date of the acquisition the judgment made in determining estimated fair value assigned to asset acquired and liability assumed in business combination well asset life can materially affect the company result of operation the fair value of identifiable intangible asset related to currently marketed product and product right are primarily determined by using an income approach through which fair value is estimated based on each asset discounted projected net cash flow the company estimate of market participant net cash flow consider historical and projected pricing margin and expense level the performance of competing product where applicable relevant industry and therapeutic area growth driver and factor current and expected trend in technology and product life cycle the time and investment that will be required to develop product and technology the ability to obtain marketing and regulatory approval the ability to manufacture and commercialize the product the extent and timing of potential new product introduction by the company competitor and the life of each asset underlying patent and any related patent term extension if any the net cash flow are then probability adjusted where appropriate to consider the uncertainty associated with the underlying assumption well the risk profile of the net cash flow utilized in the valuation the probability adjusted future net cash flow of each product are then discounted to present value utilizing an appropriate discount rate the fair value of identifiable intangible asset related to ipr are also determined using an income approach through which fair value is estimated based on each asset probability adjusted future net cash flow which reflect the different stage of development of each product and the associated probability of successful completion the net cash flow are then discounted to present value using an appropriate discount rate amount allocated to acquired ipr are capitalized and accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project upon successful completion of each ipr project merck will make determination to the then useful life of the intangible asset generally determined by the period in which the substantial majority of the cash flow are expected to be generated and begin amortization certain of the company business combination involve the potential for future payment of consideration that is contingent upon the achievement of performance milestone including product development milestone and royalty payment on future product sale the fair value of contingent consideration liability is determined at the acquisition date using unobservable input these input include the estimated amount and timing of projected cash flow the probability of success achievement of the contingent event and the risk adjusted discount rate used to present value the probability weighted cash flow subsequent to the acquisition date at each reporting period until the contingency is resolved the contingent consideration liability is remeasured at current fair value with change either expense or income recorded in earnings change in any of the input may result in significantly different fair value adjustment if the company determines the transaction will not be accounted for an acquisition of business the transaction will be accounted for an asset acquisition rather than business combination and therefore no goodwill will be recorded in an asset acquisition acquired ipr with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date in these instance product development milestone are recognized upon achievement and sale based milestone are recognized when the milestone is deemed probable by the company of being achieved revenue recognitionrecognition of revenue requires evidence of contract probable collection of sale proceeds and completion of substantially all performance obligation merck act the principal in substantially all of it customer arrangement and therefore record revenue on gross basis the majority of the company contract related to the pharmaceutical and animal health segment have single performance obligation the promise to transfer good shipping is considered immaterial in the context of the overall customer arrangement and damage or loss of good in transit are rare therefore shipping is not deemed separately recognized performance obligation the vast majority of revenue from sale of product are recognized at point in time when control of the good is transferred to the customer which the company ha determined is when title and risk and reward of of contentsownership transfer to the customer and the company is entitled to payment for certain service in the animal health segment revenue is recognized over time generally ratably over the contract term service are provided these service revenue are not material the nature of the company business give rise to several type of variable consideration including discount and return which are estimated at the time of sale generally using the expected value method although the most likely amount method is used for prompt pay discount in the sale discount are issued to customer at the point of sale through an intermediary wholesaler known chargebacks or in the form of rebate additionally sale are generally made with limited right of return under certain condition revenue are recorded net of provision for sale discount and return which are established at the time of sale in addition if collection of account receivable is expected to be in excess of one year sale are recorded net of time value of money discount which have not been material the provision for aggregate customer discount cover chargebacks and rebate chargebacks are discount that occur when contracted customer purchase through an intermediary wholesaler the contracted customer generally purchase product from the wholesaler at it contracted price plus mark up the wholesaler in turn charge the company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer the provision for chargebacks is based on expected sell through level by the company wholesale customer to contracted customer well estimated wholesaler inventory level rebate are amount owed based upon definitive contractual agreement or legal requirement with private sector and public sector medicaid and medicare part benefit provider after the final dispensing of the product to benefit plan participant the provision for rebate is based on expected patient usage well inventory level in the distribution channel to determine the contractual obligation to the benefit provider the company us historical customer segment utilization mix sale forecast change to product mix and price inventory level in the distribution channel government pricing calculation and prior payment history in order to estimate the expected provision amount accrued for aggregate customer discount are evaluated on quarterly basis through comparison of information provided by the wholesaler health maintenance organization pharmacy benefit manager federal and state agency and other customer to the amount accrued the company continually monitor it provision for aggregate customer discount there were no material adjustment to estimate associated with the aggregate customer discount provision in or summarized information about change in the aggregate customer discount accrual related to sale is follows in million january current adjustment to prior year payment balance december accrual for chargebacks are reflected direct reduction to account receivable and accrual for rebate current liability the accrued balance relative to these provision included in account receivable and accrued and other current liability were million and billion respectively at december and were million and billion respectively at december outside of the variable consideration in the form of discount and rebate are combination of commercially driven discount in highly competitive product class discount required to gain or maintain reimbursement or legislatively mandated rebate in certain european country legislatively mandated rebate are calculated based on an estimate of the government total unbudgeted spending and the company specific payback obligation rebate may also be required based on specific product sale threshold the company applies an estimated factor against it actual invoiced sale to represent the expected level of future discount or rebate obligation associated with the sale the company maintains return policy that allows it pharmaceutical customer to return product within specified period prior to and subsequent to the expiration date generally three to six month before and of contentsmonths after product expiration the estimate of the provision for return is based upon historical experience with actual return additionally the company considers factor such level of inventory in the distribution channel product dating and expiration period whether product have been discontinued entrance in the market of generic or other competition change in formulary or launch of over the counter product among others the product return provision for pharmaceutical sale percentage of net pharmaceutical sale wa in in and in outside of the return are only allowed in certain country on limited basis merck payment term for pharmaceutical customer are typically day from receipt of invoice and for animal health customer are typically day from receipt of invoice however certain product including keytruda have longer payment term some of which are up to day outside of the payment term are typically day to day although certain market have longer payment term through it distribution program with wholesaler the company encourages wholesaler to align purchase with underlying demand and maintain inventory below specified level the term of the program allow the wholesaler to earn fee upon providing visibility into their inventory level well by achieving certain performance parameter such inventory management customer service level reducing shortage claim and reducing product return information provided through the wholesaler distribution program includes item such sale trend inventory on hand on order quantity and product return wholesaler generally provide only the above mentioned data to the company there is no regulatory requirement to report lot level information to manufacturer which is the level of information needed to determine the remaining shelf life and original sale date of inventory given current wholesaler inventory level which are generally le than month the company belief that collection of order lot information across all wholesale customer would have limited use in estimating sale discount and return inventory produced in preparation for product launchesthe company capitalizes inventory produced in preparation for product launch sufficient to support estimated initial market demand typically capitalization of such inventory doe not begin until the related product candidate are in phase clinical trial and are considered to have high probability of regulatory approval the company monitor the status of each respective product within the regulatory approval process however the company generally doe not disclose specific timing for regulatory approval if the company is aware of any specific risk or contingency other than the normal regulatory approval process or if there are any specific issue identified during the research process relating to safety efficacy manufacturing marketing or labeling the related inventory would generally not be capitalized expiry date of the inventory are affected by the stage of completion the company manages the level of inventory at each stage to optimize the shelf life of the inventory in relation to anticipated market demand in order to avoid product expiry issue for inventory that are capitalized anticipated future sale and shelf life support the realization of the inventory value the inventory shelf life is sufficient to meet initial product launch requirement inventory produced in preparation for product launch capitalized at december and were million and million respectively contingency and environmental liabilitiesthe company is involved in various claim and legal proceeding of nature considered normal to it business including product liability intellectual property and commercial litigation well certain additional matter including governmental and environmental matter see note to the consolidated financial statement the company record accrual for contingency when it is probable that liability ha been incurred and the amount can be reasonably estimated these accrual are adjusted periodically assessment change or additional information becomes available for product liability claim portion of the overall accrual is actuarially determined and considers such factor past experience number of claim reported and estimate of claim incurred but not yet reported individually significant contingent loss are accrued when probable and reasonably estimable legal defense cost expected to be incurred in connection with loss contingency are accrued when probable and reasonably estimable some of the significant factor considered in the review of these legal defense reserve are follows the actual cost incurred by the company the development of the company legal defense strategy and structure in light of the scope of it litigation the number of case being brought against the company the cost and outcome of completed trial and the most current information regarding anticipated timing progression and related cost of pre trial activity and trial in the associated litigation the amount of legal defense of contentsreserves of december and of approximately million and million respectively represents the company best estimate of the minimum amount of defense cost to be incurred in connection with it outstanding litigation however event such additional trial and other event that could arise in the course of it litigation could affect the ultimate amount of legal defense cost to be incurred by the company the company will continue to monitor it legal defense cost and review the adequacy of the associated reserve and may determine to increase the reserve at any time in the future if based upon the factor set forth it belief it would be appropriate to do so the company and it subsidiary are party to number of proceeding brought under the comprehensive environmental response compensation and liability act commonly known superfund and other federal and state equivalent when legitimate claim for contribution is asserted liability is initially accrued based upon the estimated transaction cost to manage the site accrual are adjusted site investigation feasibility study and related cost assessment of remedial technique are completed and the extent to which other potentially responsible party who may be jointly and severally liable can be expected to contribute is determined the company is also remediating environmental contamination resulting from past industrial activity at certain of it site and take an active role in identifying and accruing for these cost in the past merck performed worldwide survey to ass all site for potential contamination resulting from past industrial activity where assessment indicated that physical investigation wa warranted such investigation wa performed providing better evaluation of the need for remedial action where such need wa identified remedial action wa then initiated definitive information became available during the course of investigation and or remedial effort at each site estimate were refined and accrual were established or adjusted accordingly these estimate and related accrual continue to be refined annually the company belief that there are no compliance issue associated with applicable environmental law and regulation that would have material adverse effect on the company expenditure for remediation and environmental liability were million in and are estimated to be million in the aggregate for the year through in management opinion the liability for all environmental matter that are probable and reasonably estimable have been accrued and totaled million and million at december and respectively these liability are undiscounted do not consider potential recovery from other party and will be paid out over the period of remediation for the applicable site which are expected to occur primarily over the next year although it is not possible to predict with certainty the outcome of these matter or the ultimate cost of remediation management doe not believe that any reasonably possible expenditure that may be incurred in excess of the liability accrued should exceed approximately million in the aggregate management also doe not believe that these expenditure should result in material adverse effect on the company financial condition result of operation or liquidity for any year share based compensationthe company expense all share based payment award to employee including grant of stock option over the requisite service period based on the grant date fair value of the award the company determines the fair value of certain share based award using the black scholes option pricing model which us both historical and current market data to estimate the fair value this method incorporates various assumption such the risk free interest rate expected volatility expected dividend yield and expected life of the option total pretax share based compensation expense from continuing operation wa million in million in and million in at december there wa million of total pretax unrecognized compensation expense related to nonvested stock option restricted stock unit and performance share unit award which will be recognized over weighted average period of year for segment reporting share based compensation cost are unallocated expense pension and other postretirement benefit plansnet periodic benefit cost for pension plan totaled million in million in and million in net periodic benefit credit for other postretirement benefit plan wa million in million in and million in pension and other postretirement benefit plan information for financial reporting purpose is calculated using actuarial assumption including discount rate for plan benefit obligation of contentsand an expected rate of return on plan asset the change in net periodic benefit cost year over year for pension plan are attributable to settlement charge incurred by certain plan well change in the discount rate the company reassesses it benefit plan assumption on regular basis for both the pension and other postretirement benefit plan the discount rate is evaluated on measurement date and modified to reflect the prevailing market rate of portfolio of high quality fixed income debt instrument that would provide the future cash flow needed to pay the benefit included in the benefit obligation they come due the discount rate for the company pension and other postretirement benefit plan ranged from to at december compared with range of to at december the expected rate of return for both the pension and other postretirement benefit plan represents the average rate of return to be earned on plan asset over the period the benefit included in the benefit obligation are to be paid in developing the expected rate of return the company considers long term compound annualized return of historical market data current market condition and actual return on the company plan asset using this reference information the company develops forward looking return expectation for each asset category and weighted average expected long term rate of return for target portfolio allocated across these investment category the expected portfolio performance reflects the contribution of active management appropriate for the expected rate of return for the company pension and other postretirement benefit plan will be compared to range of to in the company ha established investment guideline for it pension and other postretirement plan to create an asset allocation that is expected to deliver rate of return sufficient to meet the long term obligation of each plan given an acceptable level of risk the target investment portfolio of the company pension and other postretirement benefit plan is allocated to in equity to in international equity to in fixed income investment and up to in cash and other investment the portfolio equity weighting is consistent with the long term nature of the plan benefit obligation the expected annual standard deviation of return of the target portfolio which approximates reflects both the equity allocation and the diversification benefit among the asset class in which the portfolio invests for international pension plan the targeted investment portfolio varies based on the duration of pension liability and local government rule and regulation although significant percentage of plan asset are invested in equity concentration risk is mitigated through the use of strategy that are diversified within management guideline actuarial assumption are based upon management best estimate and judgment reasonably possible change of plus minus basis point in the discount rate assumption with other assumption held constant would have had an estimated million favorable unfavorable impact on the company net periodic benefit cost in reasonably possible change of plus minus basis point in the expected rate of return assumption with other assumption held constant would have had an estimated million favorable unfavorable impact on merck net periodic benefit cost in required funding obligation for relating to the company pension and other postretirement benefit plan are not expected to be material the preceding hypothetical change in the discount rate and expected rate of return assumption would not impact the company funding requirement net loss amount which primarily reflect difference between expected and actual return on plan asset well the effect of change in actuarial assumption are recorded component of aocl expected return for pension plan are based on calculated market related value of asset net loss amount in aocl in excess of certain threshold are amortized into net periodic benefit cost over the average remaining service life of employee restructuring costsrestructuring cost have been recorded in connection with restructuring program designed to streamline the company cost structure result the company ha made estimate and judgment regarding it future plan including future termination benefit and other exit cost to be incurred when the restructuring action take place when accruing termination cost the company will recognize the amount within range of cost that is the best estimate within the range when no amount within the range is better estimate than any other amount the company recognizes the minimum amount within the range in connection with these action management also ass the recoverability of long lived asset employed in the business in certain instance asset life have been shortened based on change in the expected useful life of the affected asset severance and other related cost are reflected within restructuring cost asset related charge are reflected within cost of sale selling general and administrative expense and research and development expense depending upon the nature of the asset of contentsimpairments of long lived assetsthe company ass change in economic regulatory and legal condition and make assumption regarding estimated future cash flow in evaluating the value of the company property plant and equipment goodwill and other intangible asset the company periodically evaluates whether current fact or circumstance indicate that the carrying value of it long lived asset to be held and used may not be recoverable if such circumstance are determined to exist an estimate of the undiscounted future cash flow of these asset or appropriate asset grouping is compared to the carrying value to determine whether an impairment exists if the asset is determined to be impaired the loss is measured based on the difference between the asset fair value and it carrying value if quoted market price are not available the company will estimate fair value using discounted value of estimated future cash flow approach goodwill represents the excess of the consideration transferred over the fair value of net asset of business acquired goodwill is assigned to reporting unit and evaluated for impairment on at least an annual basis or more frequently if impairment indicator exist by first assessing qualitative factor to determine whether it is more likely than not that the fair value of reporting unit is le than it carrying amount some of the factor considered in the assessment include general macroeconomic condition condition specific to the industry and market cost factor which could have significant effect on earnings or cash flow the overall financial performance of the reporting unit and whether there have been sustained decline in the company share price if the company concludes it is more likely than not that the fair value of reporting unit is le than it carrying amount quantitative fair value test is performed if the carrying value of reporting unit is greater than it fair value goodwill impairment charge will be recorded for the difference up to the carrying value of goodwill other acquired intangible asset excluding ipr are initially recorded at fair value assigned an estimated useful life and amortized primarily on straight line basis over their estimated useful life when event or circumstance warrant review the company will ass recoverability from future operation using pretax undiscounted cash flow derived from the lowest appropriate asset grouping impairment are recognized in operating result to the extent that the carrying value of the intangible asset exceeds it fair value which is determined based on the net present value of estimated future cash flow ipr that the company acquires in conjunction with the acquisition of business represents the fair value assigned to incomplete research project which at the time of acquisition have not reached technological feasibility the amount are capitalized and accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project the company evaluates ipr for impairment at least annually or more frequently if impairment indicator exist by performing quantitative test that compare the fair value of the ipr intangible asset with it carrying value for impairment testing purpose the company may combine separately recorded ipr intangible asset into one unit of account based on the relevant fact and circumstance generally the company will combine ipr intangible asset for testing purpose if they operate single asset and are essentially inseparable if the fair value is le than the carrying amount an impairment loss is recognized in operating result the judgment made in evaluating impairment of long lived intangible can materially affect the company result of operation tax on incomethe company effective tax rate is based on pretax income statutory tax rate and tax planning opportunity available in the various jurisdiction in which the company operates an estimated effective tax rate for year is applied to the company quarterly operating result in the event that there is significant unusual or one time item recognized or expected to be recognized in the company quarterly operating result the tax attributable to that item would be separately calculated and recorded at the same time the unusual or one time item the company considers the resolution of prior year tax matter to be such item significant judgment is required in determining the company tax provision and in evaluating it tax position the recognition and measurement of tax position is based on management best judgment given the fact circumstance and information available at the reporting date the company evaluates tax position to determine whether the benefit of tax position are more likely than not of being sustained upon audit based on the technical merit of the tax of contentsposition for tax position that are more likely than not of being sustained upon audit the company recognizes the amount of the benefit that is greater than likely of being realized upon ultimate settlement in the financial statement for tax position that are not more likely than not of being sustained upon audit the company doe not recognize any portion of the benefit in the financial statement if the more likely than not threshold is not met in the period for which tax position is taken the company may subsequently recognize the benefit of that tax position if the tax matter is effectively settled the statute of limitation expires or if the more likely than not threshold is met in subsequent period see note to the consolidated financial statement tax regulation require item to be included in the tax return at different time than the item are reflected in the financial statement timing difference create deferred tax asset and liability deferred tax asset generally represent item that can be used tax deduction or credit in the tax return in future year for which the company ha already recorded the tax benefit in the financial statement the company establishes valuation allowance for it deferred tax asset when the amount of expected future taxable income is not likely to support the use of the deduction or credit deferred tax liability generally represent tax expense recognized in the financial statement for which payment ha been deferred or expense for which the company ha already taken deduction on the tax return but ha not yet recognized expense in the financial statement recently issued accounting standardsfor discussion of recently issued accounting standard see note to the consolidated financial statement cautionary factor that may affect future resultsthis report and other written report and oral statement made from time to time by the company may contain so called forward looking statement all of which are based on management current expectation and are subject to risk and uncertainty which may cause result to differ materially from those set forth in the statement one can identify these forward looking statement by their use of word such anticipates expects plan will estimate forecast project and other word of similar meaning or negative variation of any of the foregoing one can also identify them by the fact that they do not relate strictly to historical or current fact these statement are likely to address the company growth strategy financial result product approval product potential development program environmental or other sustainability initiative and include statement related to the expected impact of the covid pandemic one must carefully consider any such statement and should understand that many factor could cause actual result to differ materially from the company forward looking statement these factor include inaccurate assumption and broad variety of other risk and uncertainty including some that are known and some that are not no forward looking statement can be guaranteed and actual future result may vary materially the company doe not assume the obligation to update any forward looking statement one should carefully evaluate such statement in light of factor including risk factor described in the company filing with the security and exchange commission especially on this form and form and in item risk factor of this annual report on form the company discus in more detail various important risk factor that could cause actual result to differ from expected or historic result the company note these factor for investor permitted by the private security litigation reform act of one should understand that it is not possible to predict or identify all such factor consequently the reader should not consider any such list to be complete statement of all potential risk or uncertainty item quantitative and qualitative disclosure about market risk the information required by this item is incorporated by reference to the discussion under financial instrument market risk disclosure in item management discussion and analysis of financial condition and result of operation of contentsitem financial statement and supplementary data financial statementsthe consolidated balance sheet of merck co inc and subsidiary of december and and the related consolidated statement of income of comprehensive income of equity and of cash flow for each of the three year in the period ended december the note to consolidated financial statement and the report dated february of pricewaterhousecoopers llp independent registered public accounting firm are follows consolidated statement of incomemerck co inc and subsidiariesyears ended december in million except per share amount cost expense and othercost of selling general and research and restructuring other income expense net income from continuing operation before tax on income from continuing net income from continuing le net income loss attributable to noncontrolling net income from continuing operation attributable to merck co inc income from discontinued operation net of tax and amount attributable to noncontrolling net income attributable to merck co inc basic earnings per common share attributable to merck co inc common shareholdersincome from continuing operation income from discontinued net income earnings per common share assuming dilution attributable to merck co inc common shareholdersincome from continuing operation income from discontinued net income consolidated statement of comprehensive incomemerck co inc and subsidiariesyears ended december in million income attributable to merck co inc other comprehensive income loss net of tax net unrealized gain loss on derivative net of net unrealized loss gain on investment net of reclassification benefit plan net gain loss and prior service credit cost net of cumulative translation adjustment comprehensive income attributable to merck co inc the accompanying note are an integral part of these consolidated financial statement of contentsconsolidated balance sheetmerck co inc and subsidiariesdecember in million except per share amount assetscash and cash equivalent account receivable net of allowance for doubtful account of in and in inventory excludes inventory of in and in in other asset see note other current current asset of discontinued operation total current property plant and equipment at cost machinery equipment and office construction in le accumulated other intangible other noncurrent asset of discontinued operation liability and equitycurrent liabilitiesloans payable and current portion of long term debt trade account accrued and other current income tax dividend current liability of discontinued operation total current long term deferred income other noncurrent noncurrent liability of discontinued operation merck co inc stockholder equitycommon stock par valueauthorized sharesissued share in and other paid in retained accumulated other comprehensive loss le treasury stock at cost share in and share in total merck co inc stockholder noncontrolling total the accompanying note are an integral part of this consolidated financial statement of contentsconsolidated statement of equitymerck co inc and subsidiariesyears ended december in million except per share amount commonstockotherpaid incapitalretainedearningsaccumulatedothercomprehensivelosstreasurystocknon controllingintereststotalbalance january net income attributable to merck co inc other comprehensive loss net of tax cash dividend declared on common stock per share treasury stock share purchased net loss attributable to noncontrolling interest distribution attributable to noncontrolling interest share based compensation plan and other balance december net income attributable to merck co inc other comprehensive loss net of tax cash dividend declared on common stock per share treasury stock share purchased net income attributable to noncontrolling interest distribution attributable to noncontrolling interest share based compensation plan and other balance december net income attributable to merck co inc other comprehensive income net of tax cash dividend declared on common stock per share treasury stock share purchased spin off of organon co net income attributable to noncontrolling interest distribution attributable to noncontrolling interest share based compensation plan and other balance december the accompanying note are an integral part of this consolidated financial statement of contentsconsolidated statement of cash flowsmerck co inc and subsidiariesyears ended december in million flow from operating activity of continuing operationsnet income from continuing operation adjustment to reconcile net income from continuing operation to net cash provided by operating activity of continuing operation intangible asset impairment income from investment in equity security net charge for the acquisition of pandion therapeutic inc charge for the acquisition of velosbio inc charge for the acquisition of peloton therapeutic inc deferred income share based net change in asset and liability account receivable inventory trade account accrued and other current income tax payable noncurrent other net cash provided by operating activity of continuing cash flow from investing activity of continuing operationscapital expenditure purchase of seagen inc common stock purchase of security and other investment proceeds from sale of security and other acquisition of acceleron pharma inc net of cash acquired acquisition of pandion therapeutic inc net of cash acquired acquisition of velosbio inc net of cash acquired acquisition of arqule inc net of cash acquired acquisition of antelliq corporation net of cash acquired acquisition of peloton therapeutic inc net of cash acquired other acquisition net of cash acquired other net cash used in investing activity of continuing operation cash flow from financing activity of continuing operationsnet change in short term borrowing payment on debt proceeds from issuance of distribution from organon co purchase of treasury stock dividend paid to stockholder proceeds from exercise of stock other net cash provided by used in financing activity of continuing discontinued operationsnet cash provided by operating net cash used in investing activity net cash used in financing activity net cash flow provided by discontinued effect of exchange rate change on cash cash equivalent and restricted cash net increase decrease in cash cash equivalent and restricted cash cash equivalent and restricted cash at beginning of year includes of restricted cash at january included in other asset see note le cash and cash equivalent related to discontinued operation cash cash equivalent and restricted cash at end of year includes of restricted cash at december included in other asset see note the accompanying note are an integral part of this consolidated financial statement of contentsnotes to consolidated financial statementsmerck co inc and subsidiary in million except per share amount nature of operationsmerck co inc merck or the company is global health care company that delivers innovative health solution through it prescription medicine vaccine biologic therapy and animal health product the company operation are principally managed on product basis and include two operating segment which are the pharmaceutical and animal health segment both of which are reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer the company previously had healthcare service segment that provided service and solution focused on engagement health analytics and clinical service to improve the value of care delivered to patient the company divested the remaining business in this segment during the first quarter of spin off of organon co on june merck completed the spin off of product from it woman health biosimilars and established brand business into new independent publicly traded company named organon co organon through distribution of organon publicly traded stock to company shareholder the distribution is expected to qualify and ha been treated tax free to the company and it shareholder for federal income tax purpose the established brand included in the transaction consisted of dermatology non opioid pain management respiratory select cardiovascular product well the rest of merck diversified brand franchise merck existing research pipeline program continue to be owned and developed within merck planned the historical result of the business that were contributed to organon in the spin off have been reflected discontinued operation in the company consolidated financial statement through the date of the spin off see note summary of accounting policiesprinciples of consolidation the consolidated financial statement include the account of the company and all of it subsidiary in which controlling interest is maintained intercompany balance and transaction are eliminated controlling interest is determined by majority ownership interest and the absence of substantive third party participating right or in the case of variable interest entity by majority exposure to expected loss residual return or both for those consolidated subsidiary where merck ownership is le than the outside shareholder interest are shown noncontrolling interest in equity investment in affiliate over which the company ha significant influence but not controlling interest such interest in entity owned equally by the company and third party that are under shared control are carried on the equity basis acquisition in business combination the acquisition method of accounting requires that the asset acquired and liability assumed be recorded of the date of the acquisition at their respective fair value with limited exception asset acquired and liability assumed in business combination that arise from contingency are generally recognized at fair value if fair value can not be determined the asset or liability is recognized if probable and reasonably estimable if these criterion are not met no asset or liability is recognized fair value is of contentsdefined the exchange price that would be received for an asset or paid to transfer liability an exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between market participant on the measurement date accordingly the company may be required to value asset at fair value measure that do not reflect the company intended use of those asset any excess of the purchase price consideration transferred over the estimated fair value of net asset acquired is recorded goodwill transaction cost and cost to restructure the acquired company are expensed incurred the operating result of the acquired business are reflected in the company consolidated financial statement after the date of the acquisition if the company determines the asset acquired do not meet the definition of business under the acquisition method of accounting the transaction will be accounted for an acquisition of asset rather than business combination and therefore no goodwill will be recorded in an asset acquisition acquired in process research and development ipr with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date foreign currency translation the net asset of international subsidiary where the local currency have been determined to be the functional currency are translated into dollar using current exchange rate the dollar effect that arise from translating the net asset of these subsidiary at changing rate are recorded in the foreign currency translation account which is included in accumulated other comprehensive loss aocl and reflected separate component of equity for those subsidiary that operate in highly inflationary economy and for those subsidiary where the dollar ha been determined to be the functional currency non monetary foreign currency asset and liability are translated using historical rate while monetary asset and liability are translated at current rate with the dollar effect of rate change included in other income expense net cash equivalent cash equivalent are comprised of certain highly liquid investment with original maturity of le than three month inventory inventory are valued at the lower of cost or net realizable value the cost of substantial majority of pharmaceutical and vaccine inventory is determined using the last in first out lifo method for both financial reporting and tax purpose the cost of all other inventory is determined using the first in first out fifo method inventory consist of currently marketed product well certain inventory produced in preparation for product launch that are considered to have high probability of regulatory approval in evaluating the recoverability of inventory produced in preparation for product launch the company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process investment investment in marketable debt security classified available for sale are reported at fair value fair value of the company investment in marketable debt security are determined using quoted market price in active market for identical asset or liability or quoted price for similar asset or liability or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability change in fair value that are not impairment related are reported net of tax in other comprehensive income oci the company considers available evidence in evaluating potential impairment of it investment in marketable debt security including the extent to which fair value is le than cost whether an allowance for credit loss is required well adverse factor that could affect the value of the security an impairment ha occurred if the company doe not expect to recover the entire amortized cost basis of the marketable debt security if the company doe not intend to sell the impaired debt security and it is not more likely than not it will be required to sell the debt security before the recovery of it amortized cost basis the amount of the impairment recognized in earnings recorded in other income expense net is limited to the portion attributed to credit loss the remaining portion of the impairment related to other factor is recognized in oci realized gain and loss for debt security are included in other income expense net investment in publicly traded equity security are reported at fair value determined using quoted market price in active market for identical asset or quoted price for similar asset or other input that are observable or can be corroborated by observable market data change in fair value are included in other income expense net unrealized gain and loss from investment that are directly owned are determined at the end of the reporting period gain and loss from ownership interest in investment fund which are accounted for equity method investment are reported on one quarter lag investment in equity security without readily determinable fair value are recorded at cost plus or minus subsequent observable price change in orderly transaction for identical of contentsor similar investment minus impairment such adjustment are recognized in other income expense net realized gain and loss for equity security are included in other income expense net revenue recognition recognition of revenue requires evidence of contract probable collection of sale proceeds and completion of substantially all performance obligation merck act the principal in substantially all of it customer arrangement and therefore record revenue on gross basis the majority of the company contract related to the pharmaceutical and animal health segment have single performance obligation the promise to transfer good shipping is considered immaterial in the context of the overall customer arrangement and damage or loss of good in transit are rare therefore shipping is not deemed separately recognized performance obligation the vast majority of revenue from sale of product are recognized at point in time when control of the good is transferred to the customer which the company ha determined is when title and risk and reward of ownership transfer to the customer and the company is entitled to payment the company recognizes revenue from the sale of vaccine to the federal government for placement into vaccine stockpile in accordance with security and exchange commission sec interpretation commission guidance regarding accounting for sale of vaccine and bioterror countermeasure to the federal government for placement into the pediatric vaccine stockpile or the strategic national stockpile this interpretation allows company to recognize revenue for sale of vaccine into government stockpile even though these sale might not meet the criterion for revenue recognition under other accounting guidance some customer have bill and hold arrangement with the company revenue for bill and hold arrangement is recognized when control transfer to the customer even though the customer doe not yet have physical possession of the good control transfer when the bill and hold arrangement ha been requested by the customer the product is identified belonging to the customer and is ready for physical transfer the product can not be directed for use by anyone but the customer and in certain circumstance the customer ha inspected and accepted the product at the company facility for certain service in the animal health segment revenue is recognized over time generally ratably over the contract term service are provided these service revenue are not material the nature of the company business give rise to several type of variable consideration including discount and return which are estimated at the time of sale generally using the expected value method although the most likely amount method is used for prompt pay discount in the sale discount are issued to customer at the point of sale through an intermediary wholesaler known chargebacks or in the form of rebate additionally sale are generally made with limited right of return under certain condition revenue are recorded net of provision for sale discount and return which are established at the time of sale in addition if collection of account receivable is expected to be in excess of one year sale are recorded net of time value of money discount which have not been material the provision for aggregate customer discount covering chargebacks and rebate wa billion in billion in and billion in chargebacks are discount that occur when contracted customer purchase through an intermediary wholesaler the contracted customer generally purchase product from the wholesaler at it contracted price plus mark up the wholesaler in turn charge the company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer the provision for chargebacks is based on expected sell through level by the company wholesale customer to contracted customer well estimated wholesaler inventory level rebate are amount owed based upon definitive contractual agreement or legal requirement with private sector and public sector medicaid and medicare part benefit provider after the final dispensing of the product to benefit plan participant the provision for rebate is based on expected patient usage well inventory level in the distribution channel to determine the contractual obligation to the benefit provider the company us historical customer segment utilization mix sale forecast change to product mix and price inventory level in the distribution channel government pricing calculation and prior payment history in order to estimate the expected provision amount accrued for aggregate customer discount are evaluated on quarterly basis through comparison of information provided by the wholesaler health maintenance organization pharmacy benefit manager federal and state agency and other customer to the amount accrued the accrued balance relative to the provision for chargebacks and rebate included in account receivable and accrued and other current liability were of contentsmillion and billion respectively at december and were million and billion respectively at december outside of the variable consideration in the form of discount and rebate are combination of commercially driven discount in highly competitive product class discount required to gain or maintain reimbursement or legislatively mandated rebate in certain european country legislatively mandated rebate are calculated based on an estimate of the government total unbudgeted spending and the company specific payback obligation rebate may also be required based on specific product sale threshold the company applies an estimated factor against it actual invoiced sale to represent the expected level of future discount or rebate obligation associated with the sale the company maintains return policy that allows it pharmaceutical customer to return product within specified period prior to and subsequent to the expiration date generally three to six month before and month after product expiration the estimate of the provision for return is based upon historical experience with actual return additionally the company considers factor such level of inventory in the distribution channel product dating and expiration period whether product have been discontinued entrance in the market of generic or other competition change in formulary or launch of over the counter product among others outside of the return are only allowed in certain country on limited basis merck payment term for pharmaceutical customer are typically day from receipt of invoice and for animal health customer are typically day from receipt of invoice however certain product including keytruda have longer payment term some of which are up to day outside of the payment term are typically day to day although certain market have longer payment term see note for disaggregated revenue disclosure depreciation depreciation is provided over the estimated useful life of the asset principally using the straight line method for tax purpose accelerated tax method are used the estimated useful life primarily range from to year for building and from to year for machinery equipment and office furnishing depreciation expense wa billion in billion in and billion in advertising and promotion cost advertising and promotion cost are expensed incurred the company recorded advertising and promotion expense of billion in billion in and billion in software capitalization the company capitalizes certain cost incurred in connection with obtaining or developing internal use software including external direct cost of material and service and payroll cost for employee directly involved with the software development these cost are included in property plant and equipment in addition the company capitalizes certain cost incurred to implement cloud computing arrangement that is considered service agreement which are included in other asset capitalized software cost are being amortized over period ranging from to year with the longer life generally associated with enterprise wide project implemented over multiple year cost incurred during the preliminary project stage and post implementation stage well maintenance and training cost are expensed incurred goodwill goodwill represents the excess of the consideration transferred over the fair value of net asset of business acquired goodwill is assigned to reporting unit and evaluated for impairment on at least an annual basis or more frequently if impairment indicator exist by first assessing qualitative factor to determine whether it is more likely than not that the fair value of reporting unit is le than it carrying amount if the company concludes it is more likely than not that the fair value of reporting unit is le than it carrying amount quantitative fair value test is performed if the carrying value of reporting unit is greater than it fair value goodwill impairment charge will be recorded for the difference up to the carrying value of goodwill acquired intangible acquired intangible include product and product right trade name and patent license and other which are initially recorded at fair value assigned an estimated useful life and amortized primarily on straight line basis over their estimated useful life ranging from to year the company periodically evaluates whether current fact or circumstance indicate that the carrying value of it acquired intangible may not be recoverable if such circumstance are determined to exist an estimate of the undiscounted of contentsfuture cash flow of these asset or appropriate asset grouping is compared to the carrying value to determine whether an impairment exists if the asset is determined to be impaired the loss is measured based on the difference between the carrying value of the intangible asset and it fair value which is determined based on the net present value of estimated future cash flow acquired in process research and development ipr that the company acquires in conjunction with the acquisition of business represents the fair value assigned to incomplete research project which at the time of acquisition have not reached technological feasibility the amount are capitalized and are accounted for indefinite lived intangible asset subject to impairment testing until completion or abandonment of the project upon successful completion of each ipr project merck will make determination to the then useful life of the intangible asset generally determined by the period in which the substantial majority of the cash flow are expected to be generated and begin amortization the company evaluates ipr for impairment at least annually or more frequently if impairment indicator exist by performing quantitative test that compare the fair value of the ipr intangible asset with it carrying value if the fair value is le than the carrying amount an impairment loss is recognized in operating result contingent consideration certain of the company acquisition involve the potential for future payment of consideration that is contingent upon the achievement of performance milestone including product development milestone and royalty payment on future product sale if the transaction is accounted for business combination the fair value of contingent consideration liability is determined at the acquisition date using unobservable input these input include the estimated amount and timing of projected cash flow the probability of success achievement of the contingent event and the risk adjusted discount rate used to present value the probability weighted cash flow subsequent to the acquisition date at each reporting period until the contingency is resolved the contingent consideration liability is remeasured at current fair value with change either expense or income recorded in earnings significant event that increase or decrease the probability of achieving development and regulatory milestone or that increase or decrease projected cash flow will result in corresponding increase or decrease in the fair value of the related contingent consideration obligation if the transaction is accounted for an acquisition of an asset rather than business contingent consideration is not recognized at the acquisition date in these instance product development milestone are recognized upon achievement and sale based milestone are recognized when the milestone is deemed probable by the company of being achieved research and development research and development is expensed incurred nonrefundable advance payment for good and service that will be used in future research and development activity are expensed when the activity ha been performed or when the good have been received rather than when the payment is made research and development expense include restructuring cost and ipr impairment charge in addition research and development expense include expense or income related to change in the estimated fair value measurement of liability for contingent consideration associated with ipr asset research and development expense also include upfront and milestone payment related to asset acquisition and licensing transaction involving clinical development program that have not yet received regulatory approval collaborative arrangement merck ha entered into collaborative arrangement that provide the company with varying right to develop produce and market product together with it collaborative partner when merck is the principal on sale transaction with third party the company recognizes sale cost of sale and selling general and administrative expense on gross basis profit sharing amount it pay to it collaborative partner are recorded within cost of sale when the collaborative partner is the principal on sale transaction with third party the company record profit sharing amount received from it collaborative partner alliance revenue within sale alliance revenue is recorded net of cost of sale and includes an adjustment to share commercialization cost between the partner in accordance with the collaboration agreement the adjustment is determined by comparing the commercialization cost merck ha incurred directly and reported within selling general and administrative expense with the cost the collaborative partner ha incurred research and development cost merck incurs related to collaboration are recorded within research and development expense cost reimbursement to the collaborative partner or payment received from the collaborative partner to share these cost pursuant to the term of the collaboration agreement are recorded increase or decrease to research and development expense of contentsin addition the term of the collaboration agreement may require the company to make payment based upon the achievement of certain developmental regulatory approval or commercial milestone upfront and milestone payment payable by merck to collaborative partner prior to regulatory approval are expensed incurred and included in research and development expense payment due to collaborative partner upon or subsequent to regulatory approval are capitalized and amortized over the estimated useful life of the corresponding intangible asset to cost of sale provided that future cash flow support the amount capitalized sale based milestone payable by merck to collaborative partner are accrued and capitalized subject to cumulative amortization catch up when probable of being achieved the amortization catch up is calculated either from the time of the first regulatory approval for indication that were unapproved at the time the collaboration wa formed or from time of the formation of the collaboration for approved product the related intangible asset that is recognized is amortized to cost of sale over it remaining useful life subject to impairment testing share based compensation the company expense all share based payment to employee over the requisite service period based on the grant date fair value of the award restructuring cost the company record liability for cost associated with exit or disposal activity in the period in which the liability is incurred in accordance with existing benefit arrangement employee termination cost are accrued when the restructuring action are probable and estimable when accruing these cost the company will recognize the amount within range of cost that is the best estimate within the range when no amount within the range is better estimate than any other amount the company recognizes the minimum amount within the range cost for one time termination benefit in which the employee is required to render service until termination in order to receive the benefit are recognized ratably over the future service period contingency and legal defense cost the company record accrual for contingency and legal defense cost expected to be incurred in connection with loss contingency when it is probable that liability ha been incurred and the amount can be reasonably estimated tax on income deferred tax are recognized for the future tax effect of temporary difference between financial and income tax reporting based on enacted tax law and rate the company evaluates tax position to determine whether the benefit of tax position are more likely than not of being sustained upon audit based on the technical merit of the tax position for tax position that are more likely than not of being sustained upon audit the company recognizes the amount of the benefit that is greater than likely of being realized upon ultimate settlement in the financial statement for tax position that are not more likely than not of being sustained upon audit the company doe not recognize any portion of the benefit in the financial statement the company recognizes interest and penalty associated with uncertain tax position component of tax on income from continuing operation the company account for the tax effect of the tax on global intangible low taxed income gilti of certain foreign subsidiary in the income tax provision in the period the tax arises use of estimate the consolidated financial statement are prepared in conformity with accounting principle generally accepted in the gaap and accordingly include certain amount that are based on management best estimate and judgment estimate are used when accounting for amount recorded in connection with acquisition including initial fair value determination of asset and liability primarily ipr other intangible asset and contingent consideration well subsequent fair value measurement additionally estimate are used in determining such item provision for sale discount and return depreciable and amortizable life recoverability of inventory including those produced in preparation for product launch amount recorded for contingency environmental liability accrual for contingent sale based milestone payment and other reserve pension and other postretirement benefit plan assumption share based compensation assumption restructuring cost impairment of long lived asset including intangible asset and goodwill and investment and tax on income because of the uncertainty inherent in such estimate actual result may differ from these estimate reclassification certain reclassification have been made to prior year amount to conform to the current year presentation of contentsrecently adopted accounting standard in december the financial accounting standard board fasb issued amended guidance on the accounting and reporting of income tax the guidance is intended to simplify the accounting for income tax by removing exception related to certain intraperiod tax allocation and deferred tax liability clarifying guidance primarily related to evaluating the step up tax basis for goodwill in business combination and reflecting enacted change in tax law or rate in the annual effective tax rate the company adopted the new guidance effective january there wa no impact to the company consolidated financial statement upon adoption in january the fasb issued new guidance intended to clarify certain interaction between accounting standard related to equity security equity method investment and certain derivative the guidance address accounting for the transition into and out of the equity method of accounting and measuring certain purchased option and forward contract to acquire investment the company adopted the new guidance effective january there wa no impact to the company consolidated financial statement upon adoption in august the fasb issued amended guidance on the accounting for convertible instrument and contract in an entity own equity the guidance remove the separation model for convertible debt instrument and preferred stock amends requirement for conversion option to be classified in equity well amends diluted earnings per share eps calculation for certain convertible debt instrument the amended guidance is effective for interim and annual period in the application of the amendment in the new guidance are to be applied either on modified retrospective or retrospective basis there wa no impact to the company consolidated financial statement upon adoption on january recently issued accounting standard not yet adopted in march the fasb issued optional guidance to ease the potential burden in accounting for or recognizing the effect of reference rate reform on financial reporting and subsequently issued clarifying amendment the guidance provides optional expedient and exception for accounting for contract hedging relationship and other transaction that reference the london interbank offered rate libor or another reference rate expected to be discontinued because of reference rate reform the optional guidance is effective upon issuance and can be applied on prospective basis at any time between january through december the company is currently evaluating the impact of adoption on it consolidated financial statement the company is progressing in it evaluation of libor cessation exposure including the review of debt related contract lease business development and licensing arrangement royalty and other agreement the company ha amended certain agreement and continues to review other agreement for potential impact with regard to debt related exposure in particular all existing interest rate swap linked to libor will mature in the company is still evaluating the impact to it libor based debt based on it evaluation thus far the company doe not anticipate material impact to it consolidated financial statement result of reference rate reform in october the fasb issued amended guidance that requires acquiring entity to recognize and measure contract asset and liability in business combination in accordance with existing revenue recognition guidance the amended guidance is effective for interim and annual period in and is to be applied prospectively early adoption is permitted on retrospective basis to the beginning of the fiscal year of adoption the adoption of this guidance will not have material impact on the company consolidated financial statement for prior acquisition however the impact in future period will be dependent upon the contract asset and contract liability acquired in future business combination in november the fasb issued new guidance to increase the transparency of transaction with government that are accounted for by applying grant or contribution accounting model by analogy the guidance requires annual disclosure of such transaction to include the nature of the transaction and the significant term and condition the accounting treatment and the impact to the company financial statement the guidance is effective for annual period beginning in and is to be applied on either prospective or retrospective basis the company is currently evaluating the impact of adoption on it consolidated financial statement spin off of organon co on june merck completed the spin off of organon through distribution of organon publicly traded stock to company shareholder in connection with the spin off each merck shareholder received one tenth of share of organon common stock for each share of merck common stock held by such shareholder the of contentsdistribution is expected to qualify and ha been treated tax free to merck and it shareholder for federal income tax purpose indebtedness of billion principal amount consisting of term loan and senior note wa issued in in connection with the spin off and assumed by organon merck is no longer the obligor of any organon debt or financing arrangement cash proceeds of billion were distributed by organon to merck in connection with the spin off also in connection with the spin off merck and organon entered into separation and distribution agreement and also entered into various other agreement to effect the spin off and provide framework for the relationship between merck and organon after the spin off including transition service agreement tsa manufacturing and supply agreement msas trademark license agreement intellectual property license agreement an employee matter agreement tax matter agreement and certain other commercial agreement under the tsa merck will provide organon various service and similarly organon will provide merck various service the provision of service under the tsa generally will terminate within month following the spin off merck and organon also entered into series of interim operating agreement pursuant to which in various jurisdiction where merck held license permit and other right in connection with marketing import and or distribution of organon product prior to the separation merck will continue to market import and distribute such product until such time the relevant license and permit are transferred to organon under such interim operating agreement and in accordance with the separation and distribution agreement merck will continue operation in the affected market on behalf of organon with organon receiving all of the economic benefit and burden of such activity additionally merck and organon entered into number of msas pursuant to which merck will manufacture and supply certain active pharmaceutical ingredient for organon toll manufacture and supply certain formulated pharmaceutical product for organon and package and label certain finished pharmaceutical product for organon similarly organon and merck entered into number of msas pursuant to which organon will manufacture and supply certain formulated pharmaceutical product for merck and package and label certain finished pharmaceutical product for merck the term of the msas range in initial duration from four year to ten year amount included in the consolidated statement of income for the above msas include sale of million and related cost of sale of million in amount included in the consolidated statement of income for the tsa wa immaterial in the amount due from organon under the above agreement wa million at december and is reflected in other current asset the amount due to organon under these agreement wa million at december and is included in accrued and other current liability the result of the woman health biosimilars and established brand business previously included in the pharmaceutical segment that were contributed to organon in the spin off well interest expense related to the debt issuance in have been reflected discontinued operation in the company consolidated statement of income income from discontinued operation net of tax and amount attributable to noncontrolling interest through june the date of the spin off prior period have been recast to reflect this presentation result of the spin off of organon merck incurred separation cost of million in and million in which are also included in income from discontinued operation net of tax and amount attributable to noncontrolling interest these cost primarily relate to professional fee for separation activity within finance tax legal and information technology function well investment banking fee of december the asset and liability associated with these business are classified asset and liability of discontinued operation in the consolidated balance sheet of contentsdetails of income from discontinued operation net of tax and amount attributable to noncontrolling interest are follows year ended december cost expense and othercost of selling general and research and restructuring other income expense net income from discontinued operation before tax income from discontinued operation net of le income of discontinued operation attributable to noncontrolling income from discontinued operation net of tax and amount attributable to noncontrolling interest reflects amount through the june spin off date detail of asset and liability of discontinued operation are follows december and cash equivalent account receivable le allowance for doubtful other current current asset of discontinued operation property plant and equipment net other intangible other noncurrent asset of discontinued operation trade account payable accrued and other current income tax payable total current liability of discontinued operation deferred income tax other noncurrent noncurrent liability of discontinued operation result of the spin off of organon merck distributed net liability of billion of june consisting of debt of billion described above goodwill of billion property plant and equipment of million cash of million inventory of million other intangible net of million and other net liability of million the spin off also resulted in net decrease to aocl of million consisting of million for the derecognition of net loss on foreign currency translation adjustment and million associated with employee benefit plan the distribution of the net liability and reduction to aocl resulted in net billion increase to other paid in capital of contentsexpenses for curtailment settlement and termination benefit provided to certain employee were incurred in connection with the spin off see note additionally all outstanding merck stock option restricted stock unit rsus and performance share unit psus whether vested or unvested were converted into adjusted merck award for current and former merck employee or organon award for organon employee see note acquisition research collaboration and license agreementsthe company continues to pursue acquisition and the establishment of external alliance such research collaboration and licensing agreement to complement it internal research capability these arrangement often include upfront payment well expense reimbursement or payment to the third party and milestone royalty or profit share arrangement contingent upon the occurrence of certain future event linked to the success of the asset in development the company also review it marketed product and pipeline to examine candidate which may provide more value through out licensing and part of it portfolio assessment process may also divest certain asset pro forma financial information for acquired business is not presented if the historical financial result of the acquired entity are not significant when compared with the company financial result transactionsin november merck acquired acceleron pharma inc acceleron publicly traded biopharmaceutical company for total consideration of billion acceleron is evaluating the transforming growth factor tgf beta superfamily of protein that is known to play central role in the regulation of cell growth differentiation and repair acceleron lead therapeutic candidate sotatercept mk ha novel mechanism of action with the potential to improve short term and or long term clinical outcome in patient with pulmonary arterial hypertension pah sotatercept is in phase trial an add on to current standard of care for the treatment of pah under previous agreement assumed by merck bristol myers squibb bm wa granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension ph field for which merck would be eligible to receive contingent milestone and royalty payment however merck retains the worldwide exclusive right to develop and commercialize sotatercept in the ph field the agreement provides for merck to pay royalty on future sale of sotatercept in the ph field to bm in addition to sotatercept acceleron portfolio includes reblozyl luspatercept first in class erythroid maturation recombinant fusion protein that is approved in the europe canada and australia for the treatment of anemia in certain rare blood disorder and is also being evaluated in phase and phase trial for additional indication for hematology therapy reblozyl is being developed and commercialized through global collaboration with bm in connection with this ongoing collaboration merck receives sale royalty from bm which could increase to maximum of based on sale level this royalty will be reduced by upon the earlier of patent expiry or generic entry on an indication by indication basis in each market merck is eligible to receive future contingent milestone payment including up to million in regulatory milestone and up to million in sale based milestone the transaction wa accounted for business combination the company incurred million of cost directly related to the acquisition of acceleron consisting primarily of share based compensation payment to settle non vested equity award attributable to postcombination service severance well investment banking and legal fee these cost were included in selling general and administrative expense and research and development cost in of contentsthe estimated fair value of asset acquired and liability assumed from acceleron is follows november and cash equivalent identifiable intangible asset ipr sotatercept product and product right reblozyl year useful life deferred income tax liability net other asset and liability total identifiable net goodwill consideration transferred the estimated fair value of the identifiable intangible asset related to sotatercept and reblozyl were determined using an income approach specifically the multi period excess earnings method the future probability weighted net cash flow were discounted to present value utilizing discount rate of for sotatercept and for reblozyl actual cash flow are likely to be different than those assumed the goodwill recognized is largely attributable to anticipated synergy expected to arise after the acquisition and wa allocated to the pharmaceutical segment the goodwill is not deductible for tax purpose in april merck acquired pandion therapeutic inc pandion clinical stage biotechnology company developing novel therapeutic designed to address the unmet need of patient living with autoimmune disease pandion is advancing pipeline of precision immune modulators targeting critical immune control node total consideration paid of billion included million of cost primarily comprised of share based compensation payment to settle equity award the transaction wa accounted for an acquisition of an asset merck recorded net asset of million primarily cash and research and development expense of billion in related to the transaction there are no future contingent payment associated with the acquisition in march merck and gilead science inc gilead entered into an agreement to jointly develop and commercialize long acting treatment in hiv that combine merck investigational nucleoside reverse transcriptase translocation inhibitor islatravir and gilead investigational capsid inhibitor lenacapavir the collaboration will initially focus on long acting oral formulation and long acting injectable formulation of these combination product with other formulation potentially added to the collaboration mutually agreed there wa no upfront payment made by either party upon entering into the agreement under the term of the agreement merck and gilead will share operational responsibility well development commercialization and marketing cost and any future revenue global development and commercialization cost will be shared gilead and merck across the oral and injectable formulation program for long acting oral product gilead will lead commercialization in the and merck will lead commercialization in the eu and the rest of the world for long acting injectable product merck will lead commercialization in the and gilead will lead commercialization in the eu and the rest of the world gilead and merck will co promote in the and certain other major market merck and gilead will share global product revenue equally until product revenue surpass certain pre agreed per formulation revenue tier upon passing billion year in net product sale for the oral combination the revenue split will adjust to gilead and merck for any revenue above the threshold upon passing billion year in net product sale for the injectable combination the revenue split will adjust to gilead and merck for any revenue above the threshold beyond the potential combination of investigational lenacapavir and investigational islatravir gilead will have the option to license certain of merck investigational oral integrase inhibitor to develop in combination with lenacapavir reciprocally merck will have the option to license certain of gilead investigational oral integrase inhibitor to develop in combination with islatravir each company may exercise it option for an investigational oral integrase inhibitor of the other company following completion of the first phase clinical trial of that integrase inhibitor upon exercise of an option the company will split development cost and revenue unless the non exercising company decides to opt out in december the food and drug administration fda placed full or partial clinical hold on investigational new drug application for certain oral implant and injectable formulation of islatravir based on of contentsobservations of decrease in total lymphocyte and cell count in some participant receiving islatravir in clinical study result of these hold merck and gilead made the decision to stop all dosing of participant in phase clinical study evaluating islatravir and lenacapavir in people living with hiv who are virologically suppressed on antiretroviral therapy the two company are assessing whether different dosing of islatravir in combination with lenacapavir may provide once weekly oral therapy option for people living with hiv merck and gilead remain committed to their collaboration in january merck entered into an exclusive license and research collaboration agreement with artiva biotherapeutics inc artiva to discover develop and manufacture car nk cell that target certain solid tumor using artiva proprietary platform merck and artiva agreed to engage in up to three different research program each covering collaboration target merck ha sole responsibility for all development and commercialization activity including regulatory filing and approval under the term of the agreement merck made an upfront payment of million which wa included in research and development expense in for license and other right for the first two collaboration target and agreed to make another upfront payment of million for license and other right for the third collaboration target when it is selected by merck and accepted by artiva in addition artiva is eligible to receive future contingent milestone payment which span all three collaboration target aggregating up to million in developmental milestone million in regulatory milestone and billion in sale based milestone the agreement also provides for merck to pay tiered royalty ranging from to on future sale transactionsin december merck acquired oncoimmune privately held clinical stage biopharmaceutical company for an upfront payment of million oncoimmune lead therapeutic candidate mk wa being evaluated for the treatment of patient hospitalized with covid the transaction wa accounted for an acquisition of an asset under the agreement prior to the completion of the acquisition oncoimmune spun out certain right and asset unrelated to the mk program to new entity owned by the existing shareholder of oncoimmune in connection with the closing of the acquisition merck invested million for ownership interest in the new entity which wa valued at million resulting in million premium merck also recognized other net liability of million the company recorded research and development expense of million in related to this transaction in merck received feedback from the fda that additional data would be needed to support potential emergency use authorization eua application and therefore the company did not expect mk would become available until the first half of given this timeline and the technical clinical and regulatory uncertainty the availability of number of medicine for patient hospitalized with covid and the need to concentrate merck resource on accelerating the development and manufacture of the most viable therapeutic and vaccine merck decided to discontinue development of mk for the treatment of covid due to the discontinuation the company recorded charge of million in which are reflected in cost of sale and relate to fixed asset and material written off well the recognition of liability for purchase commitment also in december merck acquired velosbio inc velosbio privately held clinical stage biopharmaceutical company for billion velosbio lead investigational candidate is zilovertamab vedotin mk an antibody drug conjugate targeting receptor tyrosine kinase like orphan receptor that is currently being evaluated for the treatment of patient with hematologic malignancy and solid tumor the transaction wa accounted for an acquisition of an asset merck recorded net asset of million primarily cash and research and development expense of billion in related to the transaction during the company recorded adjustment to these amount which resulted in reduction of research and development expense of million an increase to total consideration paid of million and an increase to net asset recorded of million in september merck and seagen inc seagen announced an oncology collaboration to globally develop and commercialize seagen ladiratuzumab vedotin mk an investigational antibody drug conjugate targeting liv which is currently in phase clinical trial the collaboration will pursue broad joint development program evaluating ladiratuzumab vedotin monotherapy and in combination with keytruda pembrolizumab in triple negative breast cancer hormone receptor positive breast cancer and other liv expressing solid tumor the company will equally share profit worldwide under the term of the agreement of contentsmerck made an upfront payment of million and billion equity investment in million share of seagen common stock at price of per share merck recorded million in research and development expense in related to this transaction reflecting the upfront payment well million premium relating to the equity share based on the price of seagen common stock on the closing date seagen is also eligible to receive future contingent milestone payment of up to billion including million in development milestone and billion in sale based milestone concurrent with the above transaction seagen granted merck an exclusive license to commercialize tukysa tucatinib small molecule tyrosine kinase inhibitor for the treatment of human epidermal growth factor receptor positive cancer in asia the middle east and latin america and other region outside of the canada and europe merck will be responsible for marketing application seeking approval in it territory supported by the positive result from the clinical trial merck will also co fund portion of the tukysa global development plan which encompasses several ongoing and planned trial across positive cancer including breast colorectal gastric and other cancer set forth in global product development plan merck will solely fund and conduct country specific clinical trial necessary to support anticipated regulatory application in it territory under the term of the agreement merck made upfront payment aggregating million which were recorded research and development expense in seagen is also eligible to receive future contingent regulatory approval milestone of up to million and will receive tiered royalty ranging from to based on annual sale level of tukysa in merck territory additionally in september merck acquired biologics manufacturing facility located in dunboyne ireland from takeda pharmaceutical company limited for million million the transaction wa accounted for an acquisition of an asset merck recorded property plant and equipment of million and other net asset of million there are no future contingent payment associated with the acquisition in july merck acquired the right to sentinel flavor tab and sentinel spectrum chew from virbac corporation for million sentinel product provide protection against common parasite in dog the transaction wa accounted for an acquisition of an asset merck recognized intangible asset of million related to currently marketed product and inventory of million at the acquisition date the estimated fair value of the identifiable intangible asset related to currently marketed product were determined using an income approach actual cash flow are likely to be different than those assumed the intangible asset related to currently marketed product will be amortized over their estimated useful life of year there are no future contingent payment associated with the acquisition also in july merck and ridgeback biotherapeutics lp ridgeback closely held biotechnology company closed collaboration agreement to develop molnupiravir mk an orally available antiviral candidate in clinical development for the treatment of patient with covid see note for additional information related to this collaboration in june merck acquired privately held themis bioscience gmbh themis company focused on vaccine including covid vaccine candidate and immune modulation therapy for infectious disease and cancer for million the acquisition originally provided for merck to make additional contingent payment of up to million the transaction wa accounted for business combination the company determined the fair value of the contingent consideration wa million at the acquisition date utilizing probability weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payment merck recognized intangible asset for ipr of million cash of million deferred tax asset of million and other net liability of million the excess of the consideration transferred over the fair value of net asset acquired of million wa recorded goodwill that wa allocated to the pharmaceutical segment and is not deductible for tax purpose the fair value of the identifiable intangible asset related to ipr were determined using an income approach actual cash flow are likely to be different than those assumed in january the company announced it wa discontinuing development of discussed below result in the company recorded an ipr impairment charge of million within research and development expense the company also recorded reduction in research and development expense resulting from decrease in the related liability for contingent consideration of million since future contingent milestone payment have been reduced to million in the aggregate including up to million for development milestone up to million for regulatory approval milestone and up to million for commercial milestone of contentsin may merck and the international aid vaccine initiative inc iavi nonprofit scientific research organization dedicated to addressing urgent unmet global health challenge announced collaboration to develop an investigational vaccine against sars cov being studied for the prevention of covid the agreement provided for an upfront payment by merck of million and also provided for future contingent payment based on sale merck also signed an agreement with the biomedical advanced research and development authority barda part of the office of the assistant secretary for preparedness and response within an agency of the department of health and human service to provide initial funding support to merck for this effort in january the company announced it wa discontinuing development of discussed below in january the company announced the discontinuation of the development program for it covid vaccine candidate and following merck review of finding from phase clinical study for the vaccine in these study both and were generally well tolerated but the immune response were inferior to those seen following natural infection and those reported for other sars cov covid vaccine due to the discontinuation the company recorded charge of million in of which million wa reflected in cost of sale and related to fixed asset and material written off well the recognition of liability for purchase commitment the remaining million of cost were reflected in research and development expense and represent amount related to the themis acquisition noted above an ipr impairment charge partially offset by reduction in the related liability for contingent consideration in january merck acquired arqule inc arqule publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patient with cancer and other disease total consideration paid of billion included million of share based compensation payment to settle equity award attributable to precombination service and cash paid for transaction cost on behalf of arqule the company incurred million of cost directly related to the acquisition of arqule consisting almost entirely of share based compensation payment to settle non vested equity award attributable to postcombination service these cost were included in selling general and administrative expense in arqule lead investigational candidate nemtabrutinib mk is novel oral bruton tyrosine kinase btk inhibitor currently being evaluated for the treatment of cell malignancy the transaction wa accounted for business combination the estimated fair value of asset acquired and liability assumed from arqule is follows january and cash equivalent ipr nemtabrutinib licensing arrangement for arq deferred income tax liability other asset and liability total identifiable net goodwill consideration transferred the estimated fair value of nemtabrutinib wa determined using an income approach the future probability weighted net cash flow were discounted to present value utilizing discount rate of actual cash flow are likely to be different than those assumed the goodwill wa allocated to the pharmaceutical segment and is not deductible for tax purpose in merck recorded million intangible asset impairment charge related to nemtabrutinib see note transactionsin july merck acquired peloton therapeutic inc peloton clinical stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidate targeting hypoxia inducible factor hif for the treatment of patient with cancer and other non oncology disease merck made an upfront payment of billion the transaction wa accounted for an acquisition of an asset merck recorded cash of million deferred tax liability of million and other net liability of million at the acquisition of contentsdate well research and development expense of million in related to the transaction former peloton shareholder received million milestone payment from merck in upon first commercial sale of peloton lead candidate welireg belzutifan which wa approved monotherapy in the in august former peloton shareholder are also eligible to receive million upon regulatory approval combination therapy well up to billion of sale based milestone on april merck acquired antelliq corporation antelliq leader in digital animal identification traceability and monitoring solution these solution help veterinarian farmer and pet owner gather critical data to improve management health and well being of livestock and pet merck paid billion to acquire all outstanding share of antelliq and spent billion to repay antelliq debt the transaction wa accounted for business combination the estimated fair value of asset acquired and liability assumed from antelliq is follows april and cash equivalent account property plant and identifiable intangible asset useful life ranging from year deferred income tax liability other asset and liability net total identifiable net goodwill consideration transferred the estimated fair value of identifiable intangible asset relate primarily to trade name and were determined using an income approach the future probability weighted net cash flow were discounted to present value utilizing discount rate of actual cash flow are likely to be different than those assumed the goodwill recognized is largely attributable to anticipated synergy expected to arise after the acquisition and wa allocated to the animal health segment the goodwill is not deductible for tax purpose the company incurred million of transaction cost directly related to the acquisition of antelliq consisting largely of advisory fee which are reflected in selling general and administrative expense in also in april merck acquired immune design late stage immunotherapy company employing next generation in vivo approach to enable the body immune system to fight disease for million in cash the transaction wa accounted for business combination merck recognized intangible asset of million cash of million and other net asset of million the excess of the consideration transferred over the fair value of net asset acquired of million wa recorded goodwill that wa allocated to the pharmaceutical segment and is not deductible for tax purpose the fair value of the identifiable intangible asset related to ipr were determined using an income approach actual cash flow are likely to be different than those assumed collaborative arrangementsmerck ha entered into collaborative arrangement that provide the company with varying right to develop produce and market product together with it collaborative partner both party in these arrangement are active participant and exposed to significant risk and reward dependent on the commercial success of the activity of the collaboration merck more significant collaborative arrangement are discussed below astrazenecain merck and astrazeneca plc astrazeneca entered into global strategic oncology collaboration to co develop and co commercialize astrazeneca lynparza olaparib for multiple cancer type independently merck and astrazeneca will develop and commercialize lynparza in combination with their respective pd and pd medicine keytruda and imfinzi the company are also jointly developing and of contentscommercializing astrazeneca koselugo selumetinib for multiple indication under the term of the agreement astrazeneca and merck will share the development and commercialization cost for lynparza and koselugo monotherapy and non pd pd combination therapy opportunity profit from lynparza and koselugo product sale generated through monotherapies or combination therapy are shared equally astrazeneca is the principal on lynparza and koselugo sale transaction merck record it share of lynparza and koselugo product sale net of cost of sale and commercialization cost alliance revenue and it share of development cost associated with the collaboration part of research and development expense reimbursement received from astrazeneca for research and development expense are recognized reduction to research and development cost part of the agreement merck made an upfront payment to astrazeneca and also made payment over multi year period for certain license option in addition the agreement provides for contingent payment from merck to astrazeneca related to the successful achievement of sale based and regulatory milestone merck made sale based milestone payment to astrazeneca aggregating million and million in and respectively of december sale based milestone payment accrued but not yet paid totaled million potential future sale based milestone payment of billion have not yet been accrued they are not deemed by the company to be probable at this time in and lynparza received regulatory approval triggering capitalized milestone payment of million and million respectively in the aggregate from merck to astrazeneca potential future regulatory milestone payment of billion remain under the agreement the intangible asset balance related to lynparza which includes capitalized sale based and regulatory milestone payment wa billion at december and is included in other intangible net the amount is being amortized over it estimated useful life through supported by projected future cash flow subject to impairment testing summarized financial information related to this collaboration is follows year ended december revenue lynparza alliance revenue total alliance revenue cost of sale selling general and research and december from astrazeneca included in other current asset payable to astrazeneca included in trade account payable and accrued and other current liability represents amortization of capitalized milestone payment includes accrued milestone payment eisaiin merck and eisai co ltd eisai announced strategic collaboration for the worldwide co development and co commercialization of lenvima lenvatinib an orally available tyrosine kinase inhibitor discovered by eisai under the agreement merck and eisai will develop and commercialize lenvima jointly both monotherapy and in combination with keytruda eisai record lenvima product sale globally eisai is the principal on lenvima sale transaction and merck and eisai share applicable profit equally merck record it share of lenvima product sale net of cost of sale and commercialization cost alliance revenue expense incurred during co development are shared by the two company in accordance with the collaboration agreement and reflected in research and development expense certain expense incurred solely by merck or eisai are not of contentsshareable under the collaboration agreement including cost incurred in excess of agreed upon cap and cost related to certain combination study of keytruda and lenvima under the agreement merck made an upfront payment to eisai and also made payment over multi year period for certain option right of which the final million option payment wa made in march in addition the agreement provides for contingent payment from merck to eisai related to the successful achievement of sale based and regulatory milestone merck made sale based milestone payment to eisai aggregating million million and million in and respectively of december sale based milestone payment accrued but not yet paid totaled million potential future sale based milestone payment of billion have not yet been accrued they are not deemed by the company to be probable at this time in and lenvima received regulatory approval triggering capitalized milestone payment of million and million respectively from merck to eisai of december regulatory approval milestone payment of million wa accrued but not yet paid potential future regulatory milestone payment of million remain under the agreement the intangible asset balance related to lenvima which includes capitalized sale based and regulatory milestone payment wa billion at december and is included in other intangible net the amount is being amortized over it estimated useful life through supported by projected future cash flow subject to impairment testing summarized financial information related to this collaboration is follows year ended december revenue lenvima cost of sale selling general and research and december from eisai included in other current asset payable to eisai included in accrued and other current liability payable to eisai included in other noncurrent liability represents amortization of capitalized milestone payment includes accrued milestone and future option payment includes accrued milestone payment bayer ag in the company entered into worldwide clinical development collaboration with bayer ag bayer to market and develop soluble guanylate cyclase sgc modulators including bayer adempas riociguat the two company have implemented joint development and commercialization strategy the collaboration also includes development of bayer verquvo vericiguat which wa approved in the in january in japan in june and in the eu in july under the agreement bayer commercializes adempas in the america while merck commercializes in the rest of the world for verquvo merck commercializes in the and bayer commercializes in the rest of the world both company share in development cost and profit on sale merck record sale of adempas and verquvo in it marketing territory well alliance revenue alliance revenue represents merck share of profit from sale of adempas and verquvo in bayer marketing territory which are product sale net of cost of sale and commercialization cost cost of sale includes bayer share of profit from sale in merck marketing territory in addition the agreement provided for contingent payment from merck to bayer related to the successful achievement of sale based milestone merck made sale based milestone payment to bayer of million in in following the approval of verquvo noted above merck determined it wa probable that sale of adempas and verquvo in the future would trigger the remaining million sale based milestone of contentspayment that wa outstanding under this agreement accordingly merck recorded liability of million and corresponding increase to the intangible asset related to this collaboration merck also recognized million of cumulative amortization catch up expense related to the recognition of this milestone in in january merck made this final milestone payment to bayer the intangible asset balance related to adempas which includes the acquired intangible asset balance well capitalized sale based milestone payment attributed to adempas and verquvo which reflects the portion of the final sale based milestone payment that wa attributed to verquvo were million and million respectively at december and are included in other intangible net the asset are being amortized over their estimated useful life through for adempas and through for verquvo supported by projected future cash flow subject to impairment testing summarized financial information related to this collaboration is follows year ended december revenue adempas verquvo net sale of adempas recorded by net sale of verquvo recorded by total sale cost of sale selling general and research and december from bayer included in other current asset payable to bayer included in accrued and other current liability includes amortization of intangible asset amount in includes million of cumulative amortization catch up expense noted above in addition cost of sale in all period now includes bayer share of profit from sale in merck marketing territory includes accrued milestone payment ridgeback biotherapeutics lpin july merck and ridgeback closely held biotechnology company entered into collaboration agreement to develop molnupiravir mk an orally available antiviral candidate in clinical development for the treatment of patient with covid merck gained exclusive worldwide right to develop and commercialize molnupiravir and related molecule under the term of the agreement ridgeback received an upfront payment and is eligible to receive future contingent payment dependent upon the achievement of certain developmental and regulatory approval milestone the agreement also provides for merck to reimburse ridgeback for portion of certain third party contingent milestone payment and royalty on net sale which is part of the profit share calculation merck is the principal on sale transaction recognizing sale and related cost with profit sharing amount recorded within cost of sale profit from the collaboration are split equally between the partner reimbursement from ridgeback for it share of research and development cost deducted from ridgeback share of profit are reflected decrease to research and development expense in december the fda granted eua for molnupiravir under previously announced procurement agreement with the government merck agreed to supply million course of molnupiravir to the government upon eua or approval from the fda of which approximately course were delivered in this procurement of molnupiravir is being supported in whole or in part with federal fund additionally in december japan ministry of health labor and welfare granted special approval for emergency in japan for molnupiravir under supply agreement the japanese government will purchase million course of molnupiravir of which approximately course were delivered in also in november the medicine and healthcare product regulatory agency in the united kingdom uk granted conditional marketing authorization for molnupiravir the uk government ha committed to purchase total of million course of molnupiravir of which approximately course were delivered in merck ha entered into advance purchase and supply agreement for molnupiravir in more than market of contentsmerck and ridgeback are committed to providing timely access to molnupiravir globally through comprehensive supply and access approach which includes investing at risk to produce million of course of therapy tiered pricing based on the ability of government to finance health care entering into supply agreement with government noted above allocating up to million course of therapy to the united nation child fund unicef for use in adult and granting voluntary license to generic manufacturer and to the medicine patent pool mpp to make generic molnupiravir available in more than low and middle income country following local regulatory authorization or approval merck ridgeback and emory university will not receive royalty for sale of molnupiravir under the mpp agreement molnupiravir wa invented at emory university and licensed to ridgeback for long covid remains classified public health emergency of international concern by the world health organization summarized financial information related to this collaboration is follows year ended december sale cost of sale selling general and research and development december to ridgeback included in accrued and other current liability includes royalty expense and amortization of capitalized milestone payment amount in includes upfront payment includes accrued royalty and milestone payment restructuringin merck approved global restructuring program restructuring program part of worldwide initiative focused on further optimizing the company manufacturing and supply network well reducing it global real estate footprint this program is continuation of the company plant rationalization and build on prior restructuring program the action currently contemplated under the restructuring program are expected to be substantially completed by the end of with the cumulative pretax cost to be incurred by the company to implement the program estimated to be approximately billion the company estimate that approximately of the cumulative pretax cost will result in cash outlay primarily related to employee separation expense and facility shut down cost approximately of the cumulative pretax cost will be non cash relating primarily to the accelerated depreciation of facility to be closed or divested the company recorded total pretax cost of million in million in and million in related to restructuring program activity since inception of the restructuring program through december merck ha recorded total pretax accumulated cost of approximately billion the company expects to record charge of approximately million in related to the restructuring program for segment reporting restructuring charge are unallocated expense of contentsthe following table summarizes the charge related to restructuring program activity by type of cost separationcostsaccelerateddepreciationothertotalyear ended december of sale selling general and administrative research and development restructuring year ended december cost of sale selling general and administrative research and development restructuring year ended december cost of sale selling general and administrative research and development restructuring separation cost are associated with actual headcount reduction well those headcount reduction which were probable and could be reasonably estimated accelerated depreciation cost primarily relate to manufacturing research and administrative facility and equipment to be sold or closed part of the program accelerated depreciation cost represent the difference between the depreciation expense to be recognized over the revised useful life of the asset based upon the anticipated date the site will be closed or divested or the equipment disposed of and depreciation expense determined utilizing the useful life prior to the restructuring action all the site have and will continue to operate up through the respective closure date and since future undiscounted cash flow are sufficient to recover the respective book value merck is recording accelerated depreciation over the revised useful life of the site asset anticipated site closure date particularly related to manufacturing location have been and may continue to be adjusted to reflect change resulting from regulatory or other factor other activity in and includes asset abandonment facility shut down and other related cost well pretax gain and loss resulting from the sale of facility and related asset additionally other activity includes certain employee related cost associated with pension and other postretirement benefit plan see note and share based compensation the following table summarizes the charge and spending relating to restructuring program activity separationcostsaccelerateddepreciationothertotalrestructuring reserve january payment receipt net non cash activity restructuring reserve december payment receipt net non cash activity restructuring reserve december the remaining cash outlay are expected to be substantially completed by the end of of financial instrumentsderivative instrument and hedging activitiesthe company manages the impact of foreign exchange rate movement and interest rate movement on it earnings cash flow and fair value of asset and liability through operational mean and through the use of various financial instrument including derivative instrument significant portion of the company revenue and earnings in foreign affiliate is exposed to change in foreign exchange rate the objective of and accounting related to the company foreign currency risk management program well it interest rate risk management activity are discussed below foreign currency risk managementthe company ha established revenue hedging balance sheet risk management and net investment hedging program to protect against volatility of future foreign currency cash flow and change in fair value caused by change in foreign exchange rate the objective of the revenue hedging program is to reduce the variability caused by change in foreign exchange rate that would affect the dollar value of future cash flow derived from foreign currency denominated sale primarily the euro japanese yen and chinese renminbi to achieve this objective the company will hedge portion of it forecasted foreign currency denominated third party and intercompany distributor entity sale forecasted sale that are expected to occur over it planning cycle typically no more than two year into the future the company will layer in hedge over time increasing the portion of forecasted sale hedged it get closer to the expected date of the forecasted sale the portion of forecasted sale hedged is based on assessment of cost benefit profile that consider natural offsetting exposure revenue and exchange rate volatility and correlation and the cost of hedging instrument the company manages it anticipated transaction exposure principally with purchased local currency put option forward contract and purchased collar option the fair value of these derivative contract are recorded either asset gain position or liability loss position in the consolidated balance sheet change in the fair value of derivative contract are recorded each period in either current earnings or oci depending on whether the derivative is designated part of hedge transaction and if so the type of hedge transaction for derivative that are designated cash flow hedge the unrealized gain or loss on these contract are recorded in aocl and reclassified into sale when the hedged anticipated revenue is recognized for those derivative which are not designated cash flow hedge but serve economic hedge of forecasted sale unrealized gain or loss are recorded in sale each period the cash flow from both designated and non designated contract are reported operating activity in the consolidated statement of cash flow the company doe not enter into derivative for trading or speculative purpose the company manages operating activity and net asset position at each local subsidiary in order to mitigate the effect of exchange on monetary asset and liability the company also us balance sheet risk management program to mitigate the exposure of net monetary asset that are denominated in currency other than subsidiary functional currency from the effect of volatility in foreign exchange in these instance merck principally utilizes forward exchange contract to offset the effect of exchange on exposure denominated in developed country currency primarily the euro japanese yen british pound canadian dollar and swiss franc for exposure in developing country currency including the chinese renminbi the company will enter into forward contract to offset the effect of exchange on exposure when it is deemed economical to do so based on cost benefit analysis that considers the magnitude of the exposure the volatility of the exchange rate and the cost of the hedging instrument the cash flow from these contract are reported operating activity in the consolidated statement of cash flow monetary asset and liability denominated in currency other than the functional currency of given subsidiary are remeasured at spot rate in effect on the balance sheet date with the effect of change in spot rate reported in other income expense net the forward contract are not designated hedge and are marked to market through other income expense net accordingly fair value change in the forward contract help mitigate the change in the value of the remeasured asset and liability attributable to change in foreign currency exchange rate except to the extent of the spot forward difference these difference are not significant due to the short term nature of the contract which typically have average maturity at inception of le than one year of contentsthe company also us forward exchange contract to hedge portion of it net investment in foreign operation against movement in exchange rate the forward contract are designated hedge of the net investment in foreign operation the unrealized gain or loss on these contract are recorded in foreign currency translation adjustment within oci and remain in aocl until either the sale or complete or substantially complete liquidation of the subsidiary the company excludes certain portion of the change in fair value of it derivative instrument from the assessment of hedge effectiveness excluded component change in fair value of the excluded component are recognized in oci the company recognizes in earnings the initial value of the excluded component on straight line basis over the life of the derivative instrument rather than using the mark to market approach the cash flow from these contract are reported investing activity in the consolidated statement of cash flow foreign exchange risk is also managed through the use of foreign currency debt the company senior unsecured euro denominated note have been designated and are effective economic hedge of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument are included in foreign currency translation adjustment within oci the effect of the company net investment hedge on oci and the consolidated statement of income are shown below amount of pretax gain loss recognized in other comprehensive income amount of pretax gain loss recognized in other income expense net for amount excluded from effectiveness testingyears ended december investment hedging relationshipsforeign exchange contract euro denominated note no amount were reclassified from aocl into income related to the sale of subsidiary interest rate risk managementthe company may use interest rate swap contract on certain investing and borrowing transaction to manage it net exposure to interest rate change and to reduce it overall cost of borrowing the company doe not use leveraged swap and in general doe not leverage any of it investment activity that would put principal capital at risk in january five interest rate swap with total notional amount of billion matured these swap effectively converted the company billion fixed rate note due to variable rate debt at december the company wa party to nine pay floating receive fixed interest rate swap contract designated fair value hedge of fixed rate note in which the notional amount match the amount of the hedged fixed rate note detailed in the table below instrumentpar value of debtnumber of interest rate swap heldtotal swap notional note due note due these interest rate swap matured in february the interest rate swap contract are designated hedge of the fair value change in the note attributable to change in the benchmark libor swap rate the fair value change in the note attributable to change in the libor swap rate are recorded in interest expense along with the offsetting fair value change in the swap contract see note for discussion of the pending discontinuation of libor part of reference rate reform the cash flow from these contract are reported operating activity in the consolidated statement of cash flow of contentsthe table below present the location of amount recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedge of december carrying amount of hedged liabilitiescumulative amount of fair value hedging adjustment increase decrease included in the carrying sheet line item in which hedged item is includedloans payable and current portion of long term debt long term debt presented in the table below is the fair value of derivative on gross basis segregated between those derivative that are designated hedging instrument and those that are not designated hedging instrument of december fair value ofderivativeu dollarnotionalfair value ofderivativeu dollarnotional balance sheet captionassetliabilityassetliabilityderivatives designated hedging instrument interest rate swap contractsother current asset interest rate swap contractsother asset foreign exchange contractsother current foreign exchange contractsother foreign exchange contractsaccrued and other current liability foreign exchange contractsother noncurrent liability derivative not designated hedging instrument foreign exchange contractsother current asset foreign exchange contractsaccrued and other current liability noted above the company record it derivative on gross basis in the consolidated balance sheet the company ha master netting agreement with several of it financial institution counterparties see concentration of credit risk below the following table provides information on the company derivative position subject to these master netting arrangement if they were presented on net basis allowing for the right of offset by counterparty and cash collateral exchanged per the master agreement and related credit support annex at december amount recognized in the consolidated balance sheet gross amount subject to offset in master netting arrangement not offset in the consolidated balance sheet cash collateral posted received net amount of contentsthe table below provides information regarding the location and amount of pretax gain loss of derivative designated in fair value or cash flow hedging relationship salesother income expense net other comprehensive income loss year ended december statement line item in which effect of fair value or cash flow hedge are recorded gain loss on fair value hedging relationshipsinterest rate swap contractshedged item derivative designated hedging instrument impact of cash flow hedging relationshipsforeign exchange contractsamount of gain loss recognized in oci on derivative decrease increase in sale result of aocl reclassification interest rate contractsamount of gain recognized in other income expense net on derivative amount of loss recognized in oci on derivative interest expense is component of other income expense net the table below provides information regarding the income statement effect of derivative not designated hedging instrument amount of derivative pretax gain loss recognized in incomeyears ended december not designated hedging instrumentsincome statement captionforeign exchange contract other income expense net foreign exchange contract interest rate contract other income expense net forward contract related to seagen common stockresearch and development expense these derivative contract primarily mitigate change in the value of remeasured foreign currency denominated monetary asset and liability attributable to change in foreign currency exchange rate amount in includes loss on forward exchange contract entered into in conjunction with the spin off of organon these derivative serve economic hedge of forecasted transaction these derivative serve economic hedge against rising treasury rate at december the company estimate million of pretax net unrealized gain on derivative maturing within the next month that hedge foreign currency denominated sale over that same period will be reclassified from aocl to sale the amount ultimately reclassified to sale may differ foreign exchange rate change realized gain and loss are ultimately determined by actual exchange rate at maturity of contentsinvestments in debt and equity securitiesinformation on investment in debt and equity security at december is follows amortizedcostgross unrealizedfairvalueamortizedcostgross unrealizedfairvalue gainslossesgainslossesu government and agency security foreign government corporate note and total debt publicly traded equity security total debt and publicly traded equity security unrealized net loss recorded in other income expense net on equity security still held at december were million during unrealized net gain recorded in other income expense net on equity security still held at december were million during at december and the company also had million and million respectively of equity investment without readily determinable fair value included in other asset the company record unrealized gain on these equity investment based on favorable observable price change from transaction involving similar investment of the same investee and record unrealized loss based on unfavorable observable price change which are included in other income expense net during the company recorded unrealized gain of million and unrealized loss of million related to certain of these equity investment still held at december during the company recorded unrealized gain of million and unrealized loss of million related to certain of these investment still held at december cumulative unrealized gain and cumulative unrealized loss based on observable price change for investment in equity investment without readily determinable fair value still held at december were million and million respectively at december and the company also had billion and million respectively recorded in other asset for equity security held through ownership interest in investment fund gain loss recorded in other income expense net relating to these investment fund were billion million and million for the year ended december and respectively fair value measurementsfair value is defined the exchange price that would be received for an asset or paid to transfer liability an exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between market participant on the measurement date the company us fair value hierarchy which maximizes the use of observable input and minimizes the use of unobservable input when measuring fair value there are three level of input used to measure fair value with level having the highest priority and level having the lowest level quoted price unadjusted in active market for identical asset or liability level observable input other than level price such quoted price for similar asset or liability or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability level unobservable input that are supported by little or no market activity level asset or liability are those whose value are determined using pricing model discounted cash flow methodology or similar technique with significant unobservable input well asset or liability for which the determination of fair value requires significant judgment or estimation if the input used to measure the financial asset and liability fall within more than one level described above the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument of contentsfinancial asset and liability measured at fair value on recurring basisfinancial asset and liability measured at fair value on recurring basis at december are summarized below fair value measurement usingfair value measurement using level government bond publicly traded equity other asset government and agency corporate note and publicly traded equity derivative asset forward exchange contract purchased currency option interest rate swap total asset liabilitiesother liabilitiescontingent consideration derivative liability forward exchange contract written currency option total liability investment included in other asset are restricted to use including for the payment of benefit under employee benefit plan the fair value determination of derivative includes the impact of the credit risk of counterparties to the derivative and the company own credit risk the effect of which were not significant of december and cash and cash equivalent include cash equivalent of billion which would be considered level in the fair value hierarchy of contentscontingent considerationsummarized information about the change in the fair value of liability for contingent consideration associated with business combination is follows value january addition change in estimated fair value payment other fair value december recorded in cost of sale research and development expense and other income expense net includes cumulative translation adjustment balance at december includes million recorded current liability for amount expected to be paid within the next month at december and million and million respectively of the liability relate to the termination of the sanofi pasteur msd joint venture in part of the termination merck recorded liability for contingent future royalty payment of on net sale of all merck product that were previously sold by the joint venture through december the fair value of this liability is determined utilizing the estimated amount and timing of projected cash flow using risk adjusted discount rate of to present value the cash flow the addition to contingent consideration in relate to the acquisition of themis see note the payment of contingent consideration in both year relate to the sanofi pasteur msd liability described above other fair value measurementssome of the company financial instrument such cash and cash equivalent receivables and payable are reflected in the balance sheet at carrying value which approximates fair value due to their short term nature the estimated fair value of loan payable and long term debt including current portion at december wa billion compared with carrying value of billion and at december wa billion compared with carrying value of billion fair value wa estimated using recent observable market price and would be considered level in the fair value hierarchy concentration of credit riskon an ongoing basis the company monitor concentration of credit risk associated with corporate and government issuer of security and financial institution with which it conduct business credit exposure limit are established to limit concentration with any single issuer or institution cash and investment are placed in instrument that meet high credit quality standard specified in the company investment policy guideline the majority of the company account receivable arise from product sale in the europe and china and are primarily due from drug wholesaler and retailer hospital government agency managed health care provider and pharmacy benefit manager the company monitor the financial performance and creditworthiness of it customer so that it can properly ass and respond to change in their credit profile the company also continues to monitor global economic condition including the volatility associated with international sovereign economy and associated impact on the financial market and it business the company customer with the largest account receivable balance are mckesson corporation amerisourcebergen corporation and cardinal health inc which represented approximately and respectively of total account receivable at december the company monitor the creditworthiness of it customer to which it grant credit term in the normal course of business bad debt have been minimal the company doe not normally require collateral or other security to support credit sale the company ha account receivable factoring agreement with financial institution in certain country to sell account receivable the company factored billion and billion of account receivable of december and respectively under these factoring arrangement which reduced outstanding account receivable the cash received from the financial institution is reported within operating activity in the consolidated statement of cash flow in certain of these factoring arrangement for ease of administration the company will collect customer payment related to the factored receivables which it then remit to the financial institution at december and the company had collected million and million of contentsrespectively on behalf of the financial institution which is reflected restricted cash in other current asset and the related obligation to remit the cash within accrued and other current liability the company remitted the cash to the financial institution in january and respectively the net cash flow relating to these collection are reported financing activity in the consolidated statement of cash flow the cost of factoring such account receivable wa de minimis derivative financial instrument are executed under international swap and derivative association master agreement the master agreement with several of the company financial institution counterparties also include credit support annex these annex contain provision that require collateral to be exchanged depending on the value of the derivative asset and liability the company credit rating and the credit rating of the counterparty cash collateral received by the company from various counterparties wa million at december the obligation to return such collateral is recorded in accrued and other current liability cash collateral advanced by the company to counterparties wa million at december inventoriesinventories at december consisted of good raw material and work in total approximates current cost decrease to lifo cost recognized inventory other inventory valued under the lifo method comprised approximately billion and billion at december and respectively amount recognized other asset are comprised almost entirely of raw material and work in process inventory at december and these amount included billion and billion respectively of inventory not expected to be sold within one year in addition these amount included million and million at december and respectively of inventory produced in preparation for product launch goodwill and other intangiblesthe following table summarizes goodwill activity by segment pharmaceuticalanimal healthall othertotalbalance january divestiture other balance december other balance december includes cumulative translation adjustment on goodwill balance accumulated goodwill impairment loss were million at both december and the addition to goodwill in the pharmaceutical segment in were primarily related to the acquisition of acceleron the addition to goodwill in the pharmaceutical segment in were primarily related to the acquisition of arqule and themis see note for more information on these acquisition of contentsother acquired intangible at december consisted of grosscarryingamountaccumulatedamortizationnetgrosscarryingamountaccumulatedamortizationnetproducts and product right ipr trade license and acquired intangible include product and product right ipr trade name and patent license and other which are initially recorded at fair value assigned an estimated useful life and amortized primarily on straight line basis over their estimated useful life some of the more significant acquired intangible on net basis related to human health marketed product included in product and product right above at december include reblozyl billion zerbaxa million gardasil gardasil million bridion million dificid million sivextro million and simponi million additionally the company had billion of net acquired intangible related to animal health marketed product at december of which billion relate primarily to trade name obtained through the acquisition of antelliq see note at december ipr primarily relates to mk sotatercept billion obtained through the acquisition of acceleron in see note mk nemtabrutinib billion obtained through the acquisition of arqule in see below and note and mk gefapixant million obtained through the acquisition of afferent pharmaceutical in some of the more significant net intangible asset included in license and other above at december include lynparza billion related to collaboration with astrazeneca lenvima billion related to collaboration with eisai adempas million related to collaboration with bayer and verquvo million also related to collaboration with bayer see note for additional information related to the intangible asset associated with these collaboration in the company recorded an impairment charge of billion within cost of sale related to zerbaxa ceftolozane and tazobactam for injection combination antibacterial and beta lactamase inhibitor for the treatment of certain bacterial infection in december the company temporarily suspended sale of zerbaxa and subsequently issued product recall following the identification of product sterility issue the recall constituted triggering event requiring the evaluation of the zerbaxa intangible asset for impairment the company revised it cash flow forecast for zerbaxa utilizing certain assumption around the return to market timeline and anticipated uptake in sale thereafter these revised cash flow forecast indicated that the zerbaxa intangible asset value wa not fully recoverable on an undiscounted cash flow basis the company utilized market participant assumption to determine it best estimate of the fair value of the intangible asset related to zerbaxa that when compared with it related carrying value resulted in the impairment charge noted above the company also wrote off inventory of million to cost of sale in related to the zerbaxa recall phased resupply of zerbaxa wa initiated in the fourth quarter of in the company recorded impairment charge related to marketed product and other intangible of million of this amount million related to sivextro tedizolid phosphate product for the treatment of acute bacterial skin and skin structure infection caused by designated susceptible gram positive organism part of reorganization and reprioritization of it internal sale force the company made the decision to cease promotion of sivextro in the market by the end of this decision resulted in reduced cash flow projection for sivextro which indicated that the sivextro intangible asset value wa not fully recoverable on an undiscounted cash flow basis the company utilized market participant assumption to determine it best estimate of the fair value of the intangible asset related to sivextro that when compared with it related carrying value resulted in the impairment charge noted above ipr that the company acquires through business combination represents the fair value assigned to incomplete research project which at the time of acquisition have not reached technological feasibility amount capitalized ipr are accounted for indefinite lived intangible asset subject to impairment testing until of contentscompletion or abandonment of the project upon successful completion of each ipr project the company will make separate determination to the then useful life of the asset and begin amortization in the company recorded million ipr impairment charge within research and development expense related to nemtabrutinib mk novel oral btk inhibitor currently being evaluated for the treatment of cell malignancy obtained in connection with the acquisition of arqule see note part of merck annual impairment assessment of ipr intangible asset the company estimated the current fair value of nemtabrutinib utilizing projected future cash flow the market participant assumption used to derive the forecasted cash flow were updated to reflect the current competitive landscape for nemtabrutinib including increased expected development cost for additional clinical trial data needed to develop nemtabrutinib well delay in the anticipated launch date for nemtabrutinib which collectively reduced the projected future cash flow and estimated fair value additionally the discount rate utilized to determine the current fair value of the asset wa reduced to to reflect the current risk profile of the asset the revised estimated fair value of nemtabrutinib when compared with it related carrying value resulted in the ipr impairment charge noted above the remaining ipr intangible asset related to nemtabrutinib is billion if the assumption used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib doe not progress anticipated thereby adversely affecting projected future cash flow the company may record an additional impairment charge in the future and such charge could be material in the company recorded million ipr impairment charge related to decision to discontinue the development program for covid vaccine candidate following merck review of finding from phase clinical study for the vaccine in the study wa generally well tolerated but the immune response were inferior to those seen following natural infection and those reported for other sars cov covid vaccine the discontinuation of this development program also resulted in reversal of the related liability for contingent consideration of million in the company recorded million of ipr impairment charge of this amount million relates to the write off of the intangible asset balance for program obtained in connection with the acquisition of iomet pharma ltd following review of clinical trial result conducted by merck along with external clinical trial result for similar compound the discontinuation of this clinical development program also resulted in reversal of the related liability for contingent consideration of million the ipr project that remain in development are subject to the inherent risk and uncertainty in drug development and it is possible that the company will not be able to successfully develop and complete the ipr program and profitably commercialize the underlying product candidate the company may recognize additional non cash impairment charge in the future related to other marketed product or pipeline program and such charge could be material aggregate amortization expense primarily recorded within cost of sale wa billion in billion in and billion in the estimated aggregate amortization expense for each of the next five year is follows billion billion billion billion billion loan payable long term debt and leasesloans payableloans payable at december included billion of note due in and million of long dated note that are subject to repayment at the option of the holder loan payable at december included billion of note due in billion of commercial paper borrowing and million of long dated note that are subject to repayment at the option of the holder the weighted average interest rate of commercial paper borrowing wa and for the year ended december and respectively of contentslong term debtlong term debt at december consisted of note due note due note due note due note due note due note due note due note due note due note due note due euro denominated note due note due note due note due note due note due note due euro denominated note due euro denominated note due euro denominated note due note due note due note due debenture due note due debenture due debenture due note due note due other presented in the table above includes borrowing at variable rate that resulted in effective interest rate of zero and for and respectively with the exception of the debenture due the note listed in the table above are redeemable in whole or in part at merck option at any time at varying redemption price in december the company issued billion principal amount of senior unsecured note consisting of billion of note due billion of note due billion of note due billion of note due and billion of note due merck used the net proceeds from the offering of the note the note the note and the note for general corporate purpose including the repayment of outstanding commercial paper borrowing including commercial paper borrowing in connection with merck acquisition of acceleron and other indebtedness merck allocated an amount equal to the net proceeds of the offering of the note due in to finance or refinance in whole or in part project and partnership in the company priority environmental social and governance esg area of contentseffective of november the company executed full and unconditional guarantee of the then existing debt of it subsidiary merck sharp dohme corp msd and msd executed full and unconditional guarantee of the then existing debt of the company excluding commercial paper including for payment of principal and interest these guarantee do not extend to debt issued subsequent to that date certain of the company borrowing require that merck comply with covenant and at december the company wa in compliance with these covenant the aggregate maturity of long term debt for each of the next five year are follows billion billion billion billion billion interest payment related to these debt obligation are follows million million million million million the company ha billion credit facility that matures in june the facility provides backup liquidity for the company commercial paper borrowing facility and is to be used for general corporate purpose the company ha not drawn funding from this facility leasesthe company ha operating lease primarily for manufacturing facility research and development facility corporate office employee housing vehicle and certain equipment the company determines if an arrangement is lease at inception when evaluating contract for embedded lease the company exercise judgment to determine if there is an explicit or implicit identified asset in the contract and if merck control the use of that asset embedded lease primarily associated with contract manufacturing organization are immaterial the lease term includes option to extend or terminate the lease when it is reasonably certain that merck will exercise that option real estate lease for facility have an average remaining lease term of seven year which include option to extend the lease for up to four year where applicable vehicle lease are generally in effect for four year the company doe not record short term lease lease with an initial term of month or le on the balance sheet however merck currently ha no short term lease lease expense for operating lease payment is recognized on straight line basis over the term of the lease operating lease asset and liability are recognized based on the present value of lease payment over the lease term since the company lease do not have readily determinable implicit discount rate the company us it incremental borrowing rate to calculate the present value of lease payment by asset class on quarterly basis an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the company pretax cost of debt for that same term the updated rate for each asset class are applied prospectively to new lease the company doe not separate lease component payment for rent real estate tax and insurance cost from non lease component common area maintenance cost in the event that the agreement contains both merck includes both the lease and non lease component for purpose of calculating the right of use asset and related lease liability if the non lease component are fixed for vehicle lease and employee housing the company applies portfolio approach to account for the operating lease asset and liability certain of the company lease agreement contain variable lease payment that are adjusted periodically for inflation or for actual operating expense true ups compared with estimated amount however these amount are immaterial sublease income and activity related to sale and leaseback transaction are immaterial merck lease agreement do not contain any material residual value guarantee or material restrictive covenant operating lease cost wa million in million in and million in cash paid for amount included in the measurement of operating lease liability wa million in million in and million in operating lease asset obtained in exchange for lease obligation were million in million in and million in of contentssupplemental balance sheet information related to operating lease is follows december asset liabilitiesaccrued and other current other noncurrent weighted average remaining lease term year average discount includes prepaid lease that have no related lease liability maturity of operating lease liability are follows total lease le imputed at december the company had entered into additional real estate operating lease that had not yet commenced the obligation associated with these lease total million contingency and environmental liability the company is involved in various claim and legal proceeding of nature considered normal to it business including product liability intellectual property and commercial litigation well certain additional matter including governmental and environmental matter in the opinion of the company it is unlikely that the resolution of these matter will be material to the company financial condition result of operation or cash flow given the nature of the litigation discussed below and the complexity involved in these matter the company is unable to reasonably estimate possible loss or range of possible loss for such matter until the company know among other factor what claim if any will survive dispositive motion practice ii the extent of the claim including the size of any potential class particularly when damage are not specified or are indeterminate iii how the discovery process will affect the litigation iv the settlement posture of the other party to the litigation and any other factor that may have material effect on the litigation the company record accrual for contingency when it is probable that liability ha been incurred and the amount can be reasonably estimated these accrual are adjusted periodically assessment change or additional information becomes available for product liability claim portion of the overall accrual is actuarially determined and considers such factor past experience number of claim reported and estimate of claim incurred but not yet reported individually significant contingent loss are accrued when probable and reasonably estimable legal defense cost expected to be incurred in connection with loss contingency are accrued when probable and reasonably estimable the company decision to obtain insurance coverage is dependent on market condition including cost and availability existing at the time such decision are made the company ha evaluated it risk and ha determined that the cost of obtaining product liability insurance outweighs the likely benefit of the coverage that is available and such ha no insurance for most product liability of contentsproduct liability litigationfosamaxas previously disclosed merck is defendant in product liability lawsuit in the involving fosamax fosamax litigation of december approximately case are pending against merck in either federal multidistrict litigation femur fracture mdl or state court plaintiff in the vast majority of these case generally allege that they sustained femur fracture and or other bone injury femur fracture in association with the use of fosamax in march the femur fracture mdl court dismissed with prejudice approximately case on preemption ground plaintiff in approximately of those case appealed that decision to the court of appeal for the third circuit third circuit in march the third circuit issued decision reversing the femur fracture mdl court preemption ruling and remanding the appealed case back to the femur fracture mdl court in may the supreme court decided that the third circuit had incorrectly concluded that the issue of preemption should be resolved by jury and accordingly vacated the judgment of the third circuit and remanded the proceeding back to the third circuit to address the issue in manner consistent with the supreme court opinion in november the third circuit remanded the case back to the district court in order to allow that court to determine in the first instance whether the plaintiff state law claim are preempted by federal law under the standard described by the supreme court in it opinion briefing on the issue is closed and the party await the decision of the district court discovery is presently stayed in the femur fracture mdl part of the spin off of organon organon is required to indemnify merck for all liability relating to arising from or resulting from the fosamax litigation januvia janumetas previously disclosed merck is defendant in product liability lawsuit in the involving januvia and or janumet of december merck is aware of approximately product user alleging that januvia and or janumet caused the development of pancreatic cancer and other injury most claim have been filed in multidistrict litigation before the district court for the southern district of california mdl on march the mdl court issued an omnibus order granting defendant summary judgment motion based on preemption and failure to establish general causation well granting defendant motion to exclude plaintiff expert witness the plaintiff appealed that order since that time more than half of these claim have been dismissed with prejudice to merck and on october the court of appeal for the ninth circuit dismissed the appeal to merck and two of it codefendant outside of the mdl the majority of claim have been filed in coordinated proceeding before the superior court of california county of los angeles california state court on april the court in california issued an omnibus order granting defendant summary judgment motion and also granting defendant motion to exclude plaintiff expert witness of december six product user have claim pending against merck in state court other than california including illinois in june the illinois trial court denied merck motion for summary judgment based on federal preemption merck appealed and the illinois appellate court affirmed in december merck filed petition for leave to appeal to the illinois supreme court in february in april the illinois supreme court stayed consideration of the pending petition to appeal until the supreme court issued it opinion in merck sharp dohme corp albrecht relating to the fosamax matter discussed above merck filed the opinion in albrecht with the illinois supreme court in june the petition for leave to appeal wa decided in september in which the illinois supreme court directed the intermediate appellate court to reconsider it earlier ruling the illinois appellate court issued favorable decision concluding consistent with albrecht that preemption present legal question to be resolved by the court in may the illinois appellate court issued mandate to the state trial court which of december had not scheduled case management conference or otherwise taken action in addition to the claim noted above the company ha agreed to toll the statute of limitation for approximately additional claim the company intends to continue defending against any remaining lawsuit of contentsgovernmental proceedingsas previously disclosed in the fall of the company received record subpoena from the attorney office for the district of vermont vt usao pursuant to section of the health insurance portability and accountability act of hipaa relating to an investigation of potential health care offense the subpoena sought information relating to any actual or potential business relationship or arrangement merck ha had with practice fusion inc pfi cloud based electronic health record ehr company that wa acquired by allscripts in january the company cooperated with the government and responded to that subpoena subsequently in may merck received second record subpoena from the vt usao that broadened the government information request by seeking information relating to merck relationship with any ehr company shortly thereafter the vt usao served civil investigation demand cid upon merck similarly seeking information on the company relationship with ehr vendor the cid explains that the government is conducting false claim act investigation concerning whether merck and or pfi submitted claim to federal health care program that violate the federal anti kickback statute merck is cooperating with the government investigation previously disclosed in april merck received set of investigative interrogatory from the california attorney general office pursuant to it investigation of conduct and agreement that allegedly affected or delayed competition to lantus in the insulin market the interrogatory seek information concerning merck development of an insulin glargine product and it subsequent termination well merck patent litigation against sanofi concerning lantus and the resolution of that litigation merck is cooperating with the california attorney general investigation previously disclosed in june merck received cid from the department of justice the cid request answer to interrogatory well various document regarding temperature excursion at third party storage facility containing certain merck product merck is cooperating with the government investigation and intends to produce information and or document necessary in response to the cid previously disclosed the company subsidiary in china have received and may continue to receive inquiry regarding their operation from various chinese governmental agency some of these inquiry may be related to matter involving other multinational pharmaceutical company well chinese entity doing business with such company the company policy is to cooperate with these authority and to provide response appropriate previously disclosed from time to time the company receives inquiry and is the subject of preliminary investigation activity from competition and other governmental authority in market outside the these authority may include regulator administrative authority and law enforcement and other similar official and these preliminary investigation activity may include site visit formal or informal request or demand for document or material inquiry or interview and similar matter certain of these preliminary inquiry or activity may lead to the commencement of formal proceeding should those proceeding be determined adversely to the company monetary fine and or remedial undertaking may be required commercial and other litigationzetia antitrust litigationas previously disclosed merck msd schering corporation schering plough corporation and msp singapore company llc collectively the merck defendant are defendant in putative class action and opt out lawsuit filed in on behalf of direct and indirect purchaser of zetia alleging violation of federal and state antitrust law well other state statutory and common law cause of action the case have been consolidated for pretrial purpose in federal multidistrict litigation before judge rebecca beach smith in the eastern district of virginia in december the court denied the merck defendant motion to dismiss or stay the direct purchaser putative class action pending bilateral arbitration in august the district court adopted in full the report and recommendation of the magistrate judge with respect to the merck defendant motion to dismiss on non arbitration issue thereby granting in part and denying in part merck defendant motion to dismiss in addition in june the representative of the putative direct purchaser class filed an amended complaint and in august retailer opt out plaintiff filed an amended complaint in december the district court granted the merck defendant motion to dismiss to the extent the motion sought dismissal of claim for overcharge paid by entity of contentsthat purchased generic ezetimibe from par pharmaceutical inc par pharmaceutical and dismissed any claim for such overcharge in november the direct purchaser plaintiff and the indirect purchaser plaintiff filed motion for class certification in august the district court granted in part the direct purchaser motion for class certification and certified class of direct purchaser in august the fourth circuit vacated the district court class certification order and remanded for further proceeding consistent with the court ruling in september the direct purchaser plaintiff filed renewed motion for class certification on january the magistrate judge recommended that the district court deny the motion for class certification on february the direct purchaser plaintiff filed objection to the recommendation briefing on these objection is ongoing in august the merck defendant filed motion for summary judgment and other motion and plaintiff filed motion for partial summary judgment and other motion those motion are now fully briefed and the court ha heard argument on certain of the motion the court may hold additional hearing on the other motion trial in this matter ha been adjourned also in august the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class in august the district court granted certification of class of indirect purchaser in september the merck defendant petitioned to appeal the class certification decision to the fourth circuit the fourth circuit denied that petition on september in september united healthcare service inc filed lawsuit in the district court for the district of minnesota against the merck defendant and others the uhc action the uhc action make similar allegation those made in the zetia class action well allegation about vytorin in september the judicial panel on multidistrict litigation transferred the case to the eastern district of virginia to proceed with the multidistrict zetia litigation already in progress in december humana inc filed lawsuit in the superior court of the state of california county of san francisco against merck and others alleging defendant violated state antitrust law in multiple state also in december centene corporation and others filed lawsuit in the superior court of the state of california county of san francisco against the same defendant humana both lawsuit allege similar anticompetitive act to those alleged in the zetia class action in july the california court ruled on defendant motion to quash for lack of personal jurisdiction granting the motion to the out of state claim against defendant and ordering limited jurisdictional discovery with regard to the california claim also on july humana and centene filed action against the merck defendant in new jersey in the bergen county superior court re asserting the claim that were dismissed in their california action in september the party reached an agreement that humana and centene would file their claim in new jersey federal court seek transfer of those claim to the multidistrict zetia litigation already in progress and subsequently dismiss the action previously filed in california and new jersey state court in june kaiser foundation health plan inc similarly filed lawsuit in the superior court of the state of california county of san francisco against the same defendant humana and centene the kaiser lawsuit alleges similar anticompetitive act to those alleged in the zetia class action the kaiser action wa removed to the district court for the northern district of california on july in september the judicial panel on multidistrict litigation transferred the case to the eastern district of virginia to proceed with the multidistrict zetia litigation already in progress of december all of the insurer plaintiff kaiser humana and centene are part of the multidistrict zetia litigation and are proceeding with discovery in that action on february united healthcare kaiser and humana each filed an amended complaint rotavirus vaccine antitrust litigationas previously disclosed msd is defendant in putative class action lawsuit filed in on behalf of direct purchaser of rotateq alleging violation of federal antitrust law the case were consolidated in the eastern district of pennsylvania in january the court denied msd motion to compel arbitration and to dismiss the consolidated complaint in february msd appealed the court order on arbitration to the third circuit in october the third circuit vacated the district court order and remanded for limited discovery on the issue of of contentsarbitrability on july msd filed renewed motion to compel arbitration and plaintiff filed cross motion for summary judgment to arbitrability on november the district court denied msd motion and granted plaintiff motion on december msd filed notice of appeal to the third circuit msd appeal is fully briefed and the third circuit heard argument on september bravecto litigationas previously disclosed in january the company wa served with complaint in the district court for the district of new jersey following motion practice the plaintiff filed second amended complaint on july seeking to certify nationwide class action of purchaser or user of bravecto fluralaner product in the or it territory between may and july plaintiff contend bravecto cause neurological event in dog and cat and alleges violation of the new jersey consumer fraud act breach of warranty product liability and related theory the company moved to dismiss or alternatively to strike the class allegation from the second amended complaint and that motion is pending similar case wa filed in quebec canada in may the superior court certified class of dog owner in quebec who gave bravecto chew to their dog between february and november whose dog experienced one of the condition in the post marketing adverse reaction section of the labeling approved on november the company and plaintiff each appealed the class certification decision the court of appeal of quebec heard the appeal on february and took the matter under advisement qui tam litigationas previously disclosed in june the district court for the eastern district of pennsylvania unsealed complaint that had been filed against the company under the federal false claim act by two former employee alleging among other thing that the company defrauded the government by falsifying data in connection with clinical study conducted on the mumps component of the company ii vaccine the complaint alleges the fraud took place between and the government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right the two former employee are pursuing the lawsuit without the involvement of the government in addition previously disclosed two putative class action lawsuit on behalf of direct purchaser of the ii vaccine which charge that the company misrepresented the efficacy of the ii vaccine in violation of federal antitrust law and various state consumer protection law are pending in the eastern district of pennsylvania in september the court denied merck motion to dismiss the false claim act suit and granted in part and denied in part it motion to dismiss the then pending antitrust suit result both the false claim act suit and the antitrust suit have proceeded into discovery which is now complete and the party have filed and briefed cross motion for summary judgment which are currently pending before the court merck kgaa litigationas previously disclosed in january to protect it long established brand right in the the company filed lawsuit against merck kgaa darmstadt germany kgaa historically operating the emd group in the alleging it improperly us the name merck in the kgaa ha filed suit against the company in france the uk germany switzerland mexico india australia singapore hong kong sar prc and china alleging among other thing unfair competition trademark infringement and or corporate name infringement in the uk australia singapore hong kong sar prc and india kgaa also alleges breach of the party coexistence agreement the litigation is ongoing in the with no trial date set and also ongoing in numerous jurisdiction outside of the patent litigationfrom time to time generic manufacturer of pharmaceutical product file abbreviated new drug application ndas with the fda seeking to market generic form of the company product prior to the expiration of relevant patent owned by the company to protect it patent right the company may file patent infringement lawsuit against such generic company similar lawsuit defending the company patent right may exist in other country the company intends to vigorously defend it patent which it belief are valid against infringement by company attempting to market product prior to the expiration of such patent with any litigation there can be no assurance of the outcome which if adverse could result in significantly shortened of contentsperiods of exclusivity for these product and with respect to product acquired through acquisition potentially significant intangible asset impairment charge bridion previously disclosed between january and november the company received multiple paragraph iv certification letter under the hatch waxman act notifying the company that generic drug company have filed application to the fda seeking pre patent expiry approval to sell generic version of bridion sugammadex injection in march april and december the company filed patent infringement lawsuit in the district court for the district of new jersey and the northern district of west virginia against those generic company all action in the district of new jersey have been consolidated these lawsuit which assert one or more patent covering sugammadex and method of using sugammadex automatically stay fda approval of the generic application until june or until adverse court decision if any whichever may occur earlier mylan pharmaceutical inc mylan api llc and mylan inc mylan have filed motion to dismiss in the district of new jersey for lack of venue and failure to state claim against certain defendant and in the northern district of west virginia for failure to state claim against certain defendant the new jersey motion ha not yet been decided and the west virginia action is stayed pending resolution of the new jersey motion the company ha settled with four generic company providing that these generic company can bring their generic version of bridion to the market in january which may be delayed by any applicable pediatric exclusivity or earlier under certain circumstance the company ha agreed to stay the lawsuit filed against one generic company which in exchange agreed to be bound by judgment on the merit of the consolidated action in the district of new jersey one of the generic company in the consolidated action requested dismissal of the action against it and the company did not oppose this request which wa subsequently granted by the court the company doe not expect this company to bring it generic version of bridion to the market before january or later depending on any applicable pediatric exclusivity unless the company receives an adverse court decision januvia janumet janumet xr previously disclosed the fda ha granted pediatric exclusivity with respect to januvia janumet and janumet xr which provides further six month of exclusivity in the beyond the expiration of all patent listed in the fda orange book adding this exclusivity to the term of the key patent protection extends exclusivity on these product to january the company currently anticipates that sale of januvia and janumet in the will decline significantly after this date however januvia janumet and janumet xr contain sitagliptin phosphate monohydrate and the company ha another patent covering certain phosphate salt and polymorphic form of sitagliptin salt polymorph patent which if determined to be valid would preclude generic manufacturer from making sitagliptin phosphate salt and polymorphic form until with the expiration of that patent plus pediatric exclusivity in par pharmaceutical filed suit against the company in the district court for the district of new jersey seeking declaratory judgment of invalidity of the salt polymorph patent in response the company filed patent infringement lawsuit in the district court for the district of delaware against par pharmaceutical and additional company that also indicated an intent to market generic version of januvia janumet and janumet xr following expiration of key patent protection but prior to the expiration of the salt polymorph patent and later granted patent owned by the company covering the janumet formulation where it term plus the pediatric exclusivity end in the company also filed patent infringement lawsuit against mylan in the northern district of west virginia the judicial panel on multidistrict litigation entered an order transferring the company lawsuit against mylan to the district court for the district of delaware for coordinated and consolidated pretrial proceeding with the other case pending in that district prior to the beginning of the scheduled october trial in the district court for the district of delaware on invalidity issue the company settled with all defendant scheduled to participate in that trial in the company case against mylan bench trial wa held in december in the district court for the northern district of west virginia with closing argument scheduled for april in total the company ha settled with generic company providing that these generic company can bring their generic version of januvia and janumet to the market in may or earlier under certain circumstance and their generic version of janumet xr to the market in july or earlier under certain circumstance of contentsadditionally in mylan filed petition for inter partes review ipr at the patent and trademark office uspto seeking invalidity of some but not all of the claim of the salt polymorph patent the uspto instituted ipr proceeding in may finding reasonable likelihood that the challenged claim are not valid trial wa held in february and final decision wa rendered in may holding that all of the challenged claim were not invalid mylan ha appealed the uspto decision to the court of appeal for the federal circuit in march the company filed patent infringement lawsuit in the district court for the district of delaware against zydus worldwide dmcc zydus pharmaceutical usa inc and cadila healthcare ltd collectively zydus in that lawsuit the company alleged infringement of the salt polymorph patent based on the filing of zydus application seeking approval of it sitagliptin tablet the district court for the district of delaware ha set three day bench trial in this matter beginning on october in germany generic company have sought the revocation of the supplementary protection certificate spc for janumet if the generic company are successful janumet could lose market exclusivity in germany at the same time the expiry of januvia pediatric market exclusivity in september hearing wa held in june and the court decided that the spc for janumet is invalid which decision the company ha appealed challenge to the janumet spc have also occurred in the following european country austria czech republic finland france hungary italy portugal romania slovakia and sweden other litigationthere are various other pending legal proceeding involving the company principally product liability and intellectual property lawsuit while it is not feasible to predict the outcome of such proceeding in the opinion of the company either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceeding is not expected to be material to the company financial condition result of operation or cash flow either individually or in the aggregate legal defense reserveslegal defense cost expected to be incurred in connection with loss contingency are accrued when probable and reasonably estimable some of the significant factor considered in the review of these legal defense reserve are follows the actual cost incurred by the company the development of the company legal defense strategy and structure in light of the scope of it litigation the number of case being brought against the company the cost and outcome of completed trial and the most current information regarding anticipated timing progression and related cost of pre trial activity and trial in the associated litigation the amount of legal defense reserve of december and of approximately million and million respectively represents the company best estimate of the minimum amount of defense cost to be incurred in connection with it outstanding litigation however event such additional trial and other event that could arise in the course of it litigation could affect the ultimate amount of legal defense cost to be incurred by the company the company will continue to monitor it legal defense cost and review the adequacy of the associated reserve and may determine to increase the reserve at any time in the future if based upon the factor set forth it belief it would be appropriate to do so environmental matter the company and it subsidiary are party to number of proceeding brought under the comprehensive environmental response compensation and liability act commonly known superfund and other federal and state equivalent these proceeding seek to require the operator of hazardous waste disposal facility transporter of waste to the site and generator of hazardous waste disposed of at the site to clean up the site or to reimburse the government for cleanup cost the company ha been made party to these proceeding an alleged generator of waste disposed of at the site in each case the government alleges that the defendant are jointly and severally liable for the cleanup cost although joint and several liability is alleged these proceeding are frequently resolved so that the allocation of cleanup cost among the party more nearly reflects the relative contribution of the party to the site situation the company potential liability varies greatly from site to site for some site the potential liability is de minimis and for others the final cost of cleanup have not yet been determined while it is not feasible to predict the outcome of many of these proceeding brought by federal or state agency or private litigant in the opinion of the company such proceeding should not ultimately result in any liability which of contentswould have material adverse effect on the financial condition result of operation or liquidity of the company the company ha taken an active role in identifying and accruing for these cost and such amount do not include any reduction for anticipated recovery of cleanup cost from former site owner or operator or other recalcitrant potentially responsible party in management opinion the liability for all environmental matter that are probable and reasonably estimable have been accrued and totaled million and million at december and respectively these liability are undiscounted do not consider potential recovery from other party and will be paid out over the period of remediation for the applicable site which are expected to occur primarily over the next year although it is not possible to predict with certainty the outcome of these matter or the ultimate cost of remediation management doe not believe that any reasonably possible expenditure that may be incurred in excess of the liability accrued should exceed approximately million in the aggregate management also doe not believe that these expenditure should result in material adverse effect on the company financial condition result of operation or liquidity for any year equitythe merck certificate of incorporation authorizes share of common stock and share of preferred stock capital stocka summary of common stock and treasury stock transaction share in million is follows commonstocktreasurystockcommonstocktreasurystockcommonstocktreasurystockbalance january purchase of treasury stock issuance balance december issuance primarily reflect activity under share based compensation plan share based compensation plansthe company ha share based compensation plan under which the company grant restricted stock unit rsus and performance share unit psus to certain management level employee in addition employee and non employee director may be granted option to purchase share of company common stock at the fair market value at the time of grant these plan were approved by the company shareholder at december million share collectively were authorized for future grant under the company share based compensation plan these award are settled with treasury share employee stock option are granted to purchase share of company stock at the fair market value at the time of grant these award generally vest one third each year over three year period with contractual term of year rsus are stock award that are granted to employee and entitle the holder to share of common stock the award vest the fair value of the stock option and rsu award is determined and fixed on the grant date based on the company stock price psus are stock award where the ultimate number of share issued will be contingent on the company performance against pre set objective or set of objective the fair value of each psu is determined on the date of grant based on the company stock price for rsus and psus dividend declared during the vesting period are payable to the employee only upon vesting over the psu performance period the number of share of stock that are expected to be issued will be adjusted based on the probability of achievement of performance target and final compensation expense will be recognized based on the ultimate number of share issued rsu and psu distribution will be in share of company stock after the end of the vesting or performance period subject to the term applicable to such award psu award generally vest after three year rsu award generally vest one third each year over three year period of contentstotal pretax share based compensation cost recorded in and wa million million and million respectively including million million and million respectively related to continuing operation income tax benefit for share based compensation expense recognized in and were million million and million respectively the company us the black scholes option pricing model for determining the fair value of option grant in applying this model the company us both historical data and current market data to estimate the fair value of it option the black scholes model requires several assumption including expected dividend yield risk free interest rate volatility and term of the option the expected dividend yield is based on historical pattern of dividend payment the risk free interest rate is based on the rate at grant date of zero coupon treasury note with term equal to the expected term of the option expected volatility is estimated using blend of historical and implied volatility the historical component is based on historical monthly price change the implied volatility is obtained from market data on the company traded option the expected life represents the amount of time that option granted are expected to be outstanding based on historical and forecasted exercise behavior the weighted average exercise price of option granted in and wa and per option respectively the weighted average fair value of option granted in and wa and per option respectively and were determined using the following assumption year ended december dividend risk free interest expected expected life year information relative to stock option plan activity option in thousand is follows numberof optionsweightedaverageexercisepriceweightedaverageremainingcontractualterm year aggregateintrinsicvalueoutstanding january granted exercised forfeited award transferred to organon in the spin off adjustment to merck award related to the spin off of organon outstanding december vested and expected to vest december exercisable december activity prior to the organon spin off ha not been restated in connection with the spin off of organon all outstanding merck stock option whether vested or unvested were converted into adjusted merck award for current and former merck employee or organon award for organon employee such adjusted award preserved the same intrinsic value and general term and condition including vesting were in place immediately prior to the adjustment additional information pertaining to stock option plan is provided in the table below year ended december intrinsic value of stock option exercised fair value of stock option cash received from the exercise of stock of contentsa summary of nonvested rsu and psu activity share in thousand is follows rsuspsus numberof sharesweightedaveragegrant datefair valuenumberof sharesweightedaveragegrant datefair valuenonvested january granted vested forfeited award transferred to organon in the spin off adjustment to merck award related to the spin off of organon nonvested december expected to vest december activity prior to the organon spin off ha not been restated in connection with the spin off of organon all outstanding merck rsus and psus whether vested or unvested were converted into adjusted merck award for current and former merck employee or organon award for organon employee such adjusted award preserved the same intrinsic value and general term and condition including vesting were in place immediately prior to the adjustment at december there wa million of total pretax unrecognized compensation expense related to nonvested stock option rsu and psu award which will be recognized over weighted average period of year for segment reporting share based compensation cost are unallocated expense pension and other postretirement benefit plansthe company ha defined benefit pension plan covering eligible employee in the and in certain of it international subsidiary in addition the company provides medical benefit principally to it eligible retiree and their dependent through it other postretirement benefit plan the company us december the year end measurement date for all of it pension plan and other postretirement benefit plan net periodic benefit costthe net periodic benefit cost credit for pension and other postretirement benefit plan including certain cost reported part of discontinued operation consisted of the following component pension benefitsu internationalother postretirement benefitsyears ended december cost interest expected return on plan asset amortization of unrecognized prior service cost net loss gain termination net periodic benefit cost credit net periodic benefit cost credit for pension and other postretirement benefit plan in includes expense for curtailment settlement and termination benefit provided to certain employee in connection with the spin off of organon in connection with restructuring action see note termination charge were recorded in and on pension and other postretirement benefit plan related to expanded eligibility for certain employee exiting merck also in connection with these restructuring activity curtailment and settlement were recorded on of contentscertain pension plan an increase in lump sum payment to pension plan participant also contributed to the settlement recorded during the component of net periodic benefit cost credit other than the service cost component are included in other income expense net see note with the exception of certain amount for termination benefit curtailment and settlement which are recorded in restructuring cost if the event giving rise to the termination benefit curtailment or settlement is related to restructuring action or in income from discontinued operation net of tax and amount attributable to noncontrolling interest if related to the spin off of organon each noted above obligation and funded statussummarized information about the change in plan asset and benefit obligation the funded status and the amount recorded at december is follows pension benefitsotherpostretirementbenefitsu international value of plan asset january actual return on plan company effect of exchange rate change benefit paid settlement spin off of organon other fair value of plan asset december benefit obligation january service interest actuarial gain loss benefit paid effect of exchange rate change plan amendment termination settlement spin off of organon other benefit obligation december funded status december recognized other asset accrued and other current liability other noncurrent liability actuarial gain loss primarily reflect change in discount rate at december and the accumulated benefit obligation wa billion and billion respectively for all pension plan of which billion and billion respectively related to pension plan of contentsinformation related to the funded status of selected pension plan at december is follows plan with projected benefit obligation in excess of plan assetsprojected benefit obligation fair value of plan pension plan with an accumulated benefit obligation in excess of plan assetsaccumulated benefit obligation fair value of plan plan assetsentities are required to use fair value hierarchy which maximizes the use of observable input and minimizes the use of unobservable input when measuring fair value there are three level of input used to measure fair value with level having the highest priority and level having the lowest level quoted price unadjusted in active market for identical asset or liability level observable input other than level price such quoted price for similar asset or liability or other input that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability level unobservable input that are supported by little or no market activity the level asset are those whose value are determined using pricing model discounted cash flow methodology or similar technique with significant unobservable input well instrument for which the determination of fair value requires significant judgment or estimation at december and million and million respectively or approximately of the company pension investment were categorized level asset if the input used to measure the financial asset fall within more than one level described above the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument of contentsthe fair value of the company pension plan asset at december by asset category are follows fair value measurement usingfair value measurement using level totallevel pension planscash and cash equivalent investment fundsdeveloped market emerging market equity mortgage and asset backed security equity securitiesdeveloped fixed income securitiesgovernment and agency obligation corporate obligation mortgage and asset backed security other plan asset at fair value international pension planscash and cash equivalent investment fundsdeveloped market government and agency emerging market corporate other fixed income real estate equity securitiesdeveloped fixed income securitiesgovernment and agency corporate obligation mortgage and asset backed security other investmentsinsurance contract plan asset at fair value certain investment that were measured at net asset value nav per share or it equivalent have not been classified in the fair value hierarchy the nav amount presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan asset at december and the plan level investment in insurance contract are generally valued using crediting rate that approximates market return and invest in underlying security whose market value are unobservable and determined using pricing model discounted cash flow methodology or similar technique of contentsthe table below provides summary of the change in fair value including transfer in and or out of all financial asset measured at fair value using significant unobservable input level for the company pension plan asset insurancecontractsrealestateothertotalinsurancecontractsrealestateothertotalu pension plansbalance january actual return on plan asset relating to asset still held at december relating to asset sold during the year purchase and sale net balance december international pension plansbalance january actual return on plan asset relating to asset still held at december purchase and sale net transfer in out of level balance december the fair value of the company other postretirement benefit plan asset at december by asset category are follows fair value measurement usingfair value measurement using level totallevel total cash and cash equivalent investment fundsdeveloped market emerging market equity government and agency mortgage and asset backed security equity security developed fixed income securitiesgovernment and agency obligation corporate obligation mortgage and asset backed security plan asset at fair value certain investment that were measured at net asset value nav per share or it equivalent have not been classified in the fair value hierarchy the nav amount presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan asset at december and the company ha established investment guideline for it pension and other postretirement plan to create an asset allocation that is expected to deliver rate of return sufficient to meet the long term obligation of each plan given an acceptable level of risk the target investment portfolio of the company pension and other postretirement benefit plan is allocated to in equity to in international equity to in fixed income investment and up to in cash and other investment the portfolio equity weighting is consistent with the long term nature of the plan benefit obligation the expected annual standard deviation of return of the target portfolio which approximates reflects both the equity allocation and the diversification benefit among the asset class in which the portfolio invests for international pension plan the of contentstargeted investment portfolio varies based on the duration of pension liability and local government rule and regulation although significant percentage of plan asset are invested in equity concentration risk is mitigated through the use of strategy that are diversified within management guideline expected contributionscontributions during are expected to be approximately million for pension plan approximately million for international pension plan and approximately million for other postretirement benefit plan expected benefit paymentsexpected benefit payment are follows pension benefitsinternational expected benefit payment are based on the same assumption used to measure the benefit obligation and include estimated future employee service amount recognized in other comprehensive incomenet loss amount reflect difference between expected and actual return on plan asset well the effect of change in actuarial assumption net loss amount in excess of certain threshold are amortized into net periodic benefit cost over the average remaining service life of employee the following amount were reflected component of oci pension plansother postretirementbenefit plansu internationalyears ended december gain loss arising during the period prior service cost credit arising during the period net loss gain amortization included in benefit cost prior service credit amortization included in benefit cost of contentsactuarial assumptionsthe company reassesses it benefit plan assumption on regular basis the weighted average assumption used in determining pension and other postretirement benefit plan and international pension plan information are follows pension and otherpostretirement benefit plansinternational pension plansdecember periodic benefit cost discount expected rate of return on plan salary growth interest crediting benefit obligation discount salary growth interest crediting for both the pension and other postretirement benefit plan the discount rate is evaluated on measurement date and modified to reflect the prevailing market rate of portfolio of high quality fixed income debt instrument that would provide the future cash flow needed to pay the benefit included in the benefit obligation they come due the expected rate of return for both the pension and other postretirement benefit plan represents the average rate of return to be earned on plan asset over the period the benefit included in the benefit obligation are to be paid and is determined on plan basis the expected rate of return for each plan is developed considering long term historical return data current market condition and actual return on the plan asset using this reference information the long term return expectation for each asset category and weighted average expected return for each plan target portfolio is developed according to the allocation among those investment category the expected portfolio performance reflects the contribution of active management appropriate for the expected rate of return for the company pension and other postretirement benefit plan will be compared to range of to in the health care cost trend rate assumption for other postretirement benefit plan are follows december care cost trend rate assumed for next rate to which the cost trend rate is assumed to year that the trend rate reach the ultimate trend plansthe company also maintains defined contribution saving plan in the the company match percentage of each employee contribution consistent with the provision of the plan for which the employee is eligible total employer contribution to these plan in and were million million and million respectively of other income expense netother income expense net consisted of year ended december income interest exchange income from investment in equity security net net periodic defined benefit plan credit cost other than service cost other net includes net realized and unrealized gain and loss from investment in equity security either owned directly or through ownership interest in investment fund unrealized gain and loss from investment that are directly owned are determined at the end of the reporting period while gain and loss from ownership interest in investment fund are accounted for on one quarter lag the company estimate loss of approximately million will be recorded in the first quarter of from ownership interest in investment fund other net presented in the table above in includes million of goodwill impairment charge related to certain business in the healthcare service segment which were fully divested by the first quarter of interest paid wa million in million in and million in tax on incomea reconciliation between the effective tax rate for income from continuing operation and the statutory rate is follows amounttax rateamounttax rateamounttax rateu statutory rate applied to income from continuing operation before tax differential arising from foreign earnings gilti and the foreign derived intangible income deduction tax settlement tax credit acquisition of velosbio acquisition of valuation acquisition related cost including state acquisition of oncoimmune acquisition of peloton tax cut and job act of other the tax cut and job act tcja wa enacted in december and the company reflected the impact of the tcja in it financial statement however since application of certain provision of the tcja of contentsremained subject to further interpretation in certain instance the company made reasonable estimate of the effect of the tcja which were since finalized and resulted in additional income tax expense in and the company remaining transition tax liability under the tcja which ha been reduced by payment and the utilization of foreign tax credit wa billion at december of which million is included in income tax payable and the remainder of billion is included in other noncurrent liability result of the transition tax under the tcja the company is no longer indefinitely reinvested with respect to it undistributed earnings from foreign subsidiary and ha provided deferred tax liability for foreign withholding tax that would apply the company remains indefinitely reinvested with respect to it financial statement basis in excess of tax basis of it foreign subsidiary determination of the deferred tax liability with respect to this basis difference is not practicable the foreign earnings tax rate differential in the tax rate reconciliation above primarily reflect the impact of operation in jurisdiction with different tax rate than the particularly ireland and switzerland well singapore and puerto rico which operate under tax incentive grant which begin to expire in thereby yielding favorable impact on the effective tax rate compared with the statutory rate of beginning in the company ha an additional tax incentive in the form of tax holiday in switzerland for newly active legal entity which is effective through income from continuing operation before tax consisted of year ended december tax on income from continuing operation consisted of year ended december provisionfederal state deferred foreign of contentsdeferred income tax at december consisted of assetsliabilitiesassetsliabilitiesproduct intangible and license inventory accelerated depreciation equity investment pension and other postretirement compensation unrecognized tax net operating loss and other tax credit valuation allowance total deferred tax net deferred income tax recognized other asset deferred income tax the company ha net operating loss nol carryforwards in several jurisdiction of december million of deferred tax asset on nol carryforwards relate to foreign jurisdiction valuation allowance of million have been established on these foreign nol carryforwards and other foreign deferred tax asset in addition the company ha million of deferred tax asset relating to various tax credit carryforwards and nol carryforwards valuation allowance of million have been established on these tax credit carryforwards and nol carryforwards income tax paid in and including amount attributable to discontinued operation were billion billion and billion respectively tax benefit relating to stock option exercise were million in million in and million in reconciliation of the beginning and ending amount of unrecognized tax benefit is follows january addition related to current year addition related to prior year reduction for tax position of prior year settlement lapse of statute of limitation spin off of organon balance december amount in and reflect settlement with the irs discussed below amount in includes million related to the divestiture of merck consumer care business in if the company were to recognize the unrecognized tax benefit of billion at december the income tax provision would reflect favorable net impact of billion the company is under examination by numerous tax authority in various jurisdiction globally the company belief that it is reasonably possible that the total amount of unrecognized tax benefit of december could decrease by up to approximately million in the next month result of various audit closure settlement or the expiration of the statute of limitation the ultimate finalization of the company of contentsexaminations with relevant taxing authority can include formal administrative and legal proceeding which could have significant impact on the timing of the reversal of unrecognized tax benefit the company belief that it reserve for uncertain tax position are adequate to cover existing risk or exposure interest and penalty associated with uncertain tax position amounted to benefit expense of million in million in and million in these amount reflect the beneficial impact of various tax settlement including the settlement discussed below liability for accrued interest and penalty were million and million of december and respectively in the internal revenue service irs concluded it examination of merck federal income tax return result the company wa required to make payment of million of which million related to continuing operation and million related to discontinued operation the company reserve for unrecognized tax benefit for the year under examination exceeded the adjustment relating to this examination period and therefore the company recorded million net tax benefit in of which million related to continuing operation and million related to discontinued operation this net benefit reflects reduction in reserve for unrecognized tax benefit and other related liability for tax position relating to the year that were under examination in the irs concluded it examination of merck federal income tax return result the company wa required to make payment of million of which million related to discontinued operation with an offsetting credit of million related to continuing operation the company reserve for unrecognized tax benefit for the year under examination exceeded the adjustment relating to this examination period and therefore the company recorded million net tax benefit in of which million related to continuing operation and million related to discontinued operation this net benefit reflects reduction in reserve for unrecognized tax benefit for tax position relating to the year that were under examination partially offset by additional reserve for tax position not previously reserved for the irs is currently conducting examination of the company tax return for the year and in addition various state and foreign tax examination are in progress and for these jurisdiction the company income tax return are open for examination for the period through earnings per sharethe calculation of earnings per share share in million are follows year ended december income from continuing operation attributable to merck co inc income from discontinued operation net of tax and amount attributable to noncontrolling net income attributable to merck co inc average common share common share issuable average common share outstanding assuming basic earnings per common share attributable to merck co inc common shareholder income from continuing operation income from discontinued net income earnings per common share assuming dilution attributable to merck co inc common shareholder income from continuing operation income from discontinued net income issuable primarily under share based compensation plan of contentsin and million million and million respectively of common share issuable under share based compensation plan were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive other comprehensive income loss change in each component of other comprehensive income loss are follows derivativesinvestmentsemployeebenefitplans foreign currencytranslationadjustmentaccumulated othercomprehensiveincome loss balance january net of tax other comprehensive income loss before reclassification adjustment tax other comprehensive income loss before reclassification adjustment net of reclassification adjustment pretax reclassification adjustment net of tax other comprehensive income loss net of tax balance at december net of other comprehensive income loss before reclassification adjustment pretax other comprehensive income loss before reclassification adjustment net of tax reclassification adjustment tax reclassification adjustment net of other comprehensive income loss net of tax balance at december net of tax other comprehensive income loss before reclassification adjustment tax other comprehensive income loss before reclassification adjustment net of reclassification adjustment tax reclassification adjustment net of other comprehensive income loss net of spin off of organon see note balance at december net of tax primarily relates to foreign currency cash flow hedge that were reclassified from aocl to sale represents net realized gain on the sale of available for sale debt security that were reclassified from aocl to other income expense net includes net amortization of prior service cost and actuarial gain and loss included in net periodic benefit cost see note includes pension plan net loss of billion and billion at december and respectively and other postretirement benefit plan net gain of million and million at december and respectively well pension plan prior service credit of million and million at december and respectively and other postretirement benefit plan prior service credit of million and million at december and respectively of segment reportingthe company operation are principally managed on product basis and include two operating segment which are the pharmaceutical and animal health segment both of which are reportable segment the pharmaceutical segment includes human health pharmaceutical and vaccine product human health pharmaceutical product consist of therapeutic and preventive agent generally sold by prescription for the treatment of human disorder the company sell these human health pharmaceutical product primarily to drug wholesaler and retailer hospital government agency and managed health care provider such health maintenance organization pharmacy benefit manager and other institution human health vaccine product consist of preventive pediatric adolescent and adult vaccine the company sell these human health vaccine primarily to physician wholesaler physician distributor and government entity large component of pediatric and adolescent vaccine sale are made to the center for disease control and prevention vaccine for child program which is funded by the government additionally the company sell vaccine to the federal government for placement into vaccine stockpile the animal health segment discovers develops manufacture and market wide range of veterinary pharmaceutical and vaccine product well health management solution and service for the prevention treatment and control of disease in all major livestock and companion animal specie the company also offer an extensive suite of digitally connected identification traceability and monitoring product the company sell it product to veterinarian distributor and animal producer beginning in the amortization of intangible asset previously included part of the calculation of segment profit is now included in unallocated non segment corporate expense prior period pharmaceutical and animal health segment profit have been recast to reflect this change on comparable basis the company previously had healthcare service segment that provided service and solution focused on engagement health analytics and clinical service to improve the value of care delivered to patient the company divested the remaining business in this segment during the first quarter of of contentssales of the company product were follows year ended december int ltotalu int ltotalu int ltotalpharmaceutical oncologykeytruda alliance revenue lynparza alliance revenue lenvima vaccinesgardasil gardasil proquad ii pneumovax hospital acute invanz immunologysimponi remicade isentress isentress cardiovascularalliance revenue adempas verquvo adempas other pharmaceutical total pharmaceutical segment animal health companion total animal health segment other segment sale total segment other plus international may not equal total due to rounding alliance revenue represents merck share of profit which are product sale net of cost of sale and commercialization cost see note alliance revenue represents merck share of profit from sale in bayer marketing territory which are product sale net of cost of sale and commercialization cost see note other pharmaceutical primarily reflects sale of other human health pharmaceutical product including product within the franchise not listed separately represents sale for the healthcare service segment all the business in the healthcare service segment were fully divested by the first quarter of other is primarily comprised of miscellaneous corporate revenue including revenue hedging activity well third party manufacturing sale including sale to organon other for also includes million related to the achievement of milestone for an out licensed product that triggered contingent payment to merck of contentsconsolidated sale by geographic area where derived are follows year ended december state europe middle east and asia pacific other than china and japan latin reconciliation of segment profit to income from continuing operation before tax is follows year ended december profit pharmaceutical segment animal health other segment total segment other unallocated interest interest expense amortization depreciation research and development restructuring cost other unallocated net pharmaceutical segment profit are comprised of segment sale le standard cost well selling general and administrative expense directly incurred by the segment animal health segment profit are comprised of segment sale le all cost of sale well selling general and administrative expense and research and development cost directly incurred by the segment for internal management reporting presented to the chief operating decision maker merck doe not allocate the remaining cost of sale not included in segment profit described above research and development expense incurred in merck research laboratory the company research and development division that focus on human health related activity or general and administrative expense nor the cost of financing these activity separate division maintain responsibility for monitoring and managing these cost including depreciation related to fixed asset utilized by these division and therefore they are not included in segment profit in addition cost related to restructuring activity well the amortization of intangible asset and purchase accounting adjustment are not allocated to segment other profit are primarily comprised of miscellaneous corporate profit well operating profit related to third party manufacturing sale other unallocated net includes expense from corporate and manufacturing cost center goodwill and other intangible asset impairment charge gain or loss on sale of business expense or income related to change in the estimated fair value measurement of liability for contingent consideration and other miscellaneous income or expense item of contentsequity loss from affiliate and depreciation included in segment profit is follows pharmaceuticalanimal healthall othertotalyear ended december included in segment profit equity loss from affiliate year ended december included in segment profit equity loss from affiliate year ended december included in segment profit equity loss from affiliate property plant and equipment net by geographic area where located is follows december state europe middle east and asia pacific other than china and japan latin the company doe not disaggregate asset on product and service basis for internal management reporting and therefore such information is not presented of contentsreport of independent registered public accounting firmto the board of director and stockholder of merck co inc opinion on the financial statement and internal control over financial reportingwe have audited the accompanying consolidated balance sheet of merck co inc and it subsidiary the company of december and and the related consolidated statement of income of comprehensive income of equity and of cash flow for each of the three year in the period ended december including the related note collectively referred to the consolidated financial statement also have audited the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission coso in opinion the consolidated financial statement referred to above present fairly in all material respect the financial position of the company of december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with accounting principle generally accepted in the united state of america also in our opinion the company maintained in all material respect effective internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the coso basis for opinionsthe company management is responsible for these consolidated financial statement for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in management report on internal control over financial reporting appearing under item our responsibility is to express opinion on the company consolidated financial statement and on the company internal control over financial reporting based on our audit we are public accounting firm registered with the public company accounting oversight board united state pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statement are free of material misstatement whether due to error or fraud and whether effective internal control over financial reporting wa maintained in all material respect our audit of the consolidated financial statement included performing procedure to ass the risk of material misstatement of the consolidated financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the consolidated financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the consolidated financial statement our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk our audit also included performing such other procedure we considered necessary in the circumstance we believe that our audit provide reasonable basis for our opinion definition and limitation of internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company ii provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and iii provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement of contentsbecause of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate critical audit mattersthe critical audit matter communicated below is matter arising from the current period audit of the consolidated financial statement that wa communicated or required to be communicated to the audit committee and that relates to account or disclosure that are material to the consolidated financial statement and ii involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which it relates rebate accrual medicaid managed care and medicare part described in note to the consolidated financial statement the company record certain variable consideration including discount which are estimated at the time of sale generally using the expected value method amount accrued for aggregate customer discount are evaluated on quarterly basis through comparison of information provided by the wholesaler health maintenance organization pharmacy benefit manager federal and state agency and other customer to the amount accrued certain of these discount representing portion of the accrual take the form of rebate which are amount owed based upon definitive contractual agreement or legal requirement with private sector managed care and public sector medicaid and medicare part benefit provider after the final dispensing of the product to benefit plan participant the provision for rebate is based on expected patient usage well inventory level in the distribution channel to determine the contractual obligation to the benefit provider management us historical customer segment utilization mix sale forecast change to product mix and price inventory level in the distribution channel government pricing calculation and prior payment history in order to estimate the expected provision the accrued balance relative to the provision for rebate included in accrued and other current liability wa billion of december of which the majority relates to rebate accrual medicaid managed care and medicare part the principal consideration for our determination that performing procedure relating to rebate accrual medicaid managed care and medicare part is critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing the rebate accrual the accrual are based on assumption developed using pricing information and historical customer segment utilization mix and high degree of auditor judgment subjectivity and effort in performing procedure and evaluating evidence related to these assumption addressing the matter involved performing procedure and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statement these procedure included testing the effectiveness of control relating to rebate accrual medicaid managed care and medicare part including management control over the assumption used to estimate the corresponding rebate accrual these procedure also included among others developing an independent estimate of the rebate accrual by utilizing third party data on historical customer segment utilization mix in the pricing information the term of the specific rebate program and the historical trend of actual rebate claim paid ii comparing the independent estimate to the rebate accrual recorded by management and iii testing rebate claim paid including evaluating those claim for consistency with the contractual term of the company rebate agreement pricewaterhousecoopers llpflorham park new jerseyfebruary have served the company auditor since of content supplementary dataselected quarterly financial data unaudited in million except per share amount sale gross net income from continuing operation attributable to merck co inc loss income from discontinued operation net of tax and amount attributable to noncontrolling interest net income attributable to merck co inc basic earnings per common share attributable to merck co inc common shareholdersincome from continuing operation loss income from discontinued operation net income earnings per common share assuming dilution attributable to merck co inc common shareholdersincome from continuing operation loss income from discontinued operation net income sale gross net loss income from continuing operation attributable to merck co inc income from discontinued operation net of tax and amount attributable to noncontrolling net loss income attributable to merck co inc basic loss earnings per common share attributable to merck co inc common shareholder loss income from continuing operation income from discontinued net loss income loss earnings per common share assuming dilution attributable to merck co inc common shareholder loss income from continuing operation income from discontinued net loss income amount in the fourth quarter of include charge related to the acquisition of velosbio inc and oncoimmune see note and an intangible asset impairment charge related to zerbaxa see note amount in the third quarter of include charge related to transaction with seagen inc see note amount in the second quarter of include charge related to the acquisition of pandion therapeutic inc see note reflects the result of the business that were spun off to organon on june discontinued operation for all period presented see note of contentsitem change in and disagreement with accountant on accounting and financial disclosure not applicable item control and procedure management of the company with the participation of it chief executive officer and chief financial officer ha evaluated the effectiveness of the company disclosure control and procedure based on their evaluation of the end of the period covered by this form the company chief executive officer and chief financial officer have concluded that the company disclosure control and procedure defined in rule or under the security exchange act of amended the act are effective for the fourth quarter of there have been no change in internal control over financial reporting that materially affected or are reasonably likely to materially affect the company internal control over financial reporting management is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule of the act management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in internal control integrated framework issued in by the committee of sponsoring organization of the treadway commission based on this evaluation management concluded that internal control over financial reporting wa effective of december pricewaterhousecoopers llp an independent registered public accounting firm ha performed it own assessment of the effectiveness of the company internal control over financial reporting and it attestation report is included in this form filing management reportmanagement responsibility for financial statementsresponsibility for the integrity and objectivity of the company financial statement rest with management the financial statement report on management stewardship of company asset these statement are prepared in conformity with generally accepted accounting principle and accordingly include amount that are based on management best estimate and judgment nonfinancial information included in the annual report on form ha also been prepared by management and is consistent with the financial statement to assure that financial information is reliable and asset are safeguarded management maintains an effective system of internal control and procedure important element of which include careful selection training and development of operating and financial manager an organization that provides appropriate division of responsibility and communication aimed at assuring that company policy and procedure are understood throughout the organization staff of internal auditor regularly monitor the adequacy and application of internal control on worldwide basis to ensure that personnel continue to understand the system of internal control and procedure and policy concerning good and prudent business practice annually all employee of the company are required to complete code of conduct training this training reinforces the importance and understanding of internal control by reviewing key corporate policy procedure and system in addition the company ha compliance program including an ethical business practice program to reinforce the company long standing commitment to high ethical standard in the conduct of it business the financial statement and other financial information included in the annual report on form fairly present in all material respect the company financial condition result of operation and cash flow our formal certification to the security and exchange commission is included in this form filing management report on internal control over financial reportingmanagement is responsible for establishing and maintaining adequate internal control over financial reporting such term is defined in rule under the security exchange act of the company internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle in the united state of america management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in internal control integrated of contentsframework issued in by the committee of sponsoring organization of the treadway commission based on this evaluation management concluded that internal control over financial reporting wa effective of december because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate the effectiveness of the company internal control over financial reporting of december ha been audited by pricewaterhousecoopers llp an independent registered public accounting firm stated in their report which appears herein robert daviscaroline litchfieldchief executive officer and presidentexecutive vice president and chief financial officeritem other information none item disclosure regarding foreign jurisdiction that prevent inspection not applicable of contentspart iii item director executive officer and corporate governance the required information on director and nominee is incorporated by reference from the discussion under proposal election of director of the company proxy statement for the annual meeting of shareholder to be held may information on executive officer is set forth in part of this document on page the required information on compliance with section of the security exchange act of if applicable is incorporated by reference from the discussion under the heading stock ownership information of the company proxy statement for the annual meeting of shareholder to be held may the company ha code of conduct our value and standard applicable to all employee including the principal executive officer principal financial officer principal accounting officer and controller the code of conduct is available on the company website at merck com company overview culture and value code of conduct value and standard the company intends to disclose future amendment to certain provision of the code of conduct and waiver of the code of conduct granted to executive officer and director if any on the website within four business day following the date of any amendment or waiver every merck employee is responsible for adhering to business practice that are in accordance with the law and with ethical principle that reflect the highest standard of corporate and individual behavior the required information on the identification of the audit committee and the audit committee financial expert is incorporated by reference from the discussion under the heading board meeting and committee of the company proxy statement for the annual meeting of shareholder to be held may item executive compensation the information required on executive compensation is incorporated by reference from the discussion under the heading compensation discussion and analysis summary compensation table all other compensation table grant of plan based award table outstanding equity award table option exercise and stock vested table pension benefit table nonqualified deferred compensation table and potential payment upon termination or change in control including the discussion under the subheading separation and change in control well all footnote information to the various table of the company proxy statement for the annual meeting of shareholder to be held may the required information on director compensation is incorporated by reference from the discussion under the heading director compensation and related schedule of director fee table and director compensation table of the company proxy statement for the annual meeting of shareholder to be held may the required information under the heading compensation and management development committee interlock and insider participation and compensation and management development committee report is incorporated by reference from the company proxy statement for the annual meeting of shareholder to be held may of contentsitem security ownership of certain beneficial owner and management and related stockholder matter information with respect to security ownership of certain beneficial owner and management is incorporated by reference from the discussion under the heading stock ownership information of the company proxy statement for the annual meeting of shareholder to be held may equity compensation plan informationthe following table summarizes information about the option warrant and right and other equity compensation under the company equity compensation plan of the close of business on december the table doe not include information about tax qualified plan such the merck saving plan plan categorynumber ofsecurities to beissued uponexercise ofoutstandingoptions warrantsand right weighted averageexercise price ofoutstandingoptions warrantsand right number ofsecurities remainingavailable for futureissuance under equitycompensation plan excludingsecuritiesreflected in column equity compensation plan approved by security holder equity compensation plan not approved by security holder includes option to purchase share of company common stock and other right under the following shareholder approved plan the merck co inc and incentive stock plan and the merck co inc non employee director stock option plan excludes approximately share of restricted stock unit and performance share unit assuming maximum payouts under the merck sharp dohme and incentive stock plan also excludes share of phantom stock deferred under the msd employee deferral program and share of phantom stock deferred under the merck co inc plan for deferred payment of director compensation item certain relationship and related transaction and director independence the required information on transaction with related person is incorporated by reference from the discussion under the heading related person transaction of the company proxy statement for the annual meeting of shareholder to be held may the required information on director independence is incorporated by reference from the discussion under the heading independence of director of the company proxy statement for the annual meeting of shareholder to be held may item principal accountant fee and service the information required for this item is incorporated by reference from the discussion under proposal ratification of appointment of independent registered public accounting firm for beginning with the caption pre approval policy for service of independent registered public accounting firm through fee for service provided by the independent registered public accounting firm of the company proxy statement for the annual meeting of shareholder to be held may of contentspart iv item exhibit and financial statement schedule the following document are filed part of this form financial statementsconsolidated statement of income for the year ended december and consolidated statement of comprehensive income for the year ended december and consolidated balance sheet of december and consolidated statement of equity for the year ended december and consolidated statement of cash flow for the year ended december and note to consolidated financial statementsreport of pricewaterhousecoopers llp independent registered public accounting firm pcaob id financial statement schedulesschedules are omitted because they are either not required or not applicable financial statement of affiliate carried on the equity basis have been omitted because considered individually or in the aggregate such affiliate do not constitute significant subsidiary of exhibitsexhibitnumber restated certificate of incorporation of merck co inc november incorporated by reference to merck co inc current report on form filed november no by law of merck co inc effective july incorporated by reference to merck co inc current report on form filed july no indenture dated of april between merck sharp dohme corp schering corporation and bank trust national association successor to morgan guaranty trust company of new york trustee the indenture incorporated by reference to exhibit to msd registration statement on form no first supplemental indenture to the indenture dated of october incorporated by reference to exhibit to msd registration statement on form filed september no second supplemental indenture to the indenture dated november incorporated by reference to exhibit to merck co inc current report on form filed november no third supplemental indenture to the indenture dated may incorporated by reference to exhibit to merck co inc form quarterly report for the period ended march no indenture dated november between merck co inc schering plough corporation and the bank of new york trustee the indenture incorporated by reference to exhibit to schering plough current report on form filed november no second supplemental indenture to the indenture including form of note dated november incorporated by reference to exhibit to schering plough current report on form filed november no third supplemental indenture to the indenture including form of note dated september incorporated by reference to exhibit to schering plough current report on form filed september no fifth supplemental indenture to the indenture dated november incorporated by reference to exhibit to merck co inc current report on form filed november no indenture dated of january between merck co inc and bank trust national association trustee incorporated by reference to exhibit to merck co inc current report on form filed december no description of the registrant common stock incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no description of the registrant note due note due and note due incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no description of the registrant note due and note due incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no of contentsexhibitnumber description merck co inc executive incentive plan amended and restated effective june incorporated by reference to merck co inc schedule filed april no merck co inc deferral program including the base salary deferral plan amended and restated effective december incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no merck co inc incentive stock plan amended and restated june incorporated by reference to merck co inc schedule filed april no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form quarterly report for the period ended march filed may no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by referent to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for quarterly and annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of restricted stock unit term for quarterly and annual grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed on february no performance share unit award term under the merck co inc stock incentive plan incorporated by reference to exhibit to merck co inc current report on form quarterly report for the period ended march filed may no of contentsexhibitnumber description merck co inc incentive stock plan incorporated by reference to appendix to merck co inc schedule filed april no merck co inc change in control separation benefit plan effective amended and restated of january incorporated by reference to exhibit to merck co inc current report on form filed november no merck co inc separation benefit plan amended and restated of january incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no retirement plan for the director of merck co inc amended and restated june incorporated by reference to exhibit to msd form quarterly report for the period ended june filed august no merck co inc plan for deferred payment of director compensation amended and restated effective of january distribution agreement between schering plough and centocor inc dated april incorporated by reference to exhibit to schering plough amended for the year ended december filed may no amendment agreement to the distribution agreement between centocor inc can development llc and schering plough ireland company incorporated by reference to exhibit to schering plough current report on form filed december no severance agreement and general release between merck co inc and adam schechter dated december incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no offer letter between merck co inc and jennifer zachary dated march incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for annual non qualified option grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of restricted stock unit term for annual grant under the merck co inc incentive stock plan incorporated by reference to exhibit to merck co inc form annual report for the fiscal year ended december filed february no form of stock option term for annual non qualified option grant under the merck co inc incentive stock plan form of restricted stock unit term for annual grant under the merck co inc incentive stock subsidiary of merck co inc consent of independent registered public accounting power of certified resolution of board of of rule certification of chief executive rule certification of chief financial section certification of chief executive section certification of chief financial in xbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl document sch xbrl taxonomy extension schema document cal xbrl taxonomy extension calculation linkbase document def xbrl taxonomy extension definition linkbase document lab xbrl taxonomy extension label linkbase document pre xbrl taxonomy extension presentation linkbase document cover page interactive data file formatted inline xbrl and contained in exhibit management contract or compensatory plan or arrangement certain portion of the exhibit have been omitted pursuant to request for confidential treatment the non public information ha been filed separately with the security and exchange commission pursuant to rule under the security exchange act of amended long term debt instrument under which the total amount of security authorized doe not exceed of merck co inc total consolidated asset are not filed exhibit to this report merck co inc will furnish copy of these agreement to the security and exchange commission on request item form summarynot applicable of contentssignaturespursuant to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized dated february merck co inc by robert davis chief executive officer and president by jennifer zacharyjennifer zachary attorney in fact pursuant to the requirement of the security exchange act of this report ha been signed below by the following person on behalf of the registrant and in the capacity and on the date indicated signaturestitledaterobert davischief executive officer and president principal executive officer directorfebruary litchfieldexecutive vice president and chief financial officer principal financial officerfebruary karachunsenior vice president finance global controller principal accounting officerfebruary frazierexecutive chairman and directorfebruary ellen coedirectorfebruary craigdirectorfebruary glocerdirectorfebruary lavizzo moureydirectorfebruary mayodirectorfebruary rothmandirectorfebruary russodirectorfebruary seidmandirectorfebruary thulindirectorfebruary wardendirectorfebruary wendelldirectorfebruary zachary by signing name hereto doe hereby sign this document pursuant to power of attorney duly executed by the person named filed with the security and exchange commission an exhibit to this document on behalf of such person all in the capacity and on the date stated such person including majority of the director of the company by jennifer zacharyjennifer zachary attorney in fact copy and paste below content previous next setting hover over fact for quick information on off auto scrolling position top center selecting fact from the section menu or the fact menu will automatically scroll that element to the top or middle of the viewer window this setting will have no use on ie or safari tagged data savereset search result savereset selected fact savereset tag shading hover savereset copy and paste below content previous next nested fact previous next copy and paste below content previous next